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SUMMARY
Renal transplantation offers the optimal quality of life for the 
patient requiring renal replacement therapy. The main reason for renal 
allograft failure remains immunological rejection. The discovery that 
pretransplant blood transfusion is associated with decreased graft loss 
through rejection led to the introduction of elective transfusion 
protocols for renal dialysis patients. Despite extensive research, the 
mechanism of the blood transfusion effect on transplant outcome remains 
unclear. Of the many suggested explanations, one proposed by MacLeod 
and her colleagues, claimed that Fctf-receptor blocking antibodies were 
produced after blood transfusion and correlated with renal allograft 
survival. The initial aims of the work, described in this volume were 
to confirm and extend these findings (MacLeod et al, 1982b).
Using IgG prepared from whole serum by standard chromatography, the 
association between Fc)f-receptor blocking activity and blood trans­
fusion was confirmed for both uraemic and non-uraemic subjects. The 
development of Fc)f-receptor blocking activity was shown over the; course 
of elective transfusion of previously untransfused: renal dialysis 
patients'.
IgG. preparations from transfused subjects were shown to interact 
in vitro not only with B lymphocytes as previously described, but also 
with normal, allogeneic peripheral blood and T lymphocytes, thymocytes? 
polymorphs, platelets and spermatozoa. The pattern of reactivity did 
not correspond to the Fctf-receptor bearing cell populations. The 
significance in vivo of inhibition by IgG preparations from transfused 
subjects of polymorph phagocytosis and platelet aggregation remains
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uncertain. . Perhaps relevant to attenuation of allograft rejection was 
inhibition of the mitogen response which was associated with IgG 
Fc^-receptor blocking activity.
Confirmation of the presence of FcJ-receptor blocking antibodies 
in patients potentially immunosuppressed by blood transfused was followed 
by similar experiments using IgG preparations from patients exposed to 
a wide range of alloantigens, although not necessarily in blood.
Patients with haemophilia were chosen, as a group who received clotting 
factor concentrates derived from multiple donors, and in whom there 
were recent reports of impaired indices of immune function. Like the 
recipients of blood transfusion, patients with haemophilia yielded 
IgG which blocked FcY-receptors and inhibited the mitogen response of 
lymphocytes from normal subjects.
Only a small proportion of the haemophiliac subjects were later 
found to have antibody against Human T cell Leukaemia Virus Type III, 
thought now to mark potential development of the Acquired Immunodeficiency 
Syndrome (AIDS). The epidemiology of AIDS, while consistent with 
unifactorial viral aetiology, led to suggestions that pre-existing 
immunosuppression may predispose to the expression of the virus.
Reports of anti-lymphocyte antibodies in the serum of practising
homosexual men, the risk group with the highest incidence of AIDS,
stimulated experiments to assess the prevalence of FcY-receptor blocking
antibodies in AIDS patients and in homosexual men with no evidence of
the syndrome. IgG preparations from both groups blocked FcV-receptors .
and inhibited the mitogen response of normal lymphocytes. Cross­
reactivity with spermatozoa may indicate that anti-lymphocyte antibodies
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are induced by rectal insemination. Although these experiments were 
performed before identification of the virus, and anti-viral antibody 
status was not checked, the preyalence of infection in comparable 
populations at the time of testing (1983) has been regarded as too low 
to account for these findings.
Despite the demonstration of IgG FcY-receptor blocking activity in 
subjects.with acquired immune abnormalities, no association was found 
between renal allograft survival and pretransplant IgG receptor blocking 
activity, using a variety of donor and third party FcY-receptor bearing 
cells. No conclusive explanation was found for the discrepancy between
this and-previous work (MacLeod et al, 1982a and b).
Lest the method of preparation of IgG eliminate the suggested 
association with transplant outcome, pretransplant sera were instead 
separated into fractions of graded, molecular weight. There was a
highly significant correlation between renal allograft survival and
FcY-receptor blocking activity in'the highest molecular weight fraction 
(>19S). Although the serum factor(s) responsible were not.identified, 
their presence appeared to be associated with previous transfusion of 
blood or blood products, and with diminished response to skin testing 
with Dinitrochlorobenzene. This may indicate that high molecular 
weight serum FcY-receptor blocking factors are involved in non-specific 
depression of cell-mediated immunity following blood transfusion, and 
may be regarded as predictive of successful renal transplantation.
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CHAPTER 1 
THE NEED FOR RENAL TRANSPLANTATION
The need for renal transplantation in the management of end-stage 
renal failure is unquestionable. In a field where "the idea that 
prevention is simple, available or immediately possible, is a fantasy", 
Robson (1979), the major task has become the maintenance of life by 
dialysis and transplantation.
Assessment of the relative merits of these treatments in terms of 
morbidity and mortality has been bedevilled by difficulties in 
interpretation where patients have been treated with a mixture of 
modalities and where selection bias in therapy may influence the results 
(Brunner et al, in press). Vollmer, Wahl and Blagg (1983) attempted 
to compare patient survival following dialysis and transplantation. 
Transplantation of a kidney from a live related donor conferred a 
benefit which was lost when a cadaveric allograft was used; the authors 
considered that recent improvements in immunosuppressive therapy could 
eliminate this difference.
More important than survival alone is the quality of life. A
number of workers have sought to assess the relative qualities of life
for patients on different types of renal replacement therapy, with
variable success in controlling the case-mix for the different
therapies. The most recent in a series of reports from two American
groups, those of Simmons et al in Minneapolis (1985) and Evans et al
in Seattle.(1985 a and b), consist of detailed cross-sectional
multicentre assessment using several recognised indices of physical,
emotional and social wellbeing. So far as possible in this.type of
study the results for the 859 patients studied by Evans et al (1985 a)
were adjusted for the case-taix. Both subjective and objective
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assessment of quality of life were consistently better for patients 
with functioning transplants. Indeed, transplant recipients had a 
subjective quality of life that did not differ significantly from the 
general population.
It might be naive to assume that improved quality of life were the 
sole reason for the relatively high proportion of patients in the United 
Kingdom treated by transplantation. Figures compiled by the Registry 
of the European Dialysis and Transplant Association (EDTA) show that 
on 31st December 1984 one half of patients on renal replacement therapy 
in the United Kingdom had functioning transplants. This proportion 
is similar to that in Scandinavia and Eire, but considerably greater 
than, for example, France and the Federal Republic of Germany (both 
less than one fifth) (Brunner et al, in press). Sells, Macpherson and 
Salaman (1985) have suggested that "in no other country has the presence 
of deficient dialysis programmes yielded such an energetic response 
from affiliated transplant units". The number of successful transplants 
has a direct bearing on the number of new patients who can be accepted 
onto dialysis. Figures again from the EDTA Registry show that in 1984 
the United Kingdom rate of acceptance onto renal replacement therapy 
was 35.9 patients per million population. This rate is not only lower 
than almost all of the rest of Western Europe, but reflects particularly 
rigorous selection against the elderly (Brunner et al, in press).
The absolute number of renal transplants performed continues to be
regarded as limited by the availability of organs (Sells et al, 1985).
The analysis of this problem by the Medical Services Study Group of
the Royal College of Physicians (1981) pointed out that intensive care .
facilities available to prospective donors are not uniformly adequate
for the provision of viable kidneys. Considerable effort and
publicity have been expended to achieve public and professional
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acceptance of cadaver organ transplantation with general, if not 
uniform, success. As "The Lancet" commented in 1984, "within two 
years we have seen transplantation suffer grievously from a false 
but newsworthy anxiety about the diagnosis of donor death, and then 
equally abruptly flourish as a result of a single liver transplant in 
a child". (Anonymous ,1984). With over 3000 patients in the United 
Kingdom awaiting renal transplantation, the encouragement of kidney 
donation remains essential (United Kingdom Transplant Service, .1985).
Grucial to the establishment of transplantation as the treatment 
of choice for renal failure is an increase not only in the numbers of 
transplants performed but in their success rate. Major transplant 
registries are now quoting figures approaching 80% for one-year 
survival of first cadaver allografts (Opelz 1985 b, Brunner et al 
in press),
The most important cause of graft failure remains immunological 
rejection. Four-fifths of graft losses reported in 1980-83 to the 
EDTA Registry were attributed to rejection (Brunner et al, in press). 
Interest in the clinical management of rejection has been paralleled 
by attempts to elucidate the immune response to the renal allograft. 
Current thinking on this topic is reviewed in the next chapter.
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CHAPTER 2
MECHANISMS OF REJECTION OF RENAL ALLOGRAFTS
The mechanism of allograft rejection is dependent on recognition: 
of foreign antigen by the immune system, followed by mobilisation of 
the available modes of destruction.
1. Recognition of antigen: the afferent limb of the immune response.
Genetic differences between individuals are reflected by differences 
in the glycoproteins expressed on their cell surfaces. . Those which, 
affect allograft outcome are known as histocompatibility antigens. 
Although both so-called "major" and "minor" histocompatibility antigens 
are recognised, it is the antigens of the Major Histocompatibility 
Complex which are regarded as of primary importance.
2. The Major Histocompatibility Complex
The structure of the Major Histocompatibility Complex has 
recently been summarized by de Vries and van Rood (1985) as follows:
i) HLA class-I molecules
Found on the surface of nearly all nucleated cells (for detailed . 
distribution in man, see Daar et al?1984 a). They consist of two 
polypeptide chains, one of which has a molecular weight of 44,000 
daltons and is coded in the Major Histocompatibility Complex on 
chromosome 6. The 12,000 dalton light chain is beta-2-microglobulin, 
which is coded by a gene on chromosome 15. The heavy chain penetrates 
the cell membrane, with its extracellular part folded into three 
immunoglobulin-like domains ( C< f ) «x x p ) •  microSl°bul^n
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does not penetrate the cell membrane but is associated noncovalently 
with the domain. The domain varies little, but the bC f and 
b(L domains express the polymorphism of three heavy chain genes, known 
as HLA-A, B and C. Class I molecules act as antigen presenters 
primarily to cytotoxic T lymphocytes.
ii) HLA class-II molecules
Found primarily on cells of the immune system, such as 
macrophages and other antigen-presenting cells, B lymphocytes and 
activated T lymphocytes. Other sites have been charted by Daar et‘al 
(1984 b) and include renal vascular endothelium; increased expression 
of class II antigens has been reported during allograft rejection 
(Hall et al,1984). Class-II molecules also consist of two polypeptide 
chains, both of which penetrate the cell membrane; The 34,000-daltaon 
U chain is non-covalently associated with the 29,000-dalton A chain.
Both chains are coded by genes in the HLA system on chromosome 6. At
system, and named DR, DP and DQ. Class-II molecules provide antigen 
presentation principally to helper T lymphocytes.
Matching of class I and II antigens between donor and recipient 
may reduce the likelihood of rejection. Although benefit from 
matching has not always been apparent in small studies, multicentre 
data points strongly to the benefits of tissue matching. In 
particular, matching for both B and DR loci is beneficial; Opelz 
(1985 b) has recently demonstrated a 20% difference in 1-year graft
least 5 class-II OC genes are located in the HLA
3. The effect of tissue matching on renal transplant outcome
i) Antigen matching
survival between donor-recipient pairs matched for no and four B/DR 
loci. Matching techniques are reviewed by Dick (1979).
ii) Lymphocytotoxicity testing
The methods used for lymphocytotoxicity testing are summarised by 
Kissmeyer-Nielsen and Dick (1979). If renal transplantation is 
performed when there is a positive complement-dependent cross-match 
between recipient serum and donor T lymphocytes, hyperacute rejection 
will almost invariably occur. The practice therefore is that such a 
cross-match precludes transplantation of the donor-recipient pair.
T cell cytotoxicity is the result of anti-class I antibodies produced 
following previous transplantation, transfusion or pregnancy, a process 
referred to as "sensitization".
Conversely there have been several reports that a positive B cell 
cross-match is not a disadvantage (Ettenger et al,(1976);Morris et al, 
(1977); d’Apice and Tait, (1979); Ting and Morris (1979). This could 
be because some positive B cell cross-matches are caused by auto­
antibodies (Park, Terasaki and B emoco,1977) . Chapman, Ting and 
Morris (1985) have recently suggested that non-autoreactive B cell 
antibodies are associated with poor allograft prognosis.
4. Antigen presentation by the renal allograft
Initiation of the host immune.response to the allograft requires 
donor cells presenting class.II antigens. The situation in man 
differs from that in the rodent models generally employed in the 
investigation of antigen presentation by renal allografts. Although 
renal vascular endothelium in the rat does not express class II antigens, 
in man it does (Daar et 3^1984 b) . Hirschberg, Bergh & Thorsby(1980)
have shown that antigen-bearing endothelial cells can substitute 
for accessory cells in the lymphoproliferative response of T lymphocytes 
to soluble protein antigen. Cerilli et al (1985) claimed that
a vascular endothelial cell antigen system, linked to the Major
Histocompatibility Complex, is implicated in rejection.
In the rat, the absence of class II endothelial antigens points 
more clearly to passenger donor cells in the allograft as the source 
of antigen presentation. A series of experiments before class II
antigens were identified led Guttmann, Lindquist & Ockner (1969) to
suggest that the important immunogens in renal allograft rejection 
in rats were not cells from the kidney itself but cells of 
haematopoietic origin. Klinkert, La Badie& Bowers (1982) demonstrated 
that a cell type distinct from the macrophage population, the dendritic 
cell, functioned as the accessory cell required for the rat lymphocyte 
response to periodate. Lechler and Batchelor (1982) provided further 
evidence for the importance of the dendritic passenger leucocyte in a 
series of elegant experiments. Long-surviving, enhanced renal 
allografts were transplanted into a second, unenhanced rat of the same 
strain as the first recipient. Rejection did not occur unless donor 
strain dendritic cells were injected into the new host, with neither 
T nor B lymphocytes in comparable numbers having any effect. These 
findings have been confirmed by other workers in different animal 
models. The expression of class II antigens without dendritic
cells may not be sufficient to induce the immune response (Austyn et 
al, 1985)'.
5. Destroying the renal allograft: the efferent limb of the immune
response
The broad categories of the immune response involved in rejecting
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the renal allograft are illustrated in Figures 1 to 3 (adapted from 
Stiller & Keown (1984). Not illustrated is hyperacute rejection 
resulting from preformed cytotoxic antibody against antigens of the 
Major Histocompatibility Complex (Kissmeyer-Nielsen et al, 1966).
All the mechanisms illustrated require T lymphocytes; experiments 
in rodents involving T cell depletion then reconstitution with 
phenotypes defined by monoclonal antibodies have demonstrated the 
necessity for the T helper subset (reviewed by Hayry 1984).
Histological examination of rejecting kidneys has traditionally 
divided early allograft failure other than hyperacute rejection into 
two major pathways; a) vascular: platelet thrombi and fibrin in
capillaries, foci of fibrinoid necrosis in vessel walls, and inter­
stitial haemorrhage; b) cellular: interstitial oedema, and focal
cortical infiltrates of lymphocytes, plasmacells and macrophage 
(More ,1985).
Cytological analysis of infiltrating cells has been extended by 
the development of monoclonal antibodies. Using monoclonal analysis 
of cells infiltrating rat renal allografts, Bradley, Mason & Morris 
(1985) have suggested that allograft rejection, in the rat at least, 
is mediated by specific cytotoxic T lymphocytes, and that the major 
role of the T helper cell may be to assist this process. (Figure 1)
Relative to man, the rat has a weak delayed hypersensitivity 
response. (Mason, et al, 1984) and so data based on rats may 
underestimate the importance of this response in man. (Figure 2)
The antibody response may be important even in recipients 
without preformed cytotoxins. Lymphocytotoxins formed during rejection
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are deposited in the kidney (McKenzie & Whittingham, 1968) . The 
histological changes of vascular rejection, in particular, would fit ; 
with damage to endothelium by complement-fixing antibody, with 
secondary platelet and fibrin deposition and thrombosis. Coating of 
target cells by antibody could also lead to antibody-dependent cell, 
cytotoxicity by K cells. (Figure 3)
Reviewing the evidence on mechanisms of allograft destruction, 
Hayry concluded that an immunological stimulus so great as a trans­
planted kidney was likely to provoke a number of modes of response. 
(Hayry, 1984).
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CHAPTER 3
THE DEVELOPMENT OF CLINICAL RENAL TRANSPLANTATION
1. 1900 to 1950
i) Human Organ Transplantation
"The results of clinical organ grafts have now surpassed any 
reasonable expectation based on immunological theory". Developments 
in transplantation have not always been so haphazard immunologically . 
as this comment from Caine (1984) might suggest. However, attempts 
at tissue transplantation in the early part of the century were 
based as often on folklore and an appreciation of the commercial 
possibilities as on developments in surgical technique and immuno­
logical knowledge.
New techniques of vascular anastamosis, for which Carrel took 
lasting credit and a Nobel Prize, provided scope for the enterprising 
surgeon who was not constrained by considerations of species, far 
less tissue type. Between the wars, an American move to treat 
sexual dysfunction in men by transplanting monkey testes was 
transiently lucrative, but gave no lasting benefit either social or 
scientific (Hamilton, in press;and 1984).
It would be surprising if the association with charlatanry 
deterred the medical profession from exploring the potential of 
transplantation. Between the wars, however, there was a dearth of 
clinical study. The Russian surgeon, Voronoy, has been given the 
credit for the first human cadaveric renal transplant,performed in 
1936 and an achievement marred only by the death of the patient two 
days later (Joekes, Porter and Dempster, 1957).
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Unlike the contemporary anecdotes of human organ transplantation, 
some reports of skin grafting did accept the relevance to graft 
success of genetic differences between individuals, as expressed at 
the still relatively unsophisticated level of blood grouping (Masson, 
1918; Shawan 1919).
ii) Tissue Antigens in Experimental Transplantation
Scientific interest before 1950 concentrated more on tumour than 
organ transplantation, not least because microvascular techniques for 
organ transplantation in laboratory rodents had not yet been devised. 
It was in this field that Gorer (1937) produced his classic article 
on “The genetic and antigenic basis of tumour transplantation". By 
meticulous attention to the purity of his strains of albino mice he 
was able to demonstrate clearly that sarcomas grown in one strain 
could be transplanted successfully to other mice of the same strain 
and to certain hybrid combinations, but not to outbred mice.
The point that more than simply blood grouping was necessary in 
skin grafting was summarised by Sir Peter Medawar in 1946: "The idea
that there exists an intimate relationship between the forms of 
incompatibility revealed by blood transfusion and tissue trans­
plantation has been more widely accepted than any concrete evidence 
for it allows" (Medawar 1946).
In a series of experiments during the 1940s, Medawar and Gibson 
described, the process of skin graft rejection in rabbits (Gibson and 
Medawar,1943; Medawar, 1945, 1946). Interestingly, although at the 
time the results may have been regarded by surgeons as a source of
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inspiration rather than practical guidance (Caine, 1984), reassessment 
of the data with hindsight (Medawar, 1946) shows the beneficial effect, 
of blood transfusion on graft survival long before its acceptance in 
renal transplantation (Opelz et al, 1973).
2. 1950s : Human Renal Transplantation
Attempts at human renal transplantation began in earnest in the 
1950s in the absence of maintenance dialysis, tissue matching and 
sub-lethal immunosuppression. The absence of maintenance dialysis 
not only reduced the population awaiting transplantation but justified 
the use of transplantation as a last-ditch manoeuvre to prevent:death 
from uraemia (Hamilton 1984).
Appreciation of the importance of attempting genetic matching led 
to many of the early renal transplants being between identical twins, 
although there were notable efforts at transplantation from unrelated 
donors (Hume et al, 1955; Murray, 1982). Excellent results with 
the twin pairs were not paralleled for unrelated donors; sadly these 
transplants only confirmed the importance and histological findings of 
rejection.
3. 1960s
i) Immunosuppressive Drug Therapy
The limitations of a transplant programme based on the availability 
of an identical twin highlighted the need for therapy to suppress the 
immune response to the allograft. During the late 1950s, the staple 
immunosuppressive therapy was irradiation, which seldom prevented
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allograft rejection even in near-lethal doses (Caine, 1984).
The observation that certain organic chemicals could induce 
immune suppression in laboratory animals had been made in Germany, 
in the early years of the century (Hamilton,1984 ). However, it was 
not until the 1950s that 6-mercaptopurine, an antipurine being 
developed for projected use as an antimetabolite of neoplastic cells, 
was used to induce selective immune tolerance to foreign protein in 
rabbits (Schwartz and Damashek, 1959). Caine (i960) showed some 
inhibition by 6-mercaptopurine of renal allograft rejection in dogs, 
and followed this up with better results using another purine 
analogue, Azathioprine (Caine et al, 1962).
Tentative treatment in man began; the first drug-treated 
recipient of a cadaveric kidney to survive for over a year was 
reported in 1963 and, in the reminiscences of Murray (1982), "it was 
immediately evident that drug therapy was more efficient and less 
dangerous than total body irradiation". The addition of Prednisolone 
to Azathioprine as standard immunosuppression led to what Murray (1982) 
has called "the era of boundless optimism" of the mid nineteen-sixties, 
when the advances of the previous five years were assumed to presage 
those of the next five.
ii) Leucocyte Antibodies and Antigens
The availability of less crude immunosuppressive therapy was 
paralleled by the development of maintenance haemodialysis and with it 
an increasing number of patients for whom transplantation was a 
possibility (Quinton, Dillard and Scribner, 1960). Transfusion 
policies for anaemic patients on haemodialysis were possibly, by
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to-day's standards, liberal. It was inevitable that a proportion 
of patients on regular haemodialysis would acquire antibodies to 
the newly-described leucocyte antigens (van Rood, van Leeuwen and 
Bruning, 1967).
In 1966, Kissmeyer-Nielsen et al reported the first two cases 
of hyperacute rejection of renal allografts in man. Both patients 
had been .heavily sensitized by transfusion and pregnancy, with 
pretransplant serum containing leucocyte isoagglutinins. Concern 
about sensitization contributed to a more sparing approach to the use 
of blood, in retrospect a mistake (Opelz et al, 1973).
The widespread introduction, to try to pre-empt hyperacute 
rejection, of the lymphocytotoxicity technique described by Terasaki 
and McLelland (1964) contributed to further elucidation of the HLA 
system (van Rood et al, 1967). Lymphocytotoxicity proved more 
sensitive and more reproducible than the previously used leucoagglutination 
techniques (Dick, 1979). Growing appreciation of the complexity of 
leucocyte antigens and a modicum of standardization of antigen typing 
facilitated the establishment of multicentre organ sharing schemes.
Murray's era of boundless optimism (Murray, 1982) faded with the 
realisation that neither the tissue matching nor the immunosuppressive 
therapy which was available could guarantee successful transplantation 
from unrelated donors. Far from it; one-year cadaveric graft survival 
rates quoted in 19 74 were still of the order of 50 %, no better than 
several yiears previously (Opelz et al, 1974b). Use of historical 
controls may have obscured any beneficial effect on graft survival of 
the introduction of matching for HLA-A and B loci, concurrent as this 
was with minimization of blood transfusion,
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4. 1970s
i) The Blood Transfusion Effect
If the collection of multicentre data needed any justification, 
it was amply provided by the demonstration of the beneficial effect of 
pretransplant blood transfusion on renal allograft survival (Opelz 
et al, 19.73). This was not only the most important advance in 
clinical transplantation over a decade (see Chapter 4) but stimulated 
considerable scientific interest and controversy tfs.ee Chapter 5).
ii) HLA-DR Typing
The advent of HLA-DR typing (Ting and Morris,1978a), while 
promising, did not yield widespread immediate benefit. In 1979,
Sachs commented that, of the "restricted11 number of laboratories in a 
position to type for DR, "only a few can claim to do so competently". 
Problems in standardization may have detracted from the perceived 
impact of: DR typing, although the bulk of evidence now is that DR is 
the most important known locus, with matching for both B and DR 
improving graft outcome further (Opelz, 1985 b).
5. 1980s
i) Cyclosporin A
After almost twenty years when the staples of convential immuno­
suppressive therapy were Prednisolone and Azathioprine, the position 
changed dramatically. The development of Cyclosporin A has become a 
legendary piece of pharmaceutical serendipity. Borel’s discovery of
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the immunosuppressive properties of a cyclic peptide under scrutiny 
as an antifungal agent, led to its clinical development in Cambridge 
(Borel, 1976; Caine et al, 1978).
Cyclosporin affects the initiation of the immune response by 
inhibiting interleukin release (Bunjes et al, 1981). While preventing 
the activation of precursor cytotoxic T lymphocytes;(Hess and Tutschka, 
1980), it may spare mature cytotoxic cells and permits the development 
of both antigen-specific and antigen-non-specific suppressor T 
lymphocytes (Kupiec-Weglinkski et al, 1984). In man, Cyclosporin 
seems to affect the primary humoral response to both T-dependent 
stimuli such as pokeweed mitogen and T-independent stimuli such as 
Staphylococcus aureus (Paavonen and Hayry, 1980). The primed T 
helper cell in the secondary humoral response may, however, have lost
its susceptibility to Cyclosporin (Kunkl and Klaus, 1980).
The capacity of Cyclosporin to affect primarily the inception of 
the immune response makes it ideal for organ transplantation, where 
new antigens are being introduced, but may detract from its application 
to established immune processes. Reports of successful extension of 
its use to autoimmune disease are as yet -distinctly preliminary. (Stiller 
et al, 1984; Assan et al, 1985).
There is no doubt that the introduction of Cyclosporin has led to
significant improvement in renal allograft survival, while not obviating 
the benefits of HLA-matching and pretransplant blood transfusion (Cats 
et al, 1984; Opelz, 1985 b). The initial report from the European 
Multicentre Trial Group (1983) of a one-year first cadaveric allograft 
survival rate of 72% with Cyclosporin alone against 52% with Prednisolone 
and Azathioprine has now been followed through to three years with graft
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survival of 66% and 42% respectively (Caine and Wood, 1985).
Still poorly established is the need for concomitant steroid, 
therapy. Unlike the European trial, the Canadian Multicentre Study 
Group trialC 1983) included.Prednisolone in its Cyclosporin protocol 
and reported a one-year allograft survival rate of 77%, against 66% 
with conventional immunosuppression. The concurrent administration 
of low doses of Prednisolone and Cyclosporin may yield good results 
with minimum toxicity (Thiel et al, 1984), and the addition of 
Azathioprine has also been suggested (Sutherland et al, 1985).
Enthusiasm for Cyclosporin has been only partially dimmed by 
realisation of its side-effects. Lymphomas have been regarded as 
reversible on reduction or cessation of therapy, and a consequence of 
removal o.f T-cell-mediated suppression of B cells previously infected 
by Epstein-Barr virus (Starzl et al, 1984). Tremor, paraesthesiae, 
hirstutism and gum hypertrophy have caused less anxiety - to the 
physician - than has hepatotoxicity, another drug-related problem.
Particularly worrying in the context of renal transplantation, 
is nephrotoxicity. Hypertension and a raised serum creatinine have 
been consistent findings from the initial trials onwards. Klintmalm 
et al (1984) have suggested that the progressive glomrular .sclerosis 
described by Myers et al (1984) may be dose-related. Attempts to 
avoid long-term nephrotoxicity by weaning patients off Cyclosporin 
onto conventional therapy at least three months after transplantation 
have been marred by a significant incidence of rejection . (Wood et al, 
1983; Adu Michael and McMaster, 1985).
The striking effectiveness of Cyclosporin is underlined by its
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widespread adoption despite these problems (Brunner et al, in press),
ii) Monoclonal Anti-lymphocyte Antibodies
Polyclonal anti-lymphocyte globulin preparations have been in 
use since the 1960s (Caine, 1984). Human lymphocytes or thymocytes 
are injected into another species, generally horses or rabbits. The 
resulting immune serum is then absorbed against non-lymphoid cells 
to try to remove other potentially toxic antibodies, and infused into 
the transplant recipient. While reported by some centres as effective 
in the treatment of rejection, the use of anti-lymphocyte globulin has 
been limited by batch variation, adverse reactions on administration 
and fears of over-immunosuppression (Najarian and Simmons, 1971;
Monaco, Campion and Kapnick, 1977; Stiller and Keown, 1984).
Monoclonal anti-lymphocyte antibodies are a recent refinement of 
the same principle, (McKearn et al, 1979). Now available against a 
variety of human lymphocyte subsets, monoclonal antibodies are generally 
cloned from mice. Their use in clinical renal transplantation remains 
experimental, although successes (and toxicity) have been reported using 
antibodies against mature lymphocytes and lymphoblasts (Cosimi et al, 
1981; Kirkman et al, 1983; Takahashi et al, 1983).
6. Other Developments
Over the period discussed in this chapter, there have, of course, 
been considerable advances in areas not mentioned, but relevant to the 
outcome of transplantation. Notable amongst these are improvements 
in access’ to and preservation of donor kidneys, and increased
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experience in the maintenance of reasonable general health in 
patients on regular dialysis. Of the advances mentioned above, 
more detailed consideration will now be given to the blood transfusion 
effect on renal allograft survival.
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CHAPTER 4
THE BLOOD TRANSFUSION EFFECT IN CLINICAL RENAL TRANSPLANTATION
Concern in the late 1960s about sensitization following blood 
transfusion divorced from clinical consideration the considerable 
evidence on blood transfusion and graft enhancement which had accrued 
over the previous twenty years. Although much of this came from 
species less prone than man to develop anti-lymphocyte antibodies 
(Morris, 1980) there were a few pieces of corroborati.ve evidence in 
man. The claim by'Opelz et al in 1973 that pretransplant blood 
transfusion correlated with renal allograft survival reversed the 
prevailing clinical dictum and forced a reappraisal of previous work.
1. Early evidence for the transfusion effect
Medawar concluded in 1946 from experiments in rabbits that 
"immunity to skin homografts following massive intravenous trans­
fusions of homologous whole blood is either trivial or absent". 
Shortly afterwards this was neatly, if inadvertently, demonstrated in 
a single case in man (Kearns and Reid, 1949). The success in this 
case of parent-to-son skin grafting was attributed to prior parent- 
to-son therapeutic transfusion, and was likened by Snell (1952) to 
the existing literature on tumour transplantation.
The dpyen of studies of tumour transplantation was reported by 
Flexner and Jobling in 1907. They found that preheated rat sarcoma 
cells injected intraperitoneally promoted growth of that tumour. 
Interestingly, neither unheated sarcoma cells nor heated whole blood 
affected tumour growth.
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The work of Kaliss led him to coin the term "immunological 
enhancement" for "the successful establishment of a tumor homograft ... 
as a consequence of the tumor’s contact with specific antiserum in the 
host". "Conceivably," he added, "the term could be applied to the 
experimentally prolonged survival of homografts of normal tissues" 
(Kaliss and Molomut, 1952; Kaliss, 1958).
Billingham, Brent and Medawar in 1953 described "actively 
acquired tolerance" in mice and chickens. If exposed to donor cells 
as neonates they would fail to reject skin grafts as adults. This 
effect was donor-strain specific.
The finding that survival of skin grafts in even adult mice was 
prolonged with prior transfusion of donor blood led Marino and 
Berain , (1958) to draw parallels with the description by Felton (1949) 
of "specific immunoparalysis" to pneumococcal polysaccharide. The 
conclusion that paralysis rather than saturation of the immune response 
was responsible for their findings was also reached by Stark and 
Dwyer (1959), who showed that survival of first and second skin grafts 
in rabbits was prolonged by pretreatment with donor blood. Peer
(1958) reported successful parental skin grafting to human infants 
after donor blood, although maternal grafting appeared more successful. 
Stone et al (1965) found that freemartin cattle twins with erythrocyte 
chimerism showed delayed rejection of exchanged skin grafts.
With the development of the canine renal allograft model, Egdahl
and Hume (1956) tried pretransplant cross-circulation between donor and
recipient. Conflicting results in different animal pairs may have
reflected both sensitization leading to rapid graft loss and active
enhancement of graft survival. Less inconclusive results came from
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Halasz, Orloff and Hirose (1964), who claimed that prolongation of 
renal allograft survival was achieved in every dog whom they pretreated 
with donor blood. A human case of donor-specific transfusion before 
renal transplantation was reported in 1965 by Eschbach et al. The 
authors1 pragmatic response to renal failure in one patient and bone 
marrow failure due to acute leukaemia in another was to employ cross­
circulation between the two. Both weathered this manoeuvre daily for 
4| months, during which period exchange of skin grafts proved 
unsuccessful. After the leukaemic girl succumbed to a Pseudomonas 
septicaemia, one of her kidneys was transplanted into the uraemic 
youth. On the credit side, he acquired no evidence of Pseudomonas 
sepsis or leukaemia; unfortunately, the kidney infarcted.
The first case in man where successful renal transplantation was 
preceded by donor-recipient cross-circulation was reported in 1967 
by Dossetor et al. These cases of premeditated donor-specific 
transfusion were clearly experimental. Moreover, although the 
animal work on which they were based was sound, extension of it to 
clinical transplantation was impractical for the majority of, patients. 
Donor-specific transfusion might be feasible for the small group with 
live prospective kidney donors, but the important issue clinically 
was the preparation for cadaveric transplantation of patients now 
being offered maintenance haemodialysis.
Although Dossetor et al (1967) claimed that profusely transfused 
patients did better, no direct relationship between non-donor blood 
and allograft outcome was found in other studies (Morris, Ting and 
Stocker, 1968). Rather, the deleterious effects of sensitization by 
transfusion were emphasised (Kissmeyer-Nielsen et al, 1966).
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At the same time, animal work continued to point to an 
association between previous exposure to donor cells and allograft 
survival (Zimmerman et al, 1968; Ockner, Guttmann and Lindquist,
1970). Experiments in rats using donor-strain pretreatment led 
Fabre and Morris (19 72) to underline that "pregraft exposure to 
blood transfusion might not necessarily be harmful".
2. Clinical confirmation of the transfusion effect
It was against this background of laboratory experience marred by 
clinical misfortune that Opelz and Terasaki presented their evidence 
that third party (random donor) blood transfusion Was associated with 
improved renal allograft survival. In a series of papers over several 
years (1973, 1974, 1978), their multicentre retrospective analyses 
suggested that patients given whole blood or packed red cells, but not 
frozen cells, had improved graft survival to a degree dependent on the 
amount of blood received. For example, in a study of over 1300? 
cadaveric transplants, graft survival at one year was 42% for 
recipients who had never been transfused and 71% for those who had 
received more than 20 units of blood (Opelz and Terasaki, 1978).
The association between transfusion and graft survival was 
widely confirmed and deliberate policies of pretransplant transfusion 
implemented. Analysis of results in our own centre (Briggs et al,
1978) showed a striking difference in 1-year graft survival between 
untransfused recipients (28%) and patients given whole blood (77%).
Less clear, however, was how much and what type of transfusion would 
produce most benefit with least sensitization. Opelz, Graver and 
Terasaki (1981 a) took a relaxed view of the risks of sensitization
observing that only 3 of 331 patients studied prospectively formed 
cytotoxic antibodies to more than 90% of a random donor panel after 
up to 20 units of blood. In a third of patients the titre of 
antibody fell after further transfusion (Opelz et al, 1981 b).
On the grounds that matching of histocompatibility antigens of 
blood donor and recipient might reduce sensitization,. Nube et al 
(1983) gave transfusions matched at the A and B loci, and suggested 
this manoeuvre elicited less sensitization yet full advantage. If 
substantiated this finding would suggest that the mechanism of the 
transfusion effect is not dependent on antigen discordance at the 
A or B loci. The practical difficulties of adopting a policy of 
HLA-matched transfusion for all patients are likely to deter other 
centres from following suit unless more evidence in its favour emerges. 
Not surprisingly, the main aims in the formation of elective 
transfusion protocols remain to maximise graft survival and minimize 
sensitization.
3. Amount of blood required for the transfusion effect
Although Opelz and Terasaki (1978) and Fehrman (1982) suggested 
a direct dose-response relationship, Persijn claimed, initially 
retrospectively (Persijn et al, 1979) but later prospectively (Persijn, 
D ’Amaro and van Rood, 1984), that as little as one unit of blood was
enough to provide the benefit of transfusion, although not if blood
entirely depleted of lymphocytes were used.
This finding was attributed by Terasaki (1984) to crossreactivity 
among HLA antigens sufficient to allow blood from one donor to immunise 
to many. Terasaki's own group (Horimi et al, 1983) assessed the
benefit from transfusion of only one unit in terms of 10% 1-year 
graft survival, a figure estimated by Terasaki to be compatible with
' . # r ,  '
the effect of crossreactivity.
A number of different studies looked for the transfusion effect 
with intermediate amounts of blood. Frisk, Brynger and Sandberg (1982) 
(2 units), Feduska et al (1982) (1 to 5 units) and Horimi et al (1983) 
(up to 15 units) all found improved graft survival in transfused 
subjects. In numbers of patients too small to draw definitive 
conclusions, Sirchia et al (1982) described a trend towards lower 
graft survival in patients given, instead of three standard sized 
transfusions, three small aliquots of packed red cells (mean volume 
31 ml).
The enthusiasm of a particular centre for minimising elective 
transfusion may reflect its experience of sensitization. Also, 
proponents of a donor-specific mechanism for the transfusion effect 
might advocate exposure by transfusion to a wide range of alloantigens 
prior to transplantation of a kidney bearing antigen hopefully rendered 
familiar.: Advocates of a non-specific mechanism for the transfusion
effect might argue that there was no necessity to expose the recipient 
to more than a minimal range of antigens.
A. Timing of transfusion
i) Time interval between transfusion and transplantation
Both Werner-Favre et al (1979) and Hourmant, Soulillou and Bui-
Quang (1979) noted that transfusion within the three months prior to
transplantation conferred an advantage in cadaveric allograft survival.
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This also appeared to be the case in the 402 patients reported by 
Opelz (1985 a) who had been transfused only one unit of blood previously. 
No advantage in recent transfusion was seen in nearly 6000 patients 
in the same study who had had two or more transfusions.
ii) Influence of perioperative transfusion
Despite some suggestions that perioperative transfusion 
ameliorates transplant survival (Stiller et al, 1978; Williams et al, 
1980) there are several reports to the contrary (Feduska et al, 1982; 
Glass et al, 1982; Opelz 1985 a). However, Terasaki et al (1982) 
and Opelz (1985 a) did hint at benefit in perioperative blood for 
patients never previously transfused.
5. Blood components required
i) Experimental models
In the absence of a clearcut mechanism for the transfusion effect 
(see Chapter 5), trials of various blood components have been conducted 
in various species and strain combinations. Martin et al (1982) and, 
more recently, Wood and Morris (1985), gave purified blood components 
to rats one week before renal transplantation. Whole blood, 
erythrocytes, peripheral blood lymphocytes and platelets all prolonged 
graft survival; Martin et al found that macrophages and marrow mono­
nuclear cells, but not thymocytes or plasma, did so too.
ii) Platelets
For obvious reasons, the sort of study described above (i), is
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limited to experimental animals. However, there have been clinical 
trials of platelet transfusions in man. These have been based on 
observations in Rhesus monkeys. Oh and McClure (1982) suggested that 
platelets induced a low sensitization rate, possibly due to their lack 
of class II antigens. Findings in monkeys that platelets improved 
renal allograft survival without inducing cytotoxic antibodies (Borleffs 
et al, 1982) were not confirmed by Marquet et al (1983) in beagle dogs, 
nor by Chapman in man. Chapman et al (1985 a) detected no 
sensitization following platelet transfusion but the incidence of. 
rejection during the first week following transplantation was higher 
than would have been expected in unsensitized patients. Only 3 out of 
8 patients transfused only with leucocyte-free platelets were alive 
with a functioning graft at the time of writing, from which Chapman et al 
concluded that the platelet protocol had not stimulated the trans­
fusion effect.
Few other centres have sought to assess the value of platelet 
transfusion in renal transplantation. The Collaborative 
Transplant Study collected information on 36 patients transfused with 
platelets alone, and concluded that the six-month transplant survival 
rate of only 55% did not support Borleffs1 claim (Opelz 1985 a).
iii) Leucocytes
There is clinical evidence that leucocytes are needed for the 
transfusion effect in man. This is based on attempts to reduce 
leucocytotoxin production by administering frozen, filtered or 
stored blood. Freeze-thawing of blood has been shown to reduce the
mitogen response of potentially responsive cells, possibly by 
reducing their numbers rather than their efficiency (Knight and Farrant, 
1978).
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One-year graft survival rates given in 1974 by Opelz and 
Terasaki were 53% for patients transfused with packed red cells or 
whole blood, 32% for patients who had never been transfused, and only 
20% for patients who had received frozen cells only. Persijn et al 
( 1984) compared washed (classed as leucocyte-poor) and filtered 
(classed as leucocyte-free) red cells and found that while as few 
as one unit of leucocyte-poor blood enhanced graft survival, there was 
no evidence of any benefit from leucocyte-free transfusion.
Using a protocol involving storage for at least one week,
Light advocated blood storage. This idea centred on in vitro 
observations that storage led to loss of T but not B lymphocytes.
There would be fewer class I antigens on T lymphocytes to induce 
cytotoxins but plenty of class II antigens on B lymphocytes to induce 
transplant protection (Light et al, 1982).
Animal work has not contradicted these clinical observations.
Strom, So.ulillou and Carpenter(1977)have claimed that only cells capable 
of stimulating in mixed lymphocyte cultures can induce active en­
hancement of allograft survival in rats. Using a rat cardiac allograft 
model, Lauchart, Alkins and Davies (1980) showed allograft survival 
correlated with the percentage of B lymphocytes in the immunizing cell 
population. Recipients immunized with erythrocytes or T^enriched 
lymphocytes showed no significant graft prolongation.
6. Donor-specific transfusion
i) Live related donors
With blood transfusion no longer out of bounds, the earlier animal
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work on donor-specific transfusion began to be extended to man.
Although donor-specific transfusion might have been considered an 
unwarranted exercise in HLA-identical donor-recipient pairs, and 
an unjustified risk in one-haplotype-matched pairs with low 
reactivity in mixed lymphocyte culture, the position was different 
for pairs, with high reactivity. This group had been shown to have a 
poorer renal allograft prognosis by Cochrum, Salvatierra and Belzer 
(1974). The same researchers commenced a trial of donor-specific 
transfusion in this poor-risk group of donor-recipient pairs. The 
protocol used was that subsequently adopted in most later trials, 
and indeed in our own patients reported later in this volume; 200 ml 
of whole blood or packed cell equivalent was. administered at 2-weekly 
intervals on a total of 3 occasions. The results, compared to the 
historical control group, were excellent. 95% of the patients 
transplanted had functioning grafts at one year (Salvatierra et al, 
1980). :0ther centres reported similar findings (for example,
Takahashi et al, 1982; Leivestad et al, 1982; Mendez et al, 1982).
ii) Unrelated donors
As the practice tends to be to use only close, well matched, well 
motivated relatives as live kidney donors, experience of donor-specific 
transfusion between unrelated pairs is relatively limited. Newton and 
Anderson successfully transplanted two patients after transfusion of 
peripheral blood lymphocytes from their unrelated kidney donors (Newton 
and Anderson, 1973 and 1979). Both of two recipients reported by 
Ruzany et al (1983) suffered early graft loss although they had no 
evidence of pretransplant cytotoxins. The few cases reported by 
Sollinger et al (1984) and Bowen et al (1984) were less disastrous. 
Sollinger gave donor-specific transfusion accompanied by Azathioprine
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to 20 recipients. Unrelated donors consisted of 5 wives, 1 husband 
and 1 friend; there were also 9 two-haplotype-mismatch siblings and 
4 non-first-degree relatives. The only graft lost through rejection 
at the time of reporting was one from a mismatched sibling. Of 8 
patients transplanted by Bowen, one graft (from a husband) had been 
lost at the time of reporting. The total number of recorded cases of 
donor-specific transfusion from unrelated donors is still too small for 
definitive comment.
iii) Sensitization following donor-specific transfusion
The major problem encountered in Salvatierra’s initial trial 
(Salvatierra et al, 1980) was the familiar one of sensitization. With 
the donor-specific transfusion protocol 30% of the 145 transfused, 
subjects developed anti-donor lymphocytotoxins and were excluded 
from transplantation. This sensitization rate, much higher than that 
expected from third party blood (Opelz et al, 1981 a) was duplicated 
(Ettenger et al, 1983) in subsequent reports of donor-specific trans­
fusion, such as those mentioned above (i).
Moreover, continuing transfusion from the same donor may lead to 
even higher anti-donor sensitization, as shown previously by Ferrara 
et al (1974). Ferrara’s study involved matching normal subjects into 
62 donor-recipient pairs. Each recipient then received small aliquots 
of blood from the same donor at weekly intervals. Fifty recipients 
developed anti-donor cytotoxins although 5 lost them again after further 
transfusion. Comparison with standard donor-specific transfusion 
before renal transplantation must be tempered by the differences that 
blood was: administered more often, and to non-uraemic subjects.
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The development of anti-donor lymphocytotoxins has been regarded 
as the major immunological contraindication to transplantation.
Several workers have suggested that this oversimplifies the problem;
Some anti-donor cytotoxins produced after donor-specific transfusion 
may be compatible with good graft survival (Glass et al, 1985). It is 
also possible that donor-specific transfusion could induce deleterious 
antibodies other than conventional lymphocytotoxins.
Although it is known that antibodies to blood group ABO antigens 
are important in renal transplantation, antibodies to the Rhesus and 
several other blood group systems appear unrelated to graft survival, 
(Gleason and Murray, 1967). It has been suggested that rejection 
may be associated with antibodies to Lewis antigens, which are found 
not only on red blood cells but also on lymphocytes and in plasma 
(Oriol et al, 1980; Spitalnik et al, 1984)..
Gluckman et al (1982) reported the development of antibodies to 
granulocytes and monocytes following donor-specific platelet trans­
fusion, and suggested that the latter may be relevant to Cerilli’s 
work linking antigens on monocytes to those on renal vascular endothelium. 
Indeed, Cerilli has suggested that monocyte cross-matches should be 
performed routinely, since the monocyte expresses the "vascular 
endothelial cell antigen system", and T and B lymphocytes do not.
(Cerilli et al, 1985).
iv) Avoidance of sensitization using immunosuppression
An interesting approach to the avoidance of sensitization during
both donor-specific and third party transfusion has been the use of
Azathioprine or Cyclosporin. Studies advocating this idea include
those by Anderson et al,(1983); Glass et al (1983) and Raftery et al 
(1985).- 50
Indeed it was in 1973 that Newton and Anderson first reported the use 
of Azathioprine in this context. Most studies have been successful 
but small. Garovoy et al (1985), however, have now amassed 60 
patients given Azathioprine and 101 given donor-specific transfusion 
alone. Although Azathioprine appeared helpful in reducing the incidence 
of T warm antibodies in patients with minimal pre-existing sensitization, 
those with pre-existing sensitization or previous transplants had1 a 
sensitization rate around 30% as before (.Salvatierra et al, 1980).
v) Future of donor-specific transfusion
While the use of donor-specific transfusion is scientifically 
interesting, its • apparent advantage over third party transfusion 
may be obsolete with increasing use of Cyclosporin rather than 
Azathioprine as post-transplant immunosuppression. Recent data from 
the Collaborative Transplant Study show that in one-haplotype-matched 
live related donor transplantation the one-year graft survival rate 
is around 90%. This figure is irrespective of whether the recipient 
had received donor-specific or at least three units of third party 
blood (Opelz, 1985c). From this data Opelz concluded that there : was 
no advantage in donor-specific transfusion for haploidentical 
recipients.
7. Relevance of the transfusion effect outwith transplantation
"Although it is now generally accepted that blood transfusion may 
promote the survival of renal allografts in patients treated with 
immunosuppressive drugs, the possibility that it may also modify the 
response of other hosts to other immunological stimuli has been litte 
considered". So wrote Woodruff and van Rood in 1983, introducing
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a series of parallels between the transfusion effect and clinical 
situations outwith transplantation.
Woodruff and van Rood posed the question whether reports of 
acquired immune deficiency in haempphiliacs (Menitove et al, 1983) 
could be explained by repeated administration of blood products in the 
absence of a primary infective agent. The impact on the immune system 
of clotting factor preparations is discussed further in Chapter 13.
They questioned whether the purported benefits of plasma exchange 
in autoimmune disease (reviewed by Shumak and Rock, 1984) were due 
to replacement with plasma rather than removal of immune complexes 
or autoantibody, and they touched on the apparent effectiveness of 
intravenous gammaglobulin preparations in the management of idiopathic 
thrombocytopenic purpura (Imbach et al, 1981, Schmidt et al, 1981).
Another controversial area discussed was the relation between 
blood transfusion and tumour growth. Evidence that patients on renal 
replacement therapy have an increased incidence of neoplasm has not 
been accompanied by evidence on the relation with blood transfusion 
(Halpert et al, 1985; Hanto et al, 1985; Sheil et al, 1985).
There have been persistent, but poorly controlled, claims that 
blood transfusion promotes tumour growth. Francis and Shenton (1981) 
found that transplanted experimental sarcoma in rats grew more rapidly 
in animals previously given allogeneic blood that in animals transfused 
with no or syngeneic blood. It has been claimed that the prognosis of 
colonic cancer is worsened if the patient is given blood (Burrows and; 
Tartter, 1982; Blumberg, Agarwal and Chuang, 1985). Despite claims 
that transfused and untransfused subjects were well matched, it would
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still seem likely on clinical principles that patients with more^ 
advanced disease at the time of presentation are more likely to require 
transfusion.
Mo f if at and Sunderland (1985) came up with a similar trend on 
retrospective analysis of patients with renal adeno-carcinoma. However, 
none of these reports does more than suggest that the association 
between blood transfusion and tumour growth is worth pursuing.
Woodruff and van Rood (1983) stressed the need for collection of 
more data to explain the relationship between these various, phenomena.
The experiments reported later in this volume deal not solely with 
blood transfusion in transplantation, but also with the impact on the 
immune system of exposure to other alloantigenic material, including 
blood products.
Not discussed by Woodruff and van Rood (1983) were attempts to 
adapt the transfusion effect to the management of pregnancy in women with 
recurrent spontaneous abortions. Immunization with paternal (Mowbray 
et al, 1985) or third party leucocytes (Taylor and Faulk, 1981) has been 
associated with a few successful pregnancies.
Beer et al (1981) suggested that couples with recurrent abortions 
had an increased frequency of sharing of HLA antigens. Although this 
finding Was disputed by Jeannet et al (1985), such antigen sharing 
might reduce the likelihood of production of maternal serum factors 
reducing her immune response against the fetus (Rocklin et al, 1976; 
Stimson, Strachan and Shepherd, 19 79; Power et al, 1983 a and b).
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In contrast, in renal transplantation HLA antigen sharing with 
neither blood (Nube et al, 1983) nor kidney (Opelz, 1985b) appears to 
be detrimental. It remains to be seen whether the transfusion effect 
can be extrapolated to pregnancy, and to the other situations mentioned 
in this section.
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CHAPTER 5
THE MECHANISM OF THE TRANSFUSION EFFECT ON RENAL ALLOGRAFT SURVIVAL
The purpose of this chapter is to review some of the mechanisms 
which have been suggested. Irrespective of the passion with which 
these may initially have been proposed, none is unequivocally 
established and few are mutually exclusive.
X. Prolongation of time on dialysis
This indirect mechanism for the blood transfusion effect was 
based on the observations that:
a) the number of units of blood given for therapeutic reasons 
increases with time spent on dialysis (Guttman, 1978)
b) elective blood transfusion leads to the chain of sensitization, 
exclusion from rapid transplantation, hence inadvertent 
prolongation of uraemia (Cheigh et al, 1981)
c) uraemia itself is immunosuppressive; long periods of it may
be more so (Keane and Raij, 1983).
Watson et al (1981) observed that graft survival increased and 
cell-mediated immunity decreased with time on dialysis but did not 
separate fully the effects of dialysis time and transfusion. However, 
it has been argued that the effect of transfusion is independent of 
that of uraemia, on the grounds that the transfusion effect is seen
most clearly in the first three months post-transplant and the effect
of dialysis time is spread over years (Terasaki et al, 1982; Bucin 
et al, 1984; Gilks et al, 1985).
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2. Selection of "good risk" patients
i) Immunological selection
Challenging potential recipients with donor antigens in blood 
could lead to the development of cytotoxins to preclude transplantation 
of unsuitable donor-recipient pairs. This selection effect could 
apply to either donor-specific or third party transfusion (Salvatierra 
et al, 1980; Terasaki et al, 1982). The evidence for or against 
this hypothesis is confusing.
In the view of Opelz et al (1981 a) patient selection was not the 
mechanism of the transfusion effect, on the arithmetic ground that the 
degree of improvement in graft survival could not be explained by the 
small number of recipients sensitized by transfusion. Fewer than 30% 
of the patients in this study developed any cytotoxins at all. At the 
other extreme, of course, is the 30% sensitization rate quoted for 
donor-specific transfusion (Salvatierra et al, 1980).
Also- against this hypothesis is the suggestion that removal of 
cytotoxic antibodies may enable successful transplantation across a 
previously positive cross-match. Taube et al. (1984) reported that 
plasma exchange and immunosuppression removed and prevented the 
resysnthesis of HLA antibodies enabling successful transplantation 
in 4 out of 5 highly sensitized patients. Using a comparable 
manoeuvre, Hillebrand et al (1985) noted only a transient fall in 
titres of cytotoxic antibody.
There is no doubt that cytotoxic antibodies, whether induced by 
transfusion, transplantation or pregnancy lead to an increased risk of
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graft loss (Opelz (1985 b) and accumulation of highly sensitized 
individuals on transplant waiting lists (Cheigh et al, 1981). The 
idea that these patients are in some way intrinsically untransplantable 
has been challenged recently by the United Kingdom Transplant Service 
(Bradley, Klouda and Ray, 1985). Patients with cytotoxic antibody 
reactive against more than 85% of a panel have been transplanted ,
against a negative cross-match with regard for HLA matching sub­
sidiary, and so far with moderate success.
Overall, it seems unlikely that selection is wholly responsible 
for the transfusion effect, although may well contribute to it.
ii) Selection for recipients1 original renal disease
Before elective transfusion became widespread, a plausible 
explanation for the transfusion effect could have been the effect of 
the recipient’s type of disease on his therapeutic blood requirement. 
Considering the mechanism of the transfusion effect, Opelz et al 
(1981 a) excluded a role for the original renal disease. Although 
the supporting data came from 33 centres, there were relatively few 
patients:(174) in broad diagnostic categories. There is no evidence 
that the recipient’s original disease affects graft function, except 
in the small number of patients who develop recurrent glomular disease 
or have multisystem disease (Brunner et al, in press).
3. Iron overload
Raised serum ferritin levels, as indicators of iron overload, have 
been correlated with previous transfusion (Keown, Stiller arid Descamps- 
Latscha, 1984) and with various indices of depressed immune function.
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In haemodialysis patients Waterlot et al (1985) found that raised 
serum ferritin levels were associated with an increased incidence of 
clinical infection and with diminished neutrophil function (measured 
in vitro by phagocytosis). Haemoglobin, ferritin and ferric ions can 
inhibit the lymphocyte response to mitogens and alloantigens (Matzner 
et al, 1979; Keown and Descamps-Latscha, 1983)., possibly through 
inhibition of interleukin production (Keown and Descamps-Latscha,
1983). Lustbader, Hann and Blumberg (1983) claimed that response to 
.hepatitis B vaccine correlated inversely with serum ferritin 
concentration.
The relevance of these findings to clinical transplantation was 
first suggested by results of Stark and Dwyer (1959), that injections 
of haemoglobin prior to skin grafting in rabbits prolonged graft 
survival.. The possibility that the immunosuppressive effect of blood 
transfusion might be erythrocyte-mediated was raised by Keown and 
Descamps (1979), who suggested that phagocytosis of altered erythrocytes 
inpaired subsequent macrophage function. In the later view of Keown 
et al (1984), this idea was overstated by de Sousa (1983), who 
attributed the transfusion effect to iron. While iron overload may 
contribute to non-specific immunosuppression after blood transfusion, 
its importance is undermined by the evidence for the presence of 
immunosuppression after small quantities of blood and for the absence 
of it after leucocyte-free red cells (Persijn et al, 1984).
4. Viruses transmitted by blood
Kirchner and Braun (1982) suggested that pretransplant transfusion 
might initiate or boost cell-mediated immunity against transmitted 
cytomegalovirus. This could be beneficial following transplantation,
when cytomegalovirus infection may be associated with serious super- 
infection and deterioration in renal function (Rubin and Tolkoff- 
Rubin, 1984). Against this hypothesis is the failure of Takasugi 
et al (1983) to demonstrate increased titres of anti-viral antibody 
after transfusion to an extent sufficient to explain the transfusion 
effect on graft survival.
The role of other viruses has come into prominence with the rise 
of the Acquired Immunodeficiency Syndrome(AIDS). Transmission of
the newly categorized T cell leukaemia viruses by transfusion has been 
shown (Feorino et al, 1984), but there is no seroepidemiological 
evidence to link these with the transfusion effect on allograft 
survival. Similarly, there has been considerable work on Epstein- 
Barr virus and its relationship to B cell lymphoproliferation, 
accentuated in renal transplant recipients (Hanto et al, 1985).
Reinherz et al, 1980 b) showed that T lymphocyte subsets could be 
deranged in infectious mononucleosis. This area is discussed 
further in Chapter 14 . The contents of the rest of this volume 
reflect the author’s view that the immunosuppressive effect of 
transfusion predisposes to rather than results from viral infection.
5* Alteration of T lymphocyte subsets
The availability of monoclonal antibodies to a variety of T cell 
surface antigens has led to proliferation of studies on T cell subsets, 
in disease (Krensky and Clayberger, 1985). T helper cells, necessary 
to the initiation of the immune response to the allograft 
(i3ee Chapter 2) , are broadly defined by the 0KT4 antibody, and T 
suppressor cells by the 0KT8 antibody. The ratio of 0KT4 positive 
to 0KT8 positive lymphocytes has been used as an estimate of the
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relative numbers of helper and suppressor T lymphocytes. Changes in 
lymphocyte subpopulations in blood and kidney
after renal transplantation, recently reviewed by Wood, Thompson and 
Carter (1984), have not borne out the use of the T4:T8 ratio for 
immunological monitoring of renal allograft recipients.
The relation between blood transfusion and T cell subsets has 
been investigated by several workers. Mohanakumar et al (1983) showed 
that in 8 patients awaiting renal transplantation,the T4:T8 ratio 
fell from 1.9 to 0.9 (mean values) after blood pooled from 5 donors. 
Kaplan et al (1984) noted reduction in the T4:T8 ratio in non-uraemic 
subjects with sickle cell anaemia who had received multiple blood 
transfusions.
Although these findings are interesting, the lack of specificity 
of the T4:T8 ratio detracts from its contribution to elucidating the 
transfusion effect (Krensky and Clayberger, 1985). Moreover, in a 
study reported by Kerman et al (1982) patients who had received more 
than 5 units of blood showed greater suppressor cell function in mixed 
lymphocyte culture than those who had received less blood, but had 
equivalent proportions of 0KT8 positive cells.
In the initial enthusiasm for its use, the importance of the T4:T8 
ratio has been overstated in the literature.
6. Clonal deletion
Terasaki (1984) proposed a hypothesis which, he claimed, "accounts 
for most .of the known facts about the transfusion effect". The 
evidence marshalled was attractive if not uniformly consistent with
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findings from other groups (Burlingham et al, 1985 a; Streilein,
1985). Using polyclonal T cell activators in mice, Moller (1985) 
could demonstrate no cytotoxic anti-self T cells, and gave qualified 
support to the idea that self-tolerance, and possibly transplant 
tolerance, could be mediated by clonal deletion.
Terasaki’s hypothesis is that transfusions immunize patients 
against a wide range of histocompatibility antigens. On second 
exposure, this time to antigens with the allograft, a vigorous 
anamnestic response occurs and clones of reactive cells proliferate.
If immunosuppressive therapy is introduced at this point, the 
proliferating clones are preferentially destroyed, and the host cannot 
reject the graft.
If this theory is correct, the practical consequence in patient 
management is that immunosuppression should be introduced when reactive 
clones are proliferating, that is delayed until several days after 
transplantation. Terasaki suggested that the most appropriate therapy 
at that point would be cytotoxic monoclonal anti-blast antibodies.
7. Non-specific suppression of cell-mediated immunity
Evidence for non-specific suppression of cell-mediated immunity . 
following- transfusion has been presented by a number of workers in 
uraemic and, to a lesser extent, non-uraemic subjects. This topic is 
discussed'in more detail in Chapter 10.
Dinitrochlorobenzene skin testing has been used as an in vivo 
correlate of cell-mediated immunity, diminished response being associated 
with previous blood transfusion and improved allograft survival (Watson
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et al, 1979 and 1981; Russ et al, 1984). There have been several 
studies incorporating the effect of transfusion on the mitogen response 
in vitro (for example, Fehrman and Ringden, 1981; Jeannet et al, 1982; 
Klatzmann et al, 1983 a; Smith et.al, 1983; Tait et al, 1984).
Previous work is discussed more fully in relation to the author’s 
results with mitogen stimulation in Chapter 12 i
8. Induction of non-specific serum suppressor factors
i) Alpha-2-macroglobulin
The biochemical and immunological properties of alpha-2-macro- 
globulin have been reviewed by James (1980) and are discussed further 
in Chapter 16. The first demonstration of the immunosuppressive 
properties of alpha-2-macroglobulin was by Kamrin (1959), who found' 
that its administration led to prolonged survival of skin grafts in 
mature, non-littermate rats. Subsequent reports both confirmed and 
contradicted these findings (Mowbray, 1963; Davis and Boxer, 1965).
In 19 79, Proud, Shenton and Smith claimed an association between 
the presence in pretransplant plasma of alpha-2-macroglobulin and renal 
allograft survival, and demonstrated prolongation of cardiac allograft 
survival in rats given alpha-2-macroglobulin. They speculated that 
alpha-2-macroglobulin production was increased by transfusion. These 
findings have not yet been confirmed.
ii) Pros taglandins
Lenh'ard, Gems a and Opelz (1985 a) have suggested that blood 
transfusion induces the release of prostaglandin ££, which causes
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immunosuppression through activation of T suppressor cells,
iii) Unidentified soluble suppressor substances
Non-specific soluble suppressor factors have been described 
following transfusion, primarily in connection with the specific 
suppressor cell systems discussed later in this chapter (Sasportes 
et al, 1980), and therefore mentioned here for completeness only.
9. Suppressor cell induction by transfusion
i) Non-specific suppressor cells
An increase in non-specific suppressor cell activity following 
transfusion of 2 units of packed red cells in 15 dialysis patients 
was recorded by Smith et al (1983). Suppressor cell activity, in 
this case assumed by a method involving suppression of concanavalin 
A-induced T cell biastogenesis, reached a peak three weeks after 
transfusion and then tailed off towards 20 weeks. Using similar 
methods, Lenhard et al (1982) and Tait et al (1984) also showed 
increased suppressor cell activity after transfusion, although Tait 
emphasised, appropriately, the heterogeneity of the response in his 
patients.
Using cell surface markers, Sasportes et al (1980) showed the 
presence of suppressor T lymphocytes in mixed lymphocyte culture, 
when the cells had been previously hyperimmunized against the DR 
incompatibilities depicted in the culture. These cells were 
independent of cytotoxic effectors and produced soluble suppressor 
factors. The suppressor supernates inhibited autologous cells in
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mixed lymphocyte culture. They also to a lesser extent inhibited 
allogeneic cells, leading Sasportes to suggest that both specific and 
non-specific suppressor substances were present (Sasportes et al, 1981).
Data from Lenhard et al (1982) led them to propose that immuno­
suppression after transfusion occurred in two phases. In the first 
fortnight immunosuppression was non-specific and mediated by monocytes. 
Afterwards there was an increase in T suppressor cell activity.
Smith et al (1983) failed to correlate increased suppressor cell 
activity with renal allograft survival, although by the time of 
transplantation suppressor cell activity would, from their data, have 
reverted towards normal. Agostino, Kahan and Kerman (1982) did find 
that graft outcome correlated with the level of non-specific inhibition 
of mixed lymphocyte culture by suppressor lymphocytes produced after 
transfusion. Goeken et al (1982), while demonstrating depression of 
mixed lymphocyte reactivity following transfusion in 7 of 11, patients, 
could not show concomitant suppressor cell production in co-culture 
with pre-transfusion cells.
Most recently, Klatzmann et al (1983 a and b; 1984 a) in a series 
of papers claimed the production of non-specific suppressor cells after 
transfusion. Eight out of 21 patients in the first study quoted showed 
a decrease in mixed lymphocyte reactivity after one transfusion, and 
another 5: after up to 3 transfusions. Several other patients showed 
fleeting decreases. Most reactivities were returning towards normal 
after three months.
The suppressor cells found by Klatzmann were T lymphocytes and
acted through soluble mediators which he found to be specific for the
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stimulating cells and restricted to the responder lymphocytes. The 
nature of. the suppressor factors was not established and Klatzmann did 
not speculate on the mechanism of suppressor cell production following 
transfusion. No correlation was found between suppression of mixed 
lymphocyte reactivity and suppression of cell-mediated lympholysis, 
which was also detected following transfusion, in a few subjects.
(It should be added that suppression of cell-mediated lympholysis 
following blood transfusion has not been a universal finding (Goeken 
et al, 1982; Leivestad et al, 1982)).
ii) Donor-specific suppressor cells
Donor-specific T suppressor cells inhibiting the mixed lymphocyte 
reaction in man were demonstrated by McMichael and Sasazuki (1977) •
The patient was a woman who had had 10 children by the same man. Her 
lymphocytes were unresponsive to lymphocytes from the father, and could 
suppress the response of HLA matched control lymphocytes to paternal 
cells. These effects were accentuated when her lymphocytes were 
enriched for T cells and diminished when enriched for B cells. The 
same group later suggested that identity at the HLA-D locus between 
suppressor and responder was required (Engleman et al, 1978).
The presence of donor-specific suppressor cells has also been 
claimed in patients with long-term renal allograft tolerance (Liburd 
et al, 1978; Charpentier et al, 1981; Goulmy et al, 1981). There is 
a considerable body of evidence to support this from animals (for 
example, Dorsch and Roser, 1977; Hendry et al, 1979; Marquet 
et al, 1982; Batchelor, Philips and Grennan, 1984; Hall, 1984; 
Barber, Hutchinson and Morris, 1984).
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There is less evidence to link the production of these suppressor 
cells with blood transfusion, an explanation for the transfusion effect 
proposed by Dausset and Contu (1981). An in vitro model was discussed 
by Sheehy, Mawas and Charmot (1979). Specific inhibition of the 
human mixed lymphocyte response was achieved with autologous lymphocytes 
already primed with cells from the other donor.
In vivo stimulation for this type of experiment has been provided 
by donor-specific transfusion of prospective recipients of kidneys from 
live related donors. Only a handful of the patients described by , 
Cochrum et al (1981) developed reduced responsiveness towards donor 
cells in mixed lymphocyte culture following donor-specific transfusion. 
Seven out of 10 patients studied by Leivestad et al (1982) did show 
donor-specific decreased responsiveness, but this bore no relation to 
the clinical course following transplantation from the same donor.
Half of this group also showed increased d.onor-specific cell-mediated 
lysis but again with no association with transplant outcome.
More animal work is available to show the induction of specific 
suppressor lymphocytes after transfusion. Maki et al (1982) used a 
mouse skin allograft model and showed antigen-specific suppressor cells 
following transfusion. In rats studied by Marquet et al (1982) a 
single transfusion was followed by the production of donor-specific 
suppressor cells. Transferred to a secondary host, spleen cells 
with suppressor activity could delay rejection of cardiac allografts 
culled from the same strain as the blood donor. There was also the 
suggestion of a weaker, non-specific component to the suppressor cell 
response to transfusion. Again in a rat cardiac allograft model,
Hall (1984) found specific splenic suppressor cells after transfusion.
In a rat skin graft model, Lenhard et al (1985 b) found that a 
planned transfusion protocol induced strong specific and weak non­
specific suppressor cell activity. Anti-donor cytotoxins appeared 
in increasing titres after up to three transfusions. With numbers of 
transfusions increasing up to a total of fifteen the antibody titres 
then fell. This humoral hyporeactivity persisted in spite of 
rechallenge with antigen and could be transferred by spleen cells to 
syngeneic untransfused animals. Marquet et al. (1982) made the note­
worthy comment that, although in inbred rats specific suppressor 
cells might be prominent in the blood transfusion effect, non-specific 
suppression might be more important in an outbred species like man.
10. Production of Immune complexes
Antigen-antibody complexes have been linked to the induction of 
immunosuppression. They may bind to Fc^-receptors to induce T 
lymphocytes to induce soluble suppressor substances (Greene, Fleisher 
and Waldmann, 1981. ) in the context of experimental enhancement, 
Hutchinson and Zola (1977) have suggested that antigen-reactive cells 
are specifically depleted by interaction with antigen-antibody complexes 
and subsequent opsonization. Previous evidence in man to link 
complexes with either allograft survival or blood transfusion has been 
thin,, and there is certainly no substantial evidence to link complexes 
to the transfusion effect. Carpentier found a correlation in 50 
patients between allograft survival and the detection of complexes 
before transplantation (Carpentier et al, 19-82). No association
with transfusion was shown. Ettenger (1982) showed complexes detected 
by a similar method in the serum of transfusion recipients. In 
contrast, Keusch et al (1984) found no correlation between complexes 
and either.prior transfusion or subsequent allograft survival.
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11. The production of beneficial antibodies
Numerous explanations for the blood transfusion effect have im­
plicated the production of some sort of beneficial antibodies. The 
concept that antibodies could be other than harmful owes much to 
the studies of passive graft enhancement by administration of allo- 
antibody, as reviewed by Morris (1980). Morris used the term 
passive enhancement to denote suppression of the immune response by 
passively administered donor-specific alloantibody .(tn contrast to 
active enhancement where immunosuppression is achieved by prior 
administration of antigen, and possibly mediated by antibody).
Attempts to achieve passive enhancement of renal allograft survival 
in higher animals and man have not met with the conspicuous success 
of rodent models (Morris, 1980).
i) Lymphocytotoxins directed against B lymphocytes
Iwaki et al (1978) attributed the transfusion effect to panel-
o
reactive B lymphocytotoxms of IgM class and detected at 4 C only.
A weakness of this paper was that transfusion details were not supplied. 
More solid results were provided by d’Apice and Tait (1979). Thirty 
out of 78 recipients of cadaver renal transplants had a positive B 
cell cross-match, a finding associated with improved graft outcome.
All patients had been transfused but the group with a positive B cell 
cross-match had received significantly more blood.
Other centres did not concur (Ting and Morris, 1979) and in a 
follow-up report d'Apice and Tait (1980) concluded that a positive B 
cell cross-match was more likely to be a consequence of transfusion 
independent of graft enhancement. Only 14 out of 34 cross-match-positive
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sera had anti-DR specificity and there was marked heterogeneity of 
response ;to temperature variation and platelet absorption. On these 
grounds the authors discounted the parallel drawn in the previous study 
with enhancement of rodent allografts by antibodies with anti-class 
II specificity (Davies and Alkins 1974).
Ettenger et al (1982) confirmed the production after transfusion 
of cold B lymphocytotoxins, but in too small a proportion of patients 
to account for the transfusion effect. Mohanakumar et al (1985) 
found that pretransplant sera from patients with a positive B cell 
cross-match and a successful transplant appeared to define membrane- 
bound immunoglobulins rather than DR antigens, although the relation 
to previous transfusion was not established. The recent suggestion by 
Chapman et al (1985 b) that only autoreactive B lymphocytotoxins are 
associated with satisfactory graft outcome emphasise the failure of 
this type of antibody to explain the transfusion effect.
ii) Anti-idiotype antibody
All antibody molecules share "constant" regions (the Fc portion) 
which do not contribute to antigenic specificity. Parts of immuno­
globulin molecules associated with the antigen-combining region (the 
F(ab' ) 2  portion) can serve as antigenic determinants and are known as 
idiotypes. Antibody can be produced against such idiotypes and is 
known as anti-idiotype antibody.
Anti-idiotype antibody reacts not just with antibody but with T 
and B lymphocytes with the same idiotype expressed on the cell membrane 
(Roitt et al, 1981). Jerne (1974) postulated that idiotypic inter­
actions unified the cellular and humoral components of the immune system.
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This "network" regulated the immune system and was disturbed only when 
antigen was introduced. The concept of anti-idiotypic tuning of the 
immune system has been examined in the context of autoimmune disease 
(Plotz, 1983; Cooke, Lydyard and Roitt, 1984). Manipulation of the 
idiotypic, network has been advocated as a clinical tool (Olson, Wagner 
and Leslie, 1982).
The relevance of the idiotypic network to transplantation was 
suggested initially by studies of enhancement. Hart et al (1972) 
suggested the use of anti-idiotype antibody for specific immunosuppression 
on the basis of experiments in mice. Although unable to achieve 
enhancement of rat renal allografts by anti-idiotype antibody alone,
Stuart et al (19 76) claimed that treatment with donor spleen cells and 
alloantibody yielded prolonged graft survival in conjunction with the 
appearance of anti-idiotype antibody and reduction in cell-mediated 
immunity. The mechanism suggested was specific interaction of anti­
idiotype antibody with T cell surface receptors preventing the initiation 
of the immune response. Binz and Wigzell (1976) claimed the induction 
of specific tolerance to skin grafts when rats were autoimmunized against 
their own idiotypes. Stuart, Fitch and McKeam (1982) later showed 
some prolongation of rat renal allograft survival by passive 
administration of recipient strain anti-idiotypic antibody raised 
against an anti-class I hybridoma monoclonal antibody.
A single report of anti-idiotype antibody in a patient with a 
long-surviving renal allograft came from Miyajima et al (1980). The 
patient’s serum suppressed the mixed lymphocyte reaction between cells 
from the patient and from the kidney donor. The factor causing 
suppression was removed from serum by rabbit anti-human IgG, and found 
to have a molecular weight of 7S, as expected for IgG.
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Singal, Joseph and Szewczuk (1982) proposed that blood trans­
fusion led to the production of anti-T cell idiotype antibodies which 
enhanced allograft survival. The same group have accumulated a 
number of'pieces of evidence in favour of this hypothesis. They 
duplicated Miyajima's report using third-party cells with the same 
HLA-B type as the donor (Singal et al, 1982). They associated serum 
anti-idiotype activity with previous transfusion in 17 uraemic and 
2 non-uraemic subjects (Fagnilli and Singal, 1982; Singal, Fagnilli 
and Joseph, 1983), and again used the molecular weight of the suppressor 
factor to claim that it was IgG.
In human renal transplantation, Burlingham et al (1985 a and b) 
have shown the development after donor-specific transfusion of serum 
factors which specifically inhibit the donor-recipient mixed lymphocyte 
reaction. Their conclusion that IgG is responsible is based on 
absorption studies using Protein A. Reed et al (1985) have also 
claimed that specific anti-idiotype antibody develops after donor- 
specific .transfusion ; the same group claimed that pregnancy sera 
contained specific anti-idiotypic autoantibody that reacted with T 
cell receptors for alloantigens (Suciu-Foca et al, 1985). In contrast, 
after transfusing rats, Lenhard et al (1985 c) found suppressor cells 
and failed to find anti-idiotype antibody. After transfusing renal 
patients, Takeuchi et al (1985) found both, and claimed on the strength 
of 4 patients that they were related. Further, in a total of 12 
patients they claimed an association between post-transplant rejection 
episodes and failure to produce anti-idiotype antibody after pre­
transplant transfusion.
The weaknesses of all these studies are small numbers, heterogeneity 
of recipient response to transfusion and failure to show a definite
71
relationship to graft survival.
iii) Anti-FCab'^ antibody
One group has looked at renal allograft survival in relation to 
pretransplant anti-F(ab*) ' antibodies (Chia et al, 1982; Horimi et al, 
• 1 9 8 2 ) Using the same method, Nasu et al (1980) .had found 20% of 
normal subjects to be antibody positive. Although the initial report 
on 253 patients looked as though antibody might be associated with 
improved;graft survivalC Horimi et al, 1982), the association only 
just reached statistical significance in the follow-up with 429 patients. 
Moreover, stratification of the patients for previous transfusions did 
not support an association between antibody and the transfusion effect 
(Chia et al, 1982). The authors considered also that lack of 
specificity precluded an anti-idiotype phenomenon.
iv) Fcfr-receptor blocking antibody
In a series of studies, MacLeod and her colleagues have provided 
evidence that non-cytotoxic antibodies, detected by '.their capacity to 
block the Fc^-receptor on B lymphocytes, develop following blood 
transfusion (MacLeod et al, 1982b, 1983), are HLA-1inked (MacLeod 
et al, 1985 a) are alio- rather than autoantibodies (MacLeod et al,
1985b) and are associated with human renal allograft survival (MacLeod 
et al, 1982, a and b). The background to these studies is discussed 
more fully in the next chapter.
12. Conclusions
The uniformity of the association between blood transfusion and
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renal allograft survival is not matched by the theories to explain the 
phenomenon. Marrying two of the major current schools of thought, 
van Rood (1983) has suggested that transfusion initially evokes non­
specific suppressor cells which suppress production of antibody against 
class I antigens. Then anti-idiotype antibodies form and prevent 
activation of T lymphocytes by HLA-specific antigen. Despite intense 
research effort, no single convincing explanation for the transfusion 
effect has been found. A combination of factors may prove responsible. 
The last word again goes to Caine, who commented in 1984 that "numerous 
speculations have been advanced to explain the phenomenon, indicating 
the degree of our ignorance".
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CHAPTER 6
Fc#-RECEPTORS AND RENAL TRANSPLANTATION
1. Distribution of FcV-receptors in peripheral blood
Surface receptors for the reacted Fc portions of IgG, or FcY- 
receptors, are present on a variety of cell types (Unkeless, Fleit 
and Mellman, 1981). Around 25% of peripheral blood lymphocytes carry 
FcT-receptors (Clements and Levy, 1978), including almost all B 
lymphocytes and K cells (Sandilands et al, 19 78 a and b) and the so- 
called T'K subfraction of the T lymphocyte population (Moretta etal, 
1979). Most, but not all, Fctf-receptor bearing T lymphocytes belong 
to the suppressor fraction as now defined by functional assays and 
monoclonal antibodies (Reinherz et al, 1980 a ; Callard et al, 1981). 
Normal human polymorphs, monocytes and platelets express Fctf-receptprs 
(Janossy, 1981).
There appears to be marked variation in cell-bound FcY-receptors. 
Not only may there be genetic polymorphism (Kaneoka et al, 1983; Tax 
et al, 1985), but receptors on different cell types may vary in 
molecular weight (Cohen, Sharp and Kulczycki, 1983), avidity, for IgG 
(Sandilands et al, 1978 a) and antigenicity (Winfield, Lobo and 
Hamilton, 1977; Cunningham-Rundles et al, 1980).
There have also been reports of the receptor on neoplastic . 
lymphoid cells. Ferrarini et al (1975) reported its presence on B 
cells from around half of patients with chronic lymphatic leukaemia 
and Habeshaw et al (1979) reported it in 10% of patients with non- 
Hodglcins :lymphoma.
Not all Fc^-recep tors are restricted to the cell surface. Some
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may elute spontaneously and be found in cell-free culture super­
natants (Lethibichthuy et al, 1980) and normal human serum (Reid et al, 
1983).
2. FcX -receptors and the immune response
FcV^receptors, either alone or in combination with macromolecular 
antigen:antibody complexes, have been attributed various roles in 
immune modulation (Fridman et al, 1981; MacLean et al, 1984). Fc)f- 
receptor bearing T lymphocytes may suppress T-dependent B cell 
differentiation (Moretta et al, 1979). Soluble Fctf-receptors, 
derived possibly from suppressor T lymphocytes, may impair antibody 
synthesis in vitro, (Lethibichthuy et al, 1980), and may restore 
receptor function on T cells in vivo following modulation of previous 
receptors by immune complexes (Samarut and Revillard, 1980). Recent 
evidence suggests that lymphokines released by activated T cells lead 
to increased Fcfl-receptor expression on antigen-presenting cells, and 
an augmentation control loop on T cell activation by the interaction 
between existing antibody and the monocyte FcV-receptor (Chang, 1985).
In the field of renal transplantation, Charpentier et al, (1983),
showed the existence, in patients with long-surviving allografts, of ;
T cells which specifically suppressed the proliferative response of
recipient to donor cells, and expressed both the 0KT8 antigen and 
%
FcV -receptor.
Fctf-receptors on macrophages are responsible for clearance of 
immune complexes by the reticuloendothelial system (Chang, 1985) .
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3. Fc^-receptor blocking'antibody arid the immune response
Considering the evidence for an immunomodulatory function of the 
receptor population (s), it is perhaps not surprising that antibodies 
blocking the FcK-receptor have been implicated in the immune response. 
Antibody to fluid-phase receptor could lead to formation of 
circulating immune complexes with consequent activation of suppressor 
mechanisms (Moretta et al, 1979) and/or saturation of receptor-mediated 
reticuloendothelial system clearance (Imbach et al,- 1981). Antibody 
blocking cell-bound Fc^-receptors has been shown to trigger a variety 
of suppressor mechanisms beyond simply the elution of antibody-receptor 
complexes into the serum (Daeron and Fridman, 1985).
Aggregated IgG may act on the FcV-receptor similarly to immune 
complexes (Dickler and Kunkel, 1972). It is thought that only the Fc 
portion of the antibody molecule can block the receptor directly.
Reports of blocking by FCab’^  fragments (Soulillou et al, 1978;
MacLeod et al, 1982 b) may be explained by co-capping and stripping of 
the receptor (Sarmay et al, 1979).
The finding by Ritz and Schlossman (1982),confirmed by Roberton 
et al (1984), that human complement cannot lyse effectively cells 
coated with mouse monoclonal antibody, suggests that FcK-receptor 
mediated-reticuloendothelial clearance may be the major mechanism 
for removal of cell-antibody complexes in the therapeutic use of 
monoclonal antibodies. Saturation of FcY-receptor-mediated clearance 
mechanisms has been mooted as the mode of action of pooled immuno­
globulin in suppressing autoimmune disease (Imbach et al, 1985),although 
alternative mechanisms are anti-idiotypic suppression of autoantibodies 
(Sultan et al, 1984) or enhanced suppressor T cell function (Delfraissy 
et al, 1985). 76
4. Fc^-receptor blocking antibody in renal transplantation:
the background
The relevance to transplantation of Fc^(-receptor blocking anti­
body was first raised in the early 1970s in connection with studies
of passive enhancement of rodent renal allografts. Subsequent 
exploration of this topic has been based on work linking:
i) passive enhancement with the Fc portion of IgG
ii) Fctf -receptors with class II antigens
iii) passive enhancement with antibodies against class II antigens
i) The Fc portion in passive enhancement
There is considerable evidence that the mechanism of passive 
enhancement is Fc-dependent, and, by implication, dependent on the inter­
action between this portion of the antibody molecule and the recipient’s 
Fctf-receptor population(s) (Hoffman & Kappler, 1978).
French and Batchelor (1972) were unable to show enhancement using 
relatively pure Ftab'^ preparations. Studying anti-lymphocyte serum, 
Lance, Medawar and Taub (1973) found that F(ab’ ) 2  fragments did not 
enhance, although’ all the serum enhancing activity was in the 7S 
(or IgG peak) serum fraction. Kaliss, Sinclair and Cantrell (1976) 
showed only slight suppression of cell-mediated immunity to murine 
tumour allografts using F ^ b ’^  fragments. One group showed that F ^ b ’^  
fragments alone enhanced neither mouse skin nor sarcoma allografts 
(Capel et al, 1979.} de Waal et al, 1979). Convincing evidence from a 
rat renal allograft model that enhancement required the Fc portion was 
provided by Winearls et al (1979).
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The proposal by Hutchinson and Zola (1977) that antigen-reactive 
cell opsonization could explain passive enhancement hinged on the 
necessity for the Fc portion to bind to Fc)$-receptors on monocytes and 
macrophages (Hutchinson 1980). Hutchinson and Brent (1982) went on to 
exclude the possibility that the Fc portion was needed not to bind to 
the receptor but to fix complement. They found that decomplementation 
with cobra;venom had no effect on passive enhancement of mouse skin 
allografts. Lems et al (1984) found that complement-fixing IgG2 and 
non-complement-fixing IgGI antibodies were equally effective in 
enhancement, but IgM was not (Lems et al,1981).
ii) The relation between Fcft-receptors and Class II antigens
Dickler and Sachs (1974) speculated that the Fc -receptor on mouse B
lymphocytes was either identical to or closely associated with the la
alloantigens determined by the Ir region of the H-2 complex (equivalent
to class II antigens). In 1975, Soulillou et al, carried this a step
further. They found that rat alloantiserum absorbed with donor
erythrocytes or platelets was as effective as the unabsorbed antiserum
in inducing passive enhancement of rat renal allografts. Absorbed
antibodies inhibited donor-recipient mixed lymphocyte culture and
specifically blocked donor splenic lymphocyte Fc^-receptors. This
activity was maintained through to F ^ b 1^  fragments. Soulillou et al
(1975) proposed that anti-Fc)£-receptor were actually anti-la antibodies,
and that they produced enhancement by blocking class II antigen
presentation. Dickler (1976) claimed that anti-la F ^ b ' ^  fragments
blocked Fc)J-re cep tors on both B and T cells. Using an erythrocyte-
antibody (EA) rosette inhibition assay to define Fc6-receptor blocking
activity, S:uthanthiran et al (1977b) showed that cytotoxic anti-la serum
inhibited the FcS-receptor whereas the receptor was unaffected by serum
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against class I antigens. In contrast, Dobloug et al (1981) reported 
that antibody against beta-2-microglobulin, but not antibody against 
HLA-DR antigens, would block EA rosette formation in man. Other 
workers also concluded that the Fctf-receptor and la antigen were not 
one and the same structure (Rask et al, 1975; Solheim Thorsby and 
Moller, 1976; Wofsy McDevitt and Henry, 1977; Soulillou and Peyrat, 
1979).
In a series of experiments using anti-la and anti-beta-2- 
microglobulin, Sarmay, Sanderson and Ivanyi (1979) claimed that Fctf- 
receptors could be blocked by antisera not just to la antigens but 
to any cell surface receptor. If, however, the relation found 
previously between anti-la and anti-FcK-receptor activity were entirely 
by chance, one might expect anti~Ia serum to block other cell surface 
receptors too. But Soulillou, Peyrat and Guenel (1978) found no 
evidence of blocking of the C3 receptor as detected by an EAC rosette 
inhibition assay. Klinkert et al (1982) failed to find ¥ci-receptors 
on rat dendritic cells, while noting that the cells expressed la antigens 
and may be crucial to antigen presentation of the renal allograft 
(Austyn et al, 1985). The body of evidence, however, appears to
be in favour of some unspecified association between Fc'V-re cep tors and 
class II antigens.
iii) Anti-class II antibody in passive enhancement
Davies and Alkins (1974) suggested that enhancement was mediated 
by class II antigen:antibody complexes. Catto et al (1977) found passive 
enhancement in a rat renal allograft model to be dependent on anti-la 
activity. The necessity for anti-la activity in enhancing serum was 
challenged by Jeekel et al (1977) who reported enhancement of rat renal
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allografts with antibodies against antigens associated with erythrocytes.
The findings of Suthanthiran et al (1978; 1979) of production of 
anti-la antibody during allograft rejection, and apparent abrogation of 
anti-la antibody production in passively enhanced recipients, led to their 
suggestion (Suthanthiran et al, 1978) that passive transfer of anti-la 
antibody could mediate enhancement by interfering with the recipient's 
own response to donor class II antigen. Otsubo et al (1983) claimed 
that anti-mouse la monoclonal antibody prolonged canine renal allograft 
survival. However, Soulillou et al (1980) had previously tried to 
enhance canine renal allografts with specific anti-class II serum, and 
commented that "it would seem that the rodent enhancement model works 
too smoothly".
5. Fc’K-receptor blocking antibody arid renal transplant outcome
The blurred distinction between Fctf-receptors and class II antigens 
led to the use of EA rosette inhibition assays, indicating Fctf-receptor 
blocking activity, in attempts to extrapolate to man rodent data 
concerning enhancement by anti-class II antibody. Early findings were 
not encouraging. Suthanthiran et al performed an EA rosette 
inhibition'assay on both pre-(1977) and post-transplant (1978) serum. 
Inhibition.of rosette formation was associated with graft loss. Using 
unseparated normal human peripheral blood lymphocytes, Bakkaloglu et al 
(1980) correlated rosette inhibition by post-transplant serum with 
rejection episodes. Indeed, Suthanthiran et al (1977) proposed that 
further larger studies should establish whether the EA rosette 
inhibition assay should be recommended as a "routine cross-match 
procedure to preclude renal transplantation".
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The work of Suthanthiran relied on the use of recipient serum 
ultracentrifuged to remove immune complexes and aggregates which, 
rather than IgG, could block the Fc^-receptor and inhibit rosette 
formation. Soulillou et al (1978) looked at the capacity of pre­
transplant recipient serum to inhibit EA rosette formation by donor 
B-enriched lymph node lymphocytes. Further, in 3 out of 55 cases,
IgG and FCab’)^ fragments derived from the serum samples were tested 
in parallel with serum; EA rosette inhibition was found with serum,
IgG and F(ab')^ 'fragments. No significant difference was seen in 
allograft outcome between recipients with or without: pre-transplant 
EA rosette inhibitory activity, although if anything those with 
inhibitory activity fared slightly better.
The most recent work on the relation between Fcf-receptor 
blocking antibody and renal allograft survival has come from Aberdeen, 
as mentioned briefly in discussion of the blood transfusion effect.
The presence in pre-transplant serum of non-cytotoxic Fc -receptor 
blocking activity, as detected by EA rosette inhibition, against donor 
B lymphocytes correlated well with one-year renal allograft survival. 
Graft outcome also correlated, although less well, with inhibition of 
rosette formation of B lymphocytes from panels of normal donors and 
patients with chronic lymphatic leukaemia. Rosette inhibition was 
maintained in preparations of IgG and FCab’J^ fragments (MacLeod et al, 
1982 a and b).
The same group has also provided impressive evidence for the 
development of such antibodies against paternal antigens during 
successful pregnancy (Power et al, 1983 a and b; Stewart et al, 1984). 
Family studies in the contexts of both pregnancy and transfusion have 
shown antibody development to be apparently HLA-linked, again raising
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the question of the relation between Fctf-receptors and class II 
antigens (Power et al, 1983b; MacLeod et al, 1985a). These exciting 
findings led to the series of experiments described below.
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CHAPTER 7
SUBJECTS STUDIED
1. Normal subjects
Forty-five healthy volunteers with no past history of renal 
disease or blood transfusion. Details of sex and parity are given 
overleaf.. The age range was 10 to 57 years.
Abbreviations are as under:
N : Nulliparous
P : Pregnant
M : Parous - at lease one full-term pregnancy
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Normal subjects
Initials Sex ' Parity
RA M
CB F M
DB M
EB F M
JB M
HC F M
WC. M
CF F M
GF; M
MF F N
KG F N
EH F P
BJ ' H
BK F P
AL M
CL M
GL M
JL H
NL F H
SL F M
CMcG F P
DMcK F P
JMcK M
SMcK F P
CMcL F N
HMcM M
AM (1) M
AM. (2) F N
AM (3) F M
CR F P
FR M
MR F M
SR F N
CW (1) M
CS (2) F N
CS (3) F M
GS M
MS. F P
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Normal subjects
Initials Sex Parity
AT, G P
AW F N
CW M
MW (1) M
MW (2) F M
MW' (3) F M
PW F N
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2. Transfused patients without known renal disease
Fifteen patients attending the Western Infirmary, Glasgow.
All had previously received at least 5 units of blood for a variety of 
indications as listed overleaf. No patients with haemophilia were 
included in this group. The mean age was 57 years with a range of 
22 to 84.
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Transfused subjects without known.renal disease
No. of units 
of blood
Initials Age Sex Diagnosis transfused
AC 26 F Post^partum haemorrhage 6
EC 84 F Pernicious anaemia 5
HF (1) 79 M Gas tro-intes tinal 
Angiodysplasia >100
HF (2) 72 M Pancreatitis 5
JF 57 M Gastro-intestinal bleeding 5
WF 43 M Gastro-intestinal bleeding 5
DL 55 M Diverticulitis 6
EL 22 F Trauma >10
MMcC 46 F Gastro-intestinal bleeding 15
JMcM 55 M Carcinoma of colon 5
WMcM 57 M Aplastic anaemia 98
CMcQ 81 F Sideroblastic anaemia 10
GP 75 F Gastric ulcer 5
MP 65 F Gastro-intestinal bleeding 6
MS 40 F Gastro-intestinal bleeding 8
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3. Patients with known renal disease
Patients studied were those attending the Renal Unit of the 
Western Infirmary, Glasgow, for inpatient or outpatient care, and/or 
dialysis and transplantation. Overleaf are details for each patient 
of age, sex, primary renal disease, type of renal replacement therapy
where appropriate and transfusion history. Where sequential serum
/
samples were used, the transfusion details in this section refer to 
the transfusion status at the time of the first sample. Where 
accurate .transfusion details are not available, this is indicated by 
"greater than" the minimum number of units which the patient is known 
to have received.
Abbreviations for the patient's renal disease are as follows:
BP : hypertensive nephrosclerosis
DM : diabetes mellitus 
GN : glomerulonephritis 
0 : obstructive nephropathy
PCK: polycystic kidney disease 
PN : pyelonephritis 
R : reflux nephropathy 
U : uric acid nephropathy
Abbreviations for the mode of renal replacement therapy are as 
follows:
C : continuous ambulatory peritoneal dialysis 
H : haemodialysis 
T : functioning renal transplant
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Patients with known renal disease
Renal No. of units
replacement of blood
Initials Age Sex Renal disease therapy transfused
CA 51 F U C 20
d a (i) : 23 M PN H 27
DA (2) 27 M 0 H 5
JA (1) 43 M DM C 5
JA (2) 35 M Amyloid H 9
WA 39 M GN H . 8
AB 31 M DM C 5
BB 20 M 0 C 7
CB 20 M GN H -
DB 75 M GN - -
EB (1) 62 M TB - 27
GB (2) 65 M 0 C 6
JB (2) 56 M PCK H 5
JB (3) 30 F DM C 5
JB (4) 27 F GN C 5
MB (1) . 59 F PN C 5
MB (2) : 42 F BP H H
MB (3) 68 F GN - ’ -
NB 53 F BP C 5
PB 22 M 0 H >20
SB 42 F PN H 7
CC 24 F Calculi - 6
IC (1) 38 M PN H 5
IC (2) 66 F Calculi - -
JG (1) 55 M Lupus. - -
JC (2) 31 M Alport1s T >10
JC (3) 49 F PCK H 5
LC 64 F 0 H 5
MC (1) 45 F 0 H >60
MC (2) • 39 M PCK - >30
PC 57 M BP -
TC (1) 36 M R' H 13
TC (2) 34 M GN H 5
TC (3) 52' M PN H 5
VC 56 M PN H 13
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Patients with known renal disease
Renal No. of units
replacement of blood
Initials Age Sex Renal disease therapy transfused
WC (1) 53 M U H 14
WC (2) 39 M DM - -
WC (3) 50 M BP - -
AD 44 F PN C 7
DD 42 M GN H: 13
HD 43 M PN H 10
JD 53 M BP H 12
KD 20 M GN H 7
PD 22 M GN H 20
RD 57 M GN H 10
WD (1) : 56 M PN H -
WD (2) ' 55 M PN H 17
WD (3) 48 M PN T 6
EF 66 F Lupus nephritis - -
RF 26 M R C 5
AG (1) 54 M PCK H 5
AG (2) 51 M GN C 5
AG (3) 27 M R H 35
EG 58 F GN - -
JG 20 M GN - -
TG (1) 22 M GN T 7
TG (2) 49 M BP H 6
WG (1) 50 M GN - -
WG (2) 22 M DM -
AH (1) 26 F PN H 8
AH (2) 50 F PCK - -
AH (3) 40 F BP H >50 ,
CH (1) 61 F PN T 5
CH (2) 29 F GN H 33
DH 33 M . GN H 48
FH 32 M GN - -
HH 19 M Nephronophthisis H 39
JH (1) 36 M GN H 14
JH (2) 50 M GN - -
JH (3) 41 M GN H >20
JH (4) 49 F PN
90
C 6
Patients with known renal disease
Renal No. of units
replacement of blood 
Initials Age Sex Renal disease therapy transfused
JH (5) • 26 F GN H 6
MH (1) 36 F GN - -
MH (2) 35 F GN r
SH (1) 65 M GN - -
SH (2) 40 M GN - -
WH 42 M U H 10
DI 35 M GN H 8
DJ 44 M DM C -
NJ 35 M DM C 16
AK 2 7 M GN H -
DK 32 M PN - -
EK 30 F DM H 20
TK 48 M PN H 7
WK (1) 45 M GN - -
WK (2) 37 M GN H -
DL 18 F Nephronophthisis H >40
EL 21 F PN H 12
RL 44 M GN - -
AMcC 40 F PN C 5
MMcC 53 F Analgesic C 9
AMcD 61 F PCK H 8
B McD ; 25 M 0 H 5
G McD . 25 M 0 H 15
MMcD 42 F GN T 12
RMcF 35 M GN - -
HMcG 46 M BP H 5
CMcG 61 F Analgesic - 2
JMcG (1) 50 M BP H 7
JMcG (2) 40 F GN H 10
MMcG 50 F BP H -
EMcI 49 F Analgesic H 10
JMcI (1) 63 M BP -
JMcI (2) 63 M BP - -
JMcK 62 M GN - -
MMcK 59 F DM C
FMcL 22 M PN H 5
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Patients with known renal disease
Renal No. of units
replacement of blood
Initials Age Sex Renal disease therapy ' transfi
JMcL 38 M GN H -
LMcL 54 F PN - -
MMcL 45 M BP H 4
PMcL 18 F R - -
DMcM 51 M DM -
WMcM 45 F R - -
RMcR 30 M DM H
AM (1) 51 F PN H 5
AM (2) 36 F GN H 7
CM (1) C15 F Renal agenesis C >10
CM (2) 45 F GN H 7
IM 23 M . GN H 5
JM (1) 17 M BP H 66
JM (2) 28 M GN H 5
JM (3) 35 M GN H 9
PM (1) 29 M GN H 6
PM (2) 25 F GN H -
TM (1) 33 M 5 DM T 5
TM (2) 53 M DM - -
EN 27 F PN H 11
GN 55 M GN C 6
10’D 49 F PN C 7
EO’N 58 F PCK H 6
SO 58 F PN H 12
FP 38 F PN T; 5
MP (1) 20 F GN H 8
MP (2) 24 M Alport* s H >40
MP (3) 49 F GN - -
MP (4) 33 F GN. H >80
EQ 24 F DM C 4
AR 20 M PN H 19
GR 29 F DM C 5
FR 55 M Analgesic C -
IR 38 M PN H 72
JR (1) 57 M PCK H 5
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Patients with known renal disease
Renal No. of units
replacement of blood
Initials. Age Sex Renal disease therapy transfused
JR (2) 57 F PN . H 9
MR (1) 37 F GN H 6
MR (2) 26 F . PN H 5
AS 46 F PN H 18
CS (1) 32 M GN H -
CS (2) 64 M BP - -
ES 54 M BP H 12
IS 22 M PN H 5
JS (1) 54 F Nephrocalcinosis C -
JS (2) 72 M GN - -
JS (3) 54 F PCK - >10
MS (1) 49 F GN H
MS (2) 50 F GN H 9
MS (3) 63 F PCK H >50
MS (4) 54 F Nephrocalcinosis - -
MS (5) 44 F PN H
NS 56 M Alport’s H 11 ‘
ss 16 M 0 H 15
TS (1) 50 M PCK H 5
TS (2) 47 M ' PCK H 5
ws 75 M Past ATN - 5 .
JT (1) 32 M R C 7
JT (2) 46 M GN H 5
PT 52 F BP H >10
AW 26 M GN H 1
GW 41 M PCK H 6
JW 26 F R H 8
MW 54 F Amyloid - >20
SW (1) 23 M GN H 10
SW (2) 43 M PCK H 5
FY 49 M GN H 7
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4. Patients with haemophilia
Thirty males with Factor VIII deficiency and 9 with Factor IX 
deficiency. No patient had serum Factor VIII inhibitory activity.
No patient had clinical evidence of AIDS nor of unexplained 
lymphadenopathy persisting for more than three months. None was 
known to be homosexual. None had recently travelled to Africa or 
the Caribbean.
Six of 24 patients tested since the period of this study have 
been found to have antibodies against human T-cell leukaemia virus 
Type III. All have Factor VIII deficiency and had used commercial 
Factor VIII preparations before 1979. For five years before this 
study none of the patients had received other than locally produced 
Factor VIII/IX, that is donated by voluntary donors in the West of 
Scotland.
The mean age was 28 (rangp 18 to 67 years). Listed overleaf 
are details of
a) endogenous clotting factor production (expressed as a 
percentage of normal )
b) current use of therapeutic clotting factors. The patients 
have been divided into three categories depending on the 
number of units of Factor VIII or Factor IX used during the 
previous year:
low less than 10,000 units 14 patients
medium 10,000-40,000 units 9 patients
high more than 40,000 units 16 patients
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c) previous blood transfusion: again, three categories:
never transfused 20 patients
transfused less than 5 units of blood 7 patients
transfused 5 or more units of blood 12 patients
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Haemophilia A
nitials Age
Endogenous Factor 
VIII/IX (expressed 
as % normal)
Factor VIII/IX 
usage in past
year._________
No. of units 
of blood 
transfused
AB 18 zi High 4-5
JB 33 Cl High >5
AC 32 4.1 High > 5
IC 19 2 High 0
JC 21 4.1 Medium 0
AD 21 <1 High 0
PD 22 5 High 0
AF 36 Z 1 Low 0
DF 34 4 Low > 5
EF 29 zi Low 0
DG 32 Cl High Z  5
GH 41 2 Low 4  5
DI 25 4.1 High 0
MJ 18 C 1 Medium 0
MK 18 7 Low 0:
JMcC 67 5 Medium; 0
IMcE 35 C l High 4 5
WMcK 26 C l High >5
GMcN 26 15 Nil 0.
JMcS 29 <1 Medium >5
BM (1) 38 <1 Nil 4  5
BM (2) : 28 5 Nil 4 5
HM 43 < 1 High ' > 5
NM 30 10 Medium 4  5
TM 27 4 1 High
RR 33 4 1 Medium >5
NS 23 4 1 High 0
RS 28 41 Low >5
su 28 4  1 High 0
PW 60 4 1 Low >5
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Haemophilia B
Initials Age
Endogenous Factor 
VIII/IX(expressed 
as % normal
Factor VIII/IX No. of units 
usage in past of blood 
year ______ transfused
RB
IF
AH
KMcD
RM
TM
DS
MS
RS
20
20
35
20
23
26
20
34
38
LI
Ll
LI
5
5
5
LI
L-l
LI
Low
Medium
High
Low
Low
Medium
Low
Medium
High
0
0
0
0
0
0
0
>5
5
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5. Patients attending a Genitourinary Clinic
Thirty-two patients presenting to the Genitourinary Clinic at the 
Southern General Hospital, Glasgow, with symptoms attributable to 
sexually transmitted disease. Details of individual patients are not 
given. In the 20 cases on whom a diagnosis was recorded at the 
clinic visit, diagnoses were as follows:
non-specific urethritis 8 cases
gonorrhoea 6 cases
genital warts . 2 cases
syphilis 1 case
urinary tract infection 1 case
genital Herpes, infection 1 case
moniliasis 1 case
Sexual orientation was as follows:
male homosexuals 11 cases
male heterosexuals 10 cases
female heterosexuals 11 cases
The mean age of the patients was 27 (range 19 to 43 years).
6. Patients with AIDS
a) One patient treated in the Western Infirmary. Full details of 
this case were published by Shiach et al (1984). The patient 
was a- Scottish heterosexual male who had spent some years in 
Africa. After the development of screening for antibody to
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HTLV-III, stored serum was found to be antibody-positive.
b) Six patients with clinically defined AIDS treated in San
Francisco. All were male homosexuals. Three had Kaposi's
sarcoma, and all presented with a variety of opportunistic
infections.
(
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CHAPTER 8 
TECHNIQUES USED
1. Preparation for experiments of cells from peripheral blood
Whole blood was taken from the subjects specified and kept until 
use (generally within one hour) in bottles containing a few drops of 
preservative-free heparin.
i) Peripheral blood lymphocytes (PBL)
Human mononuclear cells were obtained from heparinised whole
blood by- centrifugation over a Ficoll-metrizoate (SG = 1.077) column
(Boyum, 1968). Cells aspirated from the plasma/Ficoll interface
were washed twice in Hepes buffered Earles medium (HEM), pH = 7.3
(Gibco Laboratories, Glasgow) then resuspended in HEM supplemented with
6
10% fetal calf serum (HEM + S). Approximately 10 x 10 mononuclear 
cells in 2ml HEM + S were added to plastic tissue culture plates and 
incubated at 37°C for 2 hrs in 5% CO2  in air. Non-adherent cells 
were removed by repeated gentle washings with a Pasteur pipette 
(Ross et al, 1973). The non-adherent cells were found to have lymphoid 
cell morphology (more than 97%) and were virtually all viable as 
assessed by the exclusion of trypan blue (greater than 97%). Lymphocyte
suspensions were washed twice in (HEM), and adjusted to a final con-
6
centration of 4 x 10 cells/ml in HEM.
ii) T or B cell enriched lymphocyte suspensions
Equal volumes of PBL and neuraminidase—treated sheep erythrocytes 
(NSE) were mixed (for preparation of NSE please see 8:4:iii) and
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centrifuged . at 400g for 10 mins. The cell pellet yas incubated at 
4°C for 1 hour prior to resuspension by end over end mixing and layered 
onto Percoll(Pharmacia, Uppsala, Sweden) (SG = 1.077)
in the proportions of 3 ml cell suspension to 1 ml Percoll. Following
centrifugation at 400g for 20 mins, cells were removed from the
interface, i.e. TB* enriched and from the pellet, i.e. *Tr enriched.
Contaminating NSE were removed from the T cell suspensions by hypotonic
lysis. Both ’ B ’ and 'T' enriched populations were washed three times
6in HEM and adjusted to a final concentration of 4 x 10 /ml. 1 B’ 
cell enriched populations contained less than 2% NSE rosettirig cells 
while ' T1 enriched contained greater than 90% NSE rosetting cells.
iii) Monocytes
After the removal of the non-adherent lymphoid cells from plates 
as described above (8:l:i), the residual, adherent cells were found 
to be mainly monocytes (more than 95%) as assessed by morphology, 
latex bead phagocytosis and non-specific esterase straining. Monocytes 
were maintained in HEM + S at room temperature in 5% C0^ in air until 
required.
iv) Polymorphonuclear leucocytes (polymorphs)
Polymorphs were recovered from the bottom of the Picoll- 
metrizoate columns as described by Boyum (1968). The erythrocyte/ 
polymorph containing cell pellet was mixed with an equal volume of 
autologous plasma recovered from the top of the Ficoll-metrizoate 
columns and incubated at 4°C for 30 mins. Pre-cooled 6% Dextran 
110 was added (400pl Dextran/ml cells in plasma) and incubated at 4°C 
until the erythrocytes sedimented by 50% of the total volume. The
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polymorph rich plasma was then recovered and the cells washed twice 
in HEM by centrifuging at 200g for 5 mins. Any contaminating 
erythrocytes were removed by hypotonic lysis and the cell suspensions 
adjusted to an appropriate concentration in HEM. These cell sus­
pensions were viable (greater than 97%) as assessed by dye exclusion 
and contained greater than 95% polymorphs as assessed by morphology 
and latex bead phagocytosis.
v) Erythrocytes
Erythrocytes were obtained by sedimentation with dextran from 
the cell pellet at the bottom of the Ficoll-metrizoate column, as 
described in section 8:l:iv.
vi) Platelets
Pooled human platelets were obtained from the Glasgow and West 
of Scotland Blood Transfusion Service, Law Hospital, Carluke). 
Contaminating leucocytes were initially removed by centrifugation of 
platelet-rich plasma at 150g for 30 minutes and pure platelets 
obtained by further centrifugation at 400g for 10 minutes.
2. Preparation for experiments of cells from lymphoid organs
i) Splenic B lymphocytes
Splenic lymphocytes ffom cadaveric kidney donors were obtained 
from the' Tissue Typing Laboratory at Glasgow Royal Infirmary, where 
they had. been frozen and stored in liquid nitrogen. Enrichment for' 
B lymphocytes was performed according to the method described above .
ii) Thymus-derived T lymphocytes
Thymus tissue was collected at open heart surgery from infants 
with no known immune abnormality. Thymocytes were prepared by 
mechanical separation and resuspended until use in HEM.
3. Preparation of serum for experiments
Serum samples were taken from subjects as specified below and 
prepared for use in a variety of ways.
i) Unseparated serum
This was frozen and stored until use at -20°C.
ii) Ultracentrifuged serum
Serum either fresh or thawed was ultracentrifuged at 105,000g 
(model L2-65B Beckman ultracentrifuge) immediately prior to use; 
the lower third of the contents of each ultracentrifuged tube was 
discarded.
iii) Serutn fractions of graded molecular weight
These were prepared as described by Reid et al (1983). Five
hundred microlitre aliquots of serum were fractionated by ultra­
centrifugation at 105,0Q0g for 16 hrs at 4°C over 4 ml 20-40% dis­
continuous sucrose gradients using a model L2-65B Beckman ultra­
centrifuge. Five fractions (Fl-5) each of 720ul were collected in
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turn from the bottom of the gradient, plus one larger fraction (F6) of 
900ul. Each serum fraction was dialysed into phosphate buffered 
saline (PBS) at 4°C for 16 hrs, The approximate molecular weight of 
serum components in each fraction was estimated by screening a small 
aliquot by radial immunodiffusion using four markers: IgM, IgG, Clq
and transferrin. In all experiments, IgM was found to peak in F2,
Clq in F3, IgG in F4 and transferrin in F5. Serum fractions were 
stored at -20°C until use.
iv) IgG
IgG was obtained from serum by DEAE cellulose chromatography 
(DE52-Whatman). Both serum and DE52 were equilibrated as to pH and 
conductivity with lOmM phosphate buffer of pH 7.8 prior to chromato­
graphy. IgG preparations were dialysed into phosphate buffered saline 
(PBS) pH 7.2 for 18 hours at 4°C and ultracentrifuged at 105,000g 
for 1 hour prior to use. Small aliquots (500jil) were stored at -20°C 
and repeated freeze-thawing was avoided. The IgG preparations 
obtained were pure as assessed by immunoelectrophoresis and on radial 
immunodiffusion. The monomeric nature of these IgG preparations was 
confirmed, by polyacrylamide gel electrophoresis and by gel filtration 
(sephacryl S300-Pharmacia). In all experiments, unless otherwise 
stated, IgG preparations were used at a concentration of Img/ml in PBS.
v) Absorbed IgG preparations
A variety of cells were used, as specified in the relevant 
chapters, and obtained as recorded above. IgG preparations were 
absorbed three times at 37° for 1 hour using 200pl of packed cells in 
HEM per 500pl IgG (1 mg/ml) in PBS).
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4. Experimental techniques using lymphocytes
i) Inhibition of EA rosette formation
Full details of this method have been described previously 
(Sandilands et al, 1980).
i, a)Prep,aration of antibody-sensitised chicken erythrocytes (EA)
A 5% suspension of washed chicken E was mixed with an equal 
volume of a 1 in 500 dilution of rabbit anti-chicken E serum and 
incubated at 37°C for 1 hrs, washed twice, and adjusted to a 1% 
suspension in HEM. The preparation of this antibody to chicken E, 
which is predominantly of IgG class, has been described elsewhere 
(Sandilands et al, 1975).
i,b) Inhibition of EA rosette formation
One million monocyte-depleted human lymphocytes (separated from 
peripheral blood or lymphoid organs as described above (8.1) were 
resuspended in 120jul test or control substrate. Whole serum, serum 
fractions and IgG were prepared as aboveC 8.2) for testing* Controls 
used were fetal calf serum, phosphate buffered saline, IgG derived from 
serum from the normal donor of the target lymphocytes, and known 
inhibitory and non-inhibitory IgG preparations, where appropriate. 
Following .incubation at 4°C or 37°C for 30 minutes, cells were washed 
twice and resuspended in 120pl HEM, and mixed with an equal volume of 
chicken EA, prepared as described above. Tubes were then centrifuged 
at 200g for 5 minutes prior to resuspension of the EA rosette pellet 
and fixation in 3% glutaraldehyde. Cells were resuspended in 0.75%
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trypan blue and inspected under sealed coverslips. At least 200 
lymphocytes on each slide were counted and the percentage of lympho­
cytes forming rosettes, defined as binding two or more chicken EA, 
was determined. Results were expressed as the percentage inhibition 
of EA rosette formation from the formula:
% rosette-forming lymphocytes - % rosette-forming
in control (mean of 3) lymphocytes in test
x X
% inhibition = ---------------------------------- ----- -------- -------
% rosette-forming lymphocytes in control (mean of 3)
ii) Inhibition of EAC rosette formation
ii,a)Preparation of antibody-sensitised erythrocytes (EAC)
Five-millilitres of a 5% suspension of washed sheep erythrocytes 
was mixed with an equal volume of rabbit anti-sheep erythrocyte IgM, 
diluted 1 in 100 in HEM (Haemolysin- Flow Laboratories Ltd., Irvine, 
Aryshire). After incubation for 30 minutes at 37°C the preparation 
was washed twice in HEM, then adjusted to give a 1% suspension in HEM.
An equal volume of fresh normal human serum, diluted 1 in 80, was 
added and, following a further incubation period of 30 minutes at 
37°C, the complexes were washed twice and adjusted to a final con­
centration of 0.5% in HEM.
ii,b)Inhibition of EAC rosette formation
One million monocyte-'depleted human lymphocytes (separated from 
peripheral blood as described above (8.1)) were resuspended in 120pl test 
or control substrate (as defined above 8:4,i)). Following incubation 
at 37°C for 30 minutes cells were washed twice and resuspended in 120jul
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HEM, and mixed with an equal volume of EAC. Following centrifugation 
at 200g for 5 minutes, the pellet was incubated at 37°C for 30 minutes, 
then resuspended by vortex mixing and fixed in 3% glutaraldehyde.
Cells were resuspended in 0.75% trypan blue and inspected under sealed 
covers lips. At least 200 lymphocytes on each slide were counted, 
and results were expressed as the percentage inhibition of rosette 
formation produced by test compared with control preparations, 
according to the formula detailed above for the EA rosette inhibition • 
assay (8:4,i).
iii)Inhibition of NSE rosette formation
iii,a)Preparation of neuraminidase-treated sheep erythrocytes (NSE)
Three hundred microlitres of washed packed sheep erythrocytes was 
mixed with 60pl neuraminidase and 1.8ml HEM. This was incubated 
at 37°C for 1 hour, washed twice and adjusted to a 0.5% suspension 
in HEM.
iii,b)Inhibition of NSE rosette formation
One million monocyte-depleted human lymphocytes (separated from 
peripheral blood or lymphoid organs as described above (8:1) were 
resuspended in 120ul test or control substrate (as defined above 
(8:4,i). ' Following incubation at 37°C for 30 minutes cells were
washed twice and resuspended in 120ul HEM, then mixed with an equal 
volume of NSE. Following centrifugation at 200g for 5 minutes the 
preparations were placed overnight in an ice bath at 4°C. After 
gentle resuspension by end-over-end mixing the cells were fixed with
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3% gluteraldehyde. Cells were resuspended in 0.75% trypan blue and 
inspected under sealed coverslips. Results were expressed as the 
percentage inhibition of rosette formation produced by test compared 
with control preparations, according to the formula detailed above 
for the EA rosette inhibition assay (8:4,i).
iv) Inhibition of phytohaemagglutinin-induced blastogenesis(PHA)
Normal human peripheral blood mononuclear cells (PBMC) were 
resuspended in RPMI(Gibco)culture medium supplemented with 10% heat- 
inactivated autologous serum and antibiotics at a final concentration 
of 4 x 10^/ml. Fifty microlitres of PBMC (2 x 10“* cells), 50 pi 
serum fraction in PBS and IOjliI PHA (lOOug/ml) were incubated together 
in the wells of a flat bottomed microtitre plate. Following 
incubation at 37°C for 66 hours in a humidified atmosphere of 5% CO^ . 
in air the cells were pulsed with ^C-thymidine (0.02pCi/well) for 
6 hours, harvested on to fibreglass filters using a multiple-channel 
automated cell harvester and washed in turn with distilled water, 5% 
trichloroacetic acid and methanol. The filters were dried at 37°C, 
placed in glass vials containing 5mls of scintillation fluid and the 
radioactivity counted in an automated B counter (Packard). Results 
were expressed as the percentage inhibition of PHA response produced 
by the IgG as compared with control wells (Controls >3000 cpm).
v) Inhibition of antibody-dependent cell-mediated cytotoxicity
and Natural Killer cell function.
Peripheral blood mononuclear cells, pretreated with IgG obtained 
from subjects as described above, (8:3:iv), were incubated with 
“*^Cr-labelled target cells a) antibody (IgG) sensitised Chang liver
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cells at a lymphocyte:target cell ratio of 33:1 for 20 hrs at 37°C 
or b) K526 cells at 20:1 for 4 hrs at 37°C. "*^ Cr release was
measured in the supernatant using an automated gamma counter. Minimum 
and maximum release was determined by incubating labelled target 
cells in medium alone or in 10% SDS respectively. In the antibody- 
dependent cell-mediated cytotoxicity assay spontaneous cytotoxicity 
(in the absence of anti-Chang serum) was also calculated and sub­
tracted from the total cytotoxicity to give a value for net antibody 
dependent cytotoxicity. Results were expressed as percentage 
inhibition of cytotoxicity induced by IgG as compared with cell 
suspensions which were incubated with medium above in place of IgG 
(Sandilands et al, 1976; Kay, Fagnani & Bonnard, 1979).
vi) Exclusion of complement-dependent cytotoxicity
Samples of serum and IgG were screened for lymphocytotoxicity at 22°C 
against peripheral blood lymphocytes from the donor panel used 
routinely in transplantation by the Tissue Typing Laboratory at 
Glasgow Royal Infirmary. Testing was performed, courtesy of 
Professor H.M.Dick, by staff of the Tissue Typing Laboratory, using 
standard techniques (Kissmeyer-Nielsen and Dick, 1979).
5. Experimental technique using monocytes: inhibition of EA rosette
formation
Human monocytes adherent to plastic plates (as prepared in 
sections 8:l,i and 8:1,iii) were incubated at 37°C for 30 minutes in 
5% carbon dioxide in air, together with Iml HEM + S (8:l,i) and 500ul 
test or control substrate. The plates were then rinsed 6 times with 
HEM prior to rosette formation with chicken EA in situ as described 
previously (8:4,i; Sandilands et al, 1980).
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6. Experimental techniques using polymorphs
i) Inhibition of EA rosette formation
The same method was employed as for lymphocytes (8:4:i) using 
one million polymorphs suspended in 250jil HEM.
ii) Inhibition of phagocytosis of IgG-coated latex beads
Normal human peripheral blood polymorphs were preincubated with
IgG prepared from serum as described above (8:3:iv). Following two
6washes in HEM, 2 x 10 polymorphs were resuspended in 50jil HEM + S 
and incubated at 37°C for 30 mins together with an equal volume of IgG 
coated latex beads (Wellcotest lytm beads - diluted 1:2 HEM + S) .
Following fixation with 3% glutaraldehyde the cells were resuspended 
in 1 drop of 0.75% trypan blue and counted under coverslips. Cells 
containing ten or more beads within the cytoplasm were counted as 
positive. Results were expressed as the percentage inhibition of 
phagocytosis of latex-IgG as compared with control suspensions pre­
treated with PBS or with normal IgG. Under these conditions approximately 
85% of the polymorphs observed appeared to have ingested latex-IgG.
iii) Inhibition of polymorph phagocytosis of radiolabelled 
Staphylococcus aureus •
A modification of the method of Peterson et al (1977) was used.
10 ml of Mueller-Hinton broth was inoculated with Staphylococcus aureus
(Cowan strain). To measure bacterial uptake the inoculated broth also
3contained lOOul of H adenine (20uCi mmol specific activity:Radiochemical 
Centre, Amersham). The broths were incubated overnight at 37°C. The 
bacteria were washed 3 times in sterile saline. The concentration of
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organisms was adjusted to 1 x 10 colony forming units/ml using a 
Cecil spectrophotometer. An optical density of 0.025 at 620nm 
corresponded to 1 x 10^ colony forming units/ml. This was checked 
by pour plate methods.
Bacteria were opsonized with an equal volume of pooled human serum 
diluted in Gel-Hanks ( Gibco). Opsonization of Staphylococcus
aureus with 10% serum was found to give optimum phagocytosis. The 
bacteria were incubated in serum at 37°C in an orbital shaking incubator 
(150 rpm). After 15 minutes the bacteria were centrifuged at 3000 rpm 
for 20 minutes and resuspended in the original volume of Gel-Hanks.
Normal polymorphs (obtained using method 8:l:iv) were incubated at 
37°C for 1 hour in IgG preparations (8:3:iv) or RPMI medium (Gibco) as 
control. After incubation samples were removed, washed and resuspended 
in Gel-Hanks at 1 x 10^/ml.
To measure phagocytic uptake triplicate scintillation vials 
containing 0.1 ml of polymorphs and opsonized bacteria were incubated 
at 37°C in an orbital shaking incubator. A 1:1 ratio of polymorphs: 
bacteria was found to give optimum phagocytosis. After 15 minutes the 
vials were removed and 3 ml scintillation fluid added to one (A) of each 
trio (United Technologies, Packard, Caversham). Three ml of ice-cold 
phosphate buffered saline was added to the second vial (B) . To the third 
vial (C) was added 1 ml of 500ug/ml lysostaphin (220 U/mg:Sigma) in 
phosphate buffered saline. This vial was reincubated at 37°C for 20 
minutes, washed 3 times with phosphate buffered saline, and 3 ml 
scintillation fluid was added.
All 3 vials were washed 3 times with phosphate buffered saline at
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900 rpm for 5 minutes. After the final wash the pellet was resuspended
in scintillation fluid. The amount of radioactivity was determined
using a liquid scintillation counter.
All experiments contained control vials (D) in which polymorphs 
were replaced by Gel-Hanks.
The percentage of bacteria taken up or ingested by the polymorphs 
was calculated from the number of counts per minute from each vial, 
using the formulae below:
B - D
% uptake =   x 100
C ” D x 100% ingestion = -----------
7. Experimental technique using platelets: 
inhibition of aggregation
Normal human platelets were obtained fresh from whole blood 
anticoagulated with 3.8% trisodium citrate by centrifugation to obtain 
platelet rich plasma. The rate of platelet aggregation was measured 
by the standard turbidometric technique as described by Born (1962). 
Briefly, a standard volume (100 jul) of various dilutions of IgG (normal 
or from transfused patients) in saline (lOOjil) were added to 200 ul 
platelet rich plasma and incubated at 37°C for 5 minutes prior to the 
addition of 1 pg collagen. The rate of platelet aggregation was then 
estimated; using a Malins two channel aggregometer (change in optical 
density per second) and the results expressed as the percentage inhibition 
of aggregation induced by IgG from patients or from normal controls,
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8. Detection of antibodies to spermatozoa: The Tray Agglutination Test
Antibodies to spermatozoa were detected by the tray agglutination 
test as described by Dor, Rudak & Aitken (1981). Briefly, 5 ul aliquots 
of IgG at dilutions ranging from 1 mg/ml to 0.05 ug/ml in PBS were 
incubated under liquid paraffin for 1 hour at 37°C with 1 ul fresh normal 
human semen. Agglutination was recorded using an inverted microscope 
at a magnification x 100.
9. Extraction of IgG-bindjng proteins from Factor VIII concentrate 
using affinity chromatography
IgG prepared from serum by DEAE chromatography (8:3:iv) was adjusted 
to a concentration of lOmg/ml in phosphate buffered saline and coupled 
with cyanogen bromide activated Sepharose 4B beads (Pharmacia) to give 
an 8 ml volume of beads. This was added to 6 ml reconstituted 
lyophilized Factor VIII preparation.’ (=Hemofil Batch 059IV048A, obtained 
from Glasgow Royal Infirmary). After end-over-end mixing at 4°C for 
18 hours, the beads were washed in phosphate buffered saline until all 
non-specifically absorbed protein (assessed by measuring the optical 
density at 280nm) was removed, and a column was prepared (1 x 15 cm 
column - -Pharmacia).
IgG-binding proteins were eluted using glycine HC1 buffer at pH 
2.8; 4 x 2 ml fractions were collected once the pH of the eluate. began
to fall. ' Each fraction was neutralized with solid Na^HPO^, then 
dialysed into phosphate buffered saline. The fraction containing most 
protein (assessed as previously by optical density) was designated that 
containing Hemofil-derived "antigen".
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10. Polyacrylamide (gDS-PAGE) slab gel, electyophoresjs
A 7.5% non-reducing slab gel was prepared after the method of 
Laemmli ,(1970). Two glass slab gel plates were clamped and sealed 
with 30% aery1amide. Between them was poured 7.5% running gel, 
consisting of 6 ml 30% acrylamide, 6 ml buffer (TRIS 185g/l, SDS 4g/l, 
pH adjusted to 8.9 with N HC1), 100 ul 10% ammonium persulphate, 
lOul M tetramethylenediamine, and 12 ml distilled water. After 
addition of a layer of isobutanol the gel was left to set for one hour. 
After excess isobutanol was tipped off, the remainder of .the space 
between the plates was filled with 3% stacking gel, consisting of 2.4ml 
30% acrylamide, 6 ml buffer (TRIS 59g/l, SDS 4g/l, pH adjusted to 6.7 
with N.HC1), 200 ul 10% ammonium persulphate, 10 ul tetramethylenediamine, 
and 15.6 ml distilled water.
To create wells for substrate, a plastic comb was inserted while 
the gel set. After the comb was removed, to each well was added 
50 ul of the sample substrate to undergo electrophoresis, and 10 ul of 
sample beffer. This buffer was prepared by mixing 7.5 ml stacking 
gel buffer, Ig SDS and 2.5 ml distilled water. The mixture was warmed 
until the SDS dissolved, and then 1 ml glycerol and 4 ml. 1% bromophenol 
blue dye were added. Dalton markers (Sigma) were included in all 
experiments.
The gel plates were clamped to the electrophoretic apparatus.
The upper tank (negative terminal) was filled with buffer consisting of 
TRIS 6.3g/l, glycine 4g/l and SDS lg/1. The lower tank (positive 
terminal) was filled with buffer consisting of TRIS 0.1g/l and SDS lg/1, 
with pH adjusted to 8.1 using 5 N HC1. The gel was subjected to a 
current of 40 mA until the dye front was almost at the foot of the plates.
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After the current and plates were disconnected, the gel was 
incubated at 37°C for 18 hours i,n 0.1% PAGE Blue stain (BDH), in a 
solution consisting of methanol, distilled water and glacial acetic 
acid (volumes in ratio,5:4:1). Then, until the gel pattern appeared 
clear, the gel was suspended in a solution of distilled water, methanol 
and glacial acetic acid (volumes in ratio 8:1:1).
11. Absorption of substrate with Protein A "
One millilitre of Sepharose 4B beads, alone or with Protein A 
(Pharmacia), in phosphate buffered saline, was resuspended in 0.5 ml 
substrate (for example, serum fraction 1, prepared by method 8:3*iii 
above). After end-'over-end mixing at room temperature for one hour, 
the beads were removed by centrifugation and the supernatant used for: 
subsequent experiments.
12. Statistical analysis
Statistical analysis of results was performed using standard 
methods detailed in the text and described by von Fraunhofer and Murray 
(1976).
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CHAPTER 9
THE PREVALENCE OF FcVRECEPTOR BLOCKING ANTIBODIES IN NORMAL- SUBJECTS
1. Introduction
i) Background
As outlined in Chapters 5 and 6, the production of Fcft-receptor 
blocking antibodies was suggested in 1982 as the missing link between 
blood transfusion and renal allograft survival (MacLeod et al, 1982 b). 
Despite further promising evidence from the same group, no reports have 
emerged of similar work from other centres, apart from that described 
in this volume.
At the start in 1983 of this study the general aims were to confirm 
and extend MacLeod’s findings. It was decided to use the EA rosette 
inhibition assay,already in standard use in this laboratory for . 
assessment of Fc'S-receptor blocking (Sandilands et al, 1980; and 
8:4:i). At the outset the intention was to focus on IgG class antibody. 
Because of the possibility of serum factors other than IgG blocking the 
Fc'X-receptor and giving a "false positive" result, the decision was 
taken to use not serum but IgG for experimental work.
Using this assay, Bakkaloglu et al (1980) found in 50 normal 
subjects that the upper limit of inhibition of EA rosette formation of 
normal human peripheral blood lymphocytes by whole serum was 30%. No
"normal" limits for this assay have been defined using IgG.
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ii) Aims: of the study
The purpose of the experiments described in this chapter was to 
define the extent in the author’s hands of EA rosette inhibition by 
IgG from normal subjects, to use for comparison with subjects studied 
in later chapters.
The reports by Power et al (1983 a and b)and Stewart et al (1984) 
of FcY-receptor blocking antibodies in association with successful 
pregnancy led to specific consideration of pregnant and multiparous 
women as subgroups of the normal population.
2. Materials and Methods
i) Subjects studied
Serum samples were obtained from the following groups of normal 
volunteers, none of whom had previously received blood or blood products
a) 13 male members of hospital staff (mean age 34, range 17 - 60 yrs)
b) 7 nulliparous female members of hospital staff (mean age 21, 
range 19 - 26 yrs)
c) 7 pregnant members of hospital staff (mean age 26, range 
23 - 35 yrs). All were in the second trimester of their 
first pregnancy.
d) 11 multiparous members of hospital staff or their families 
(mean age 46, range 33 - 56 yrs)
ii) Methods used
IgG was obtained from serum samples by DEAE Chromatography 
as described above (8:3:iv) and adjusted to a concentration of Img/ml
in phosphate buffered saline. IgG preparations were ultracentrifuged 
at 105,000g for one hour prior to use lest aggregates of IgG had formed 
during freeze-thawing (Sandilands et al, 1980).
The EA rosette inhibition assay was performed on IgG preparations 
as described above (8:4:i). Peripheral blood lymphocytes, obtained 
from unselected healthy members of hospital staff, were used as the 
source of FcX-receptor bearing cells. The assay was performed at 
both 4°C and 37°C. Controls used at each temperature were phosphate 
buffered saline alone, and phosphate buffered saline containing IgG 
obtained from serum from the donor of the target lymphocytes. Control 
percentages of at least 15% EA rosette-forming cells were deemed 
acceptable (Sandilands et al, 1980). Cytotoxicity was excluded by 
2-stage testing at 22°C against a 23-donor panel of peripheral blood 
lymphocytes.
3. Results
Control results were comparable for both temperatures and for 
phosphate buffered saline alone or with IgG from the normal lymphocyte 
donor. In no IgG preparation was significant cytotoxicity against 
peripheral blood lymphocytes demonstrated. Results of the EA rosette 
inhibition assay, taken to reflect degree of Fctf-receptor blocking 
activity, for the various groups studied are depicted below (Figures 
4 to 6).
Figure 4 shows percentage inhibition of EA rosette formation by 
IgG preparations from the 13 males and 7 nulliparous females. The 
maximum percentage inhibition at either temperature was 35%, with no
• "f"
difference detected between males and females. Mean - standard
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deviation percentage inhibition for all 20 patients was 15 - 12 at 
4°C, 7 * 9 at 37°C, and 11 - 11 overall.
Figure 5 shows percentage inhibition of EA rosette formation by 
IgG preparations from the 7 nulliparous, 7 pregnant and 11 multiparous 
women. Three subjects in each of the latter two groups showed 
percentages at both temperatures outwith the ranges depicted in 
Figure 4. Using non-parametric statistical analysis (Mann-Whitney 
U test), only the difference between the nulliparous and pregnant 
women reached statistical significance (P<0.05).
Figure 6 shows the result of an experiment to see whether Fc$- 
receptor blocking activity was removed by ultracentrifugation at 
100,000g for one hour. The failure to do so suggests that IgG, 
rather than contaminating aggregates, was responsible for blocking 
activity in the 6 preparations tested.
Table 1 shows the results obtained when simultaneous testing was 
performed on 10 control lymphocyte preparations rosetted in the presence 
of phosphate buffered saline alone, and with IgG from a known "positive" 
and a known "negative" preparation. This indicates the extent of 
internal and intra-observer variation of the assay in the hands of the 
author.
4. Discussion
The results presented in this chapter provide a reference range 
for comparison of results in later chapters using the EA rosette . 
inhibition assay to test preparations of IgG at concentration Img/ml 
in phosphate buffered saline. The decision as to which percentage 
of inhibition of EA rosette formation to designate "significant" is
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arbitrary, and previous workers haye adopted differing criteria (for 
example, Suthanthiran et al, 1977; Sandilands et al, 1980; MacLeod 
et al, 1982 a).
In the normal nulliparous subjects studied here, no IgG preparation 
inhibited rosette formation to a degree greater than 35% of the control 
value. Overall, the mean percentage inhibition of rosette formation 
at either temperature was 11%, and the value for the mean + 2 standard 
deviations of the mean was 33%. On the basis of these results it was 
decided to regard percentages greater than 35% as outwith the normal : 
range, denoting significant inhibition of rosette formation.
It is necessary also to take into account women’s obstetric 
histories. The results reported here confirm the demonstration by 
Power et al (1983 a and b) that a proportion of women presently or 
previously pregnant may have non-cytotoxic Fctf-receptor blocking IgG 
class antibody. In these experiments the IgG preparations were not 
tested against paternal lymphocytes. Although previous work suggests 
that testing against paternal lymphocytes would yield a higher pro­
portion of "positive" results, the women studied here were being 
considered for use as a control population for a population of multi­
parous renal dialysis patients, for whom testing against unrelated 
donors was more practicable than against their husbands (see Chapter 10).
It is interesting to note that the studies of Power et al (1983 a 
and b) and Stewart et al (1984) show EA rosette inhibitory activity 
of maternal sera against paternal B lymphocytes. Although some of the 
inhibitory activity of the IgG preparations here may be directed against 
the B cell Fc)5-receptor, inhibitory activity as great as 98% (Figure 5) 
can only be explained by inhibition of more than just the B cell receptor 
(Sandilands et al, 1980).
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5. Conclusions
i) Normal values for the EA rosette inhibition assay were obtained 
using IgG preparations in phosphate buffered saline. It was decided 
to regard percentages of EA rosette inhibition greater than 35%
as outwith the normal range for IgG preparations from men and nulliparous 
women.
ii) Several pregnant and multiparous women had results outwith this 
range. .
121
CHAPTER:10
THE ASSOCIATION BETWEEN BLOOD TRANSFUSION AND Fc^-RECEPTOR
BLOCKING ANTIBODIES
1. Introduction
i) Background
The association between blood transfusion and serum Fctf-receptor 
blocking activity has been noted in renal dialysis patients by 
MacLeod et al (1982b, 1983, 1985a), using B lymphocytes from normal 
subjects and patients with chronic lymphatic leukaemia. Discussed in 
this chapter are experiments to assess the prevalence of Fctf-receptor 
blocking antibodies in IgG preparations from transfused subjects with 
and without renal failure.
ii) Aims of the study
The experiments described in this chapter were designed to answer 
the following questions:
a) Is previous blood transfusion associated with the presence of 
non-cytotoxic IgG class FcX-receptor blocking antibodies in 
renal dialysis patients?
b) Are similar antibodies found in transfused subjects without 
known renal disease?
c) Is the presence of antibodies associated with clinical variables 
other than transfusion?
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d) Does antibody activity vary with the lymphocyte donor used?
If so, can the variation be attributed to the donor’s tissue
type?
2. Materials and Methods
i) Subjects studied
*
Serum samples were taken from the groups of subjects listed 
below:
a) Normal subjects: the results for these subjects were obtained
as described in Chapter 9. Twenty (13 male) had had no
transfusions or pregnancies, and 11 were untransfused multiparous
women (considered separately below in Figure 8).
b) Untransfused uraemic subjects: Ten (6 male) subjects with renal 
disease (mean age 45, range 22 - 72 years). All had a serum 
creatinine greater than 600 /imol/1. None had received blood 
or blood products. Two had had previous full-term pregnancies.
c) Transfused uraemic subjects: Fifty-four (30 male) uraemic subjects
on maintenance dialysis (mean age 39, range 19 65 years). All
had received at least 5 units of whole blood or :packed cells, the 
Renal Unit protocol for elective transfusion prior to entry to
the pool waiting for cadaveric transplantation. Nineteen patients 
of both sexes were on continuous ambulatory peritoneal dialysis 
and the rest on haemodialysis. Nine of the women had had previous 
full-term pregnancies.
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d) Transfused non-uraemic subjects; Ten subjects (5 male) with no 
known renal disease and a serum creatinine less than 130 jimol/1 
(mean age 60, range 26 -84). Two! had had previous full-term 
pregnancies. All had received within the past 5 years at least 
5 units of whole blood or packed cells, for a variety of 
indications detailed in Chapter 7:2.
ii) Methods used
IgG prepared from serum samples as described above (8:3:iv) was 
tested for FcK-receptor blocking activity using the EA rosette 
inhibition assay (8:4:i). Peripheral blood lymphocytes, obtained 
from unselected healthy members of hospital staff, were used as the 
source of•Fc^-receptor bearing cells. The assay was performed at 
both 4°C and 37°C. Phosphate buffered saline alone was used for the 
controls at each temperature with control values of at least 15% 
rosette-forming lymphocytes deemed acceptable. Cytotoxicity was 
excluded by 2-stage testing at 22°C against a 23-donor panel of 
peripheral blood lymphocytes. ■ .
3. Results
Figure 7 shows percentage inhibition of EA rosette formation at 
4°C and 37°C by IgG preparations from the subjects detailed above.
Previous transfusion of at least 5 units of blood is associated in both 
uraemic and non-uraemic subjects with the presence of Fcft-receptor 
blocking IgG antibody.
That Fctf-receptor blocking is not a consequence of uraemia is shown . 
by results for the untransfused uraemic and transfused non-uraemic subjects.
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IgG preparations from all of the 10 transfused non-uraemic subjects 
gave Fcft-receptor blocking at both temperatures.
Of the 54 transfused uraemic subjects, at 4°C 14 and at 37°C
31 had FcjX-receptor blocking antibody activity. This difference
between the prevalences of antibody activity at the two temperatures
2was highly statistically significant (P^O.OOl X test). No patient 
had antibody activity at 4°C alone. Similarly, the differences in the 
prevalences of antibody activity at both temperatures between IgG 
preparations from transfused uraemic and non-uraemic subjects were 
highly significant (X^ test, 4°C P<0.001, 37°C P<0.01).
There was no evidence that variables other than transfusion caused 
the increased prevalence of Fctf-receptor blocking activity seen in 
transfused subjects. None of the patients studied was pregnant.
Only two of the non-uraemic subjects had had pregnancies, one two and 
one over fifty years previously. This is insufficient to explain the 
uniform FcY-receptor blocking activity in the non-uraemic transfused 
group.
Nine of the transfused uraemic group had had full-term pregnancies,
all at least five years previously. In this they were similar to the
multiparous control group,to whom they are compared in Figure 8. At
4°C there was no difference between the Fctf-receptor blocking activity
of IgG from transfused and untransfused women. However, at 37°C IgG
from 6 out of 9 transfused and from only 3 out of 11 untransfused women
2
showed blocking activity outwtth the normal range. Using the X test 
with Yates correction, this difference between the groups reached 
statistical significance (P<0.05).
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The transfused subjects as a whole were older than the untransfused 
subjects. However, within each group there was no evidence of increasing 
antibody activity with age.
Within the group of transfused dialysis patients there was, as shown, 
in Figure 7, considerable variation in the capacity of IgG preparations 
to inhibit EA rosette formation. No association was found between 
inhibition at either temperature and the patient’s age, sex, primary 
renal disease, mode of dialysis, length of time on dialysis or HLA type.
Nor was any association seen between rosette inhibition and 
biochemical control of renal failure, as reflected by routine measure­
ments at the time of sampling of serum urea, creatinine and phosphate. 
Serum ferritin was not measured.
There was no obvious association with drug therapy. Unlike' the 
non-uraemic transfused subjects, almost all the dialysis patients were 
taking multivitamin preparations and aluminium-based phosphate binders; 
there was no apparent association between rosette inhibition and 
routine measurements of serum aluminium. ,
In one of the 54 patients the transfusion history was confused by 
his having had a number of units of blood in another centre. For 
the other 53 patients the number of units of blood (of any type) 
transfused at the time of the sample used was plotted against Fc}(- 
receptor inhibition at 37°C in Figure 9. No correlation was seen; 
the same applied when the results at 4°C were used (not illustrated).
The variation was unlikely to be due to differences in concentration 
of antibody, as all IgG preparations had been standardized by
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spectrophotometry to a concentration of Img/ml. Figure 10 shows 
that, despite variation in degree of rosette inhibition with serial 
dilutions of IgG preparations, Fctf-receptor blocking activity was not
g
completely removed by dilution to 1 in 10 of preparations from 
transfused dialysis patients.
Table 2 shows the variation in results obtained when IgG 
preparations from 15 transfused uraemic subjects were tested for 
inhibition of EA rosette formation at 37°C against peripheral blood 
lymphocytes from 4 unrelated normal subjects in, parallel. No obvious 
pattern of reactivity against the antigens common to the lymphocyte 
donors was seen.
Only. 3 of the IgG preparations studied had cytotoxic activity ' 
against more than 10% of the donor lymphocyte panel used for tissue 
typing. ' All 3 subjects were dialysis patients who had received 
multiple transfusions; one had also had two full-term pregnancies.
4. Pis cussion
The findings in this chapter confirm the association reported by 
MacLeod et al (1982 b) between blood transfusion and FcK-receptor 
blocking antibodies. Previous work has concentrated on B lymphocytes 
rather than unseparated peripheral blood lymphocytes, because of early 
evidence linking la antigens to Fc)(-receptors on the surface of B 
lymphocytes (Chapter 6:4:ii). The results described here show that 
antibodies associated with transfusion may be detected using peripheral 
blood lymphocytes. It is unlikely that the high levels of inhibition 
of EA rosette formation seen in some subjects can be explained by 
antibodies blocking only B lymphocyte Fc^-receptors (Unkeless et al, 
1981). Experiments to confirm Fc^-receptor blocking activity against
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T lymphocytes are.described in Chapter 12.
The use of IgG separated by DEAE chromatography, while more time- 
consuming than the use of serum, confirmed that IgG was responsible 
for the Fcfr-receptor blocking activity. This does not preclude the 
existence in serum of other Fctf-receptor blocking factors.
It is interesting that more IgG preparations were found to have 
FcV-receptor blocking activity when the EA rosette inhibition assay was 
performed at 37°C than at 4°C. Only at 37°C was a significant 
difference found between transfused and untransfused multiparous women. 
This may be compared to the increased sensitivity at 37°C of lympho- 
cytotoxicity testing (Kissmeyer-Nielsen and Dick, 1979), and may reflect 
temperature-dependent differences in antigen expression on the cell 
surface. It is unlikely to be a kinetic phenomenon as continuing the 
period of incubation at 4°C for up to one hour did not increase the 
sensitivity of the assay (results not shown). In each case, peripheral 
blood lymphocytes from the same normal donor were used for testing at 
both temperatures and no IgG preparation had Fc&-receptor blocking 
activity at 4°C only.
Previous studies of transfusion-related Fc -receptor blocking 
antibodies have employed EA rosette.inhibition at 4°C only (MacLeod 
1982b, 1983, 1985a). In the first report from the Aberdeen group 
linking the transfusion effect to FcV-receptor blocking antibodies 
(MacLeod et al, 1982b), 10 out of 11 patients with, and 9 out of 20 
patients without pretransplant serum Fc -receptor blocking activity, had 
functioning transplants after one year.
As a test to predict renal allograft survival the assay had, from 
these figures, much greater specificity (92%) than sensitivity (53%)
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(Alderson, 1976). Of the 54 transfused uraemic subjects reported here 
14 (26%) at 4°C and 31 (57%) at 37°C had FdJf-receptor blocking activity 
against lymphocytes from a normal donor. It is tempting to speculate 
whether doubling the sensitivity of the assay by performing it at 37°C 
might also double its sensitivity as a predictive test for renal 
allograft^ survival.
In contrast to the results for the uraemic subjects, IgG preparations 
from all 10 transfused subjects without known renal disease had 
Fc8-receptor blocking activity at both temperatures. This homo­
geneity was not reflected in the patients' clinical histories, the only 
common factor being that each had in the past received at least 5 units 
of blood (Chapter 7:2).
The difference in prevalence of antibody between the uraemic and 
non-uraemic groups in this study could not be explained by an increased 
prevalence of cytotoxicity of IgG preparations from the non-uraemic 
group (Morito et al, 1978). There have been suggestions that cytotoxic 
antibody formation may be greater in non-uraemic patients. Ferrara 
et al (1974) repeatedly transfused normal recipients with blood from 
the same donor, and found that all but 20% of recipients eventually ' 
developed anti-donor cytotoxins. The majority of patients studied by 
Varghese et al (1981) and Fehrman and Ringden (1982) had detectable 
cytotoxins after transfusion for chronic anaemia in the absence of renal 
failure. There have been no previous reports of non-cytotoxic 
Fctf -receptor blocking antibodies in transfused non-uraemic subjects.
Assessment of the "normal" response to transfusion is complicated 
by the difficulties in dissociating the effects of transfusion from the 
effects of the underlying disease. For example, it has been reported 
that activated T lymphocytes may suppress haematopoiesis in patients
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with aplastic anaemia (Bacigalupo et al, 1980; Torok-Storb and 
Hansen, 1982; Nakao et al, 1984). Yet the uncertainty remains that 
these suppressor lymphocytes could be a consequence of transfusion 
not disease (Singer et al, 1978; Torok-Storb et al, 1980; Zoumbos 
et al, 1985).
The effects of transfusion and uraemia have also been difficult to 
distinguish (Guttman, 1978). Scanty transfusion details hinder 
interpretation of the bulk of the literature (reviewed by Goldblum and 
Reed, 1980; Keane and Raij, 1983). There have been conflicting 
reports on the antibody response in patients with uraemia although 
serum immunoglobulin levels have been regarded as normal (Goldblum and 
Reed, 1980)
Balch (1955) found no evidence of impairment of the capacity of 
patients vith post-traumatic acute renal failure to synthesise tetanus 
antitoxin after booster inoculation with tetanus toxoid. Stoloff et al, 
(1958) reported normal responses to booster diphtheria toxoid in 
Schick-negative uraemic patients. Wilson, Kirkpatrick and Talmage 
(1965) found that uraemic subjects had poor responses to typhoid 
vaccine despite having encountered it previously.
More recently, Bramwell et al (1985) found that impaired response 
to hepatitis B vaccine in dialysis patients was predicted by impairment 
of cell-mediated immunity, as assessed by skin testing with 
Dinitrochlorobenzene. Although the link with transfusion was not 
discussed, the same group had shown a relationship among prior transfusion, 
poor response to Dinitrochlorobenzene and improved renal allograft survival 
(Watson et al, 1979 and 1981),
The results in this study suggest that uraemia may be associated
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with reduction in the prevalence of FcX-receptor blocking antibodies 
in transfused subjects. Multiparous women may have antibody activity, 
but no further clinical variables associated with the presence of 
antibodies were identified.
The FcY-receptor blocking activity of IgG preparations from 
transfused dialysis patients varied with the donor of the receptor- 
bearing lymphocytes. The apparent lack of association with the HLA-A,
B or DR type of the lymphocyte donor echoes the findings of MacLeod 
et al (1982a), although MacLeod et al (1985a) suggested from a family 
study that FcV-receptor blocking antibodies showed HLA linkage. It 
is possible that the antibodies are directed against an undefined 
class II antigen system expressed on the cell surface in association 
with the FcY-receptor (MacLeod et al, 1982b).
Genetic polymorphism of the FcY-receptor itself could also 
contribute to the variation. Kaneoka et al (1983) and Tax et al 
(1985) have proposed that polymorphism of Fc^-receptors is not HLA- 
linked and is responsible for the heterogeneity of the human lymphocyte 
response to mouse monoclonal antibodies.
It is possible that the antibodies are directed against the range 
of alloantigens expressed by previous blood donors. Access to 
information about blood donors, for example their HLA types, was not 
readily available. The situation in which it would be feasible to 
study the antibody response to a particular donor • is that of donor- 
specific transfusion prior to haploidentical live related donor 
transplantation. Experiments with donor-specific transfusion are 
discussed in Chapter 11.
The results of this cross-sectional study show a strong association
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between previous blood transfusion and the presence of Fc^-receptor 
blocking antibodies. Confirmation of the association would be 
previded by following untransfused patients over a protocol of elective 
transfusion. This is discussed further in the next chapter.
5. Conclusions
i) Previous blood transfusion was associated with the presence of 
non-cytotoxic IgG class antibodies detected by their.capacity 
to block Fcft-receptors on peripheral blood lymphocytes from 
normal subjects.
ii) More IgG preparations from transfused renal dialysis patients 
were found to have Fctf-receptor blocking activity when tested 
at 37°C than at 4°C.
iii) IgG preparations from fewer uraemic than non-uraemic subjects 
had Fctf -receptor blocking activity.
iv) No clinical variables other than previous transfusion and 
pregnancy were identified as associated with the presence in 
uraemic subjects of Fcif-receptor blocking antibodies.
v) IgG preparations varied in Fc^receptor blocking activity with 
the peripheral blood lymphocyte donor used.
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CHAPTER 11
THE PRODUCTION OF Fc^-RECEPTOR BLOCKING ANTIBODIES FOLLOWING 
ELECTIVE BLOOD TRANSFUSION IN RENAT DIALYSIS PATIENTS
1. Introduction
i) Background:
The last chapter illustrated the association between previous 
blood transfusion and non-cytotoxic IgG class antibodies detected by 
their capacity to block the Fctf-receptors on peripheral blood lympho­
cytes. Demonstration of this association is, however, incomplete in 
a purely cross-sectional study. The experiments presented in this 
chapter follow renal dialysis patients over the course of the elective 
transfusion protocols designed to prepare them for transplantation.
ii) Aims of the study
The experiments described in this chapter were devised to answer 
the following questions:
a) Do Fc&-receptor blocking antibodies develop over the course of 
elective third party blood transfusion?
b) Do donor-specific Fc-receptor blocking antibodies develop after 
dorior-specific transfusion from a, haploidentical relative?
2. Materials and Methods
i) Subjects studied
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a) Ten untransfused renal dialysis patients (8 male, mean age 37, 
range 19 - 49 years) undergoing electiye third party transfusion 
before entering the pool for cadayeric renal transplantation.
The elective transfusion protocol consisted of five units of 
packed cells from different donors transfused at fortnightly 
intervals.
b) Ten renal dialysis patients (5 male, mean age 27, range 15 
- 52' years) undergoing donor-specific transfusion from a 
haploidentical relative. The donor-specific transfusion 
protocol adopted in Glasgow was that of Salvatierra et al (1980). 
The prospective renal allograft donor provided one unit of blood, 
which was given to the recipient in three aliquots at fortnightly 
intervals. All but 2 patients had received previous third party 
blood. The donor in 6 cases was a sibling and in the other 4.
a parent.
ii) Methods used
Serum samples were taken from each subject before the course of 
transfusion and two weeks after each transfusion. IgG preparations 
were made from each sample, and stored and ultracentrifuged as before 
prior to use (8:3:iv).
IgG preparations from the group undergoing third party transfusion 
were tested for FcV-receptor blocking actiyity against normal human 
peripheral blood lymphocytes, using the EA rosette inhibition assay 
at both 4°C and 37°C. IgG preparations from the group undergoing 
donor-specific transfusion were tested against peripheral blood 
lymphocytes from the blood donor, from other first degree relatives
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and from unrelated controls. Phosphate buffered saline alone was 
used for the controls. Cytotoxicity was excluded by 2-stage testing 
at 22°C against a standard tissue typing panel as previously.
3. Results
Figure 11 shows the percentage inhibition of EA rosette formation 
at 4°C and 37°C by IgG prepared from serum samples taken from patients 
before and after the 5 unit course of third party blood. A significant 
increase in inhibition at both temperatures was noted after trans­
fusion (P4.0.05, Wilcoxon Matched Pairs Signed-Rank Test). Two 
patients in this group were found to have cytotoxic antibody following 
transfusion.
Figure 12 shows more detailed results for 2 patients, testing IgG 
preparations after each unit of third party blood. Patient B had no 
antibody response to transfusion in this assay. Although IgG from 
patient A developed FcX’-receptor blocking activity at 4°C later in the 
transfusion protocol than at 37°C, this was not a consistent finding 
in other patients studied.
The results of donor-specific transfusion are shown in Figure 13.
No subject had had a successful pregnancy, and it would seem likely that 
the 3 patients who had evidence of anti^donor Fc'tf-receptor blocking 
antibody:even before donor-specific transfusion had acquired it through 
third party transfusion. One of only 2 previously untransfused 
patients developed anti-donor cytotoxic antibody, and the other showed 
no FcY-receptor blocking activity after transfusion against either 
peripheral blood or B lymphocytes from the donor sibling, their parents
or 4 other siblings. Only 2 of the 10 patients studied developed non-
135
cytotoxic anti-donor FcV-receptor blocking 'antibody. Using the Wilcoxon 
test again no significant change in anti-donor antibody activity at 
either temperature was demonstrated after transfusion.
The high incidence of prior third party transfusion and the small 
number of patients developing non-cytotoxic antibody after donor-specific 
transfusion unfortunately render non-contributory the family studies, 
which were undertaken in order to try to demonstrate HLA-linkage of 
antibody production! Both patients who developed non-cytotoxic anti­
donor antibody had received third party blood before donor-specific 
transfusion from their mothers. Each failed to develop anti-paternal 
antibodybut was found to have Fc)J-receptor blocking activity after 
transfusion in each case against one of three siblings. . However, in 
one family pretransfusion IgG also blocked the sibling's peripheral 
blood lymphocyte EA rosette formation. In the other the relevant 
sibling was an identical HLA match to the patient. In each case 
donor-specific transfusion was accompanied by the development of anti­
body against unrelated subjects as well as the blood donor.
4. Discussion
The results in this chapter show that IgG class antibodies which, 
block Fc't-receptors on normal peripheral blood lymphocytes develop over 
the course of a three-month, five unit, elective blood transfusion 
protocol in renal dialysis patients. This has already been shown for 
B lymphocytes by MacLeod et al (1982b, 1983).
The relative clarity of the results for third party transfusion 
contrasts with those for donor-specific transfusion. Although one 
family study has been published by MacLeod et al (1985a) there have been
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no published reports of Fc8-receptor antibody production in protocols 
of donor-specific transfusion prior to haploidentical live, related 
donor renal transplantation,
The reports of anti-idiotypic antibody after donor-specific 
transfusion are discussed in Chapter 5:11: ii, and share the weaknesses 
of the results of donor-specific transfusion in this study (Burlingham 
et al, 1985a and b ; Reed et al, 1985; Takeuchi et al, 1985). Although 
the number of patients is relatively respectable (10), 8 of these had 
had previous third party blood. Had the antibody response to donor- 
specific transfusion been less varied, it might have been easier to 
comment on the results.
In particular, the effort expended on family studies was not 
worthwhile. The lack of HLA-linked pattern of Fc^-receptor blocking 
activity .could in most cases have been ascribed to previous, third 
party blood. Of the 2 patients who had never been transfused, one 
developed cytotoxic antibody and the other developed no Fc#-receptor 
blocking antibody activity against unseparated or B lymphocytes from 
any family member. The latter patient had excellent graft function 
18 months after receiving a kidney from the blood donor.
Transplant outcome bore no relation to the development of Fd$- 
receptor blocking antibodies against donor peripheral blood lymphocytes 
following donor-specific transfusion. Four out of the 10 original 
donor-recipient pairs did not proceed to transplantation because of the 
development of cytotoxic antibodies in the recipient or the discovery 
of medical contraindications in the donor. Of the 6 who did reach 
transplantation, 5 kidneys were functioning at one year. The sixth 
was lost through rejection at 9 months. The recipient had developed
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non-cytotoxic anti-donor FcXVreceptor blocking antibodies during the 
course of donor-specific transfusion, but had also had large amounts 
of third party blood.
Consideration of these results suggests that any follow-up study 
should include only patients who have never had third party blood.
The number of such patients in any one centre may be small. It is 
perhaps worth noting that, although donor-specific transfusion has been 
widely used, the Collaborative Transplant Study has recently failed to 
report any advantage in transplant survival over third party blood 
(Opelz, 1985c).- Our own centre has now discontinued donor-specific 
transfusion after hyperacute rejection of a kidney. This case was 
not one of those studied here and rejection may have been related to 
the later finding of a positive monocyte crossmatch (Cerilli et al, 
1985).
5. Conclusions
i) Elective third party blood transfusion is associated in renal 
dialysis patients with the development of non-cytotoxic IgG 
class antibodies detected by their capacity to block FcY-receptors 
on peripheral blood lymphocytes from normal subjects.
ii) No consistent association was seen between donor-specific 
transfusion and the development of similar antibodies directed 
against lymphocytes from the blood donor. This may have been 
related to previous third party transfusion.
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CHAPTER 12
THE, SPECTRUM OF CELLULAR REACTIVITY OF TRANSFUSION-RELATED 
Fc%-RECEPTOR BLOCKING ANTIBODIES
1. Introduction
i) Background
Having confirmed in the previous chapters the association between 
blood transfusion and the production of FcJf-receptor blocking antibodies, 
the next task was to delineate the spectrum of cellular activity of 
IgG preparations obtained from multiply transfused subjects.
ii) Aims of the study
The experiments described in this chapter were designed to answer 
the following questions:
a) Can transfusion-related IgG class antibodies, detected by their 
capacity to block FcV-receptors on allogeneic peripheral blood 
lymphocytes, be shown to block Fc^-receptors on other cells’
b) Can IgG preparations from transfused subjects inhibit Fc&'-receptor 
mediated cell functions in vitro?
c) Do IgG preparations with Fctf-receptor blocking activity block 
other cell surface receptors also?
2. Materials and Methods
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i) Subjects studied
Peripheral blood lymphocytes were obtained (8:1:i) from the 
following subjects:
a) 40 untransfused normal volunteers
b) 11 patients with serum creatinine greater than 600 micromols/1 
who were not on maintenance dialysis and had never been transfused
c) 5 patients with serum creatinine greater than 600 micromols/1 who 
had received at least 2 units of blood but were not on maintenance 
dialysis
d) 10 patients with functioning renal transplants (serum creatinine 
less than 300 micromols/1) who had received at least five units of 
blood prior to transplantation and were on maintenance immuno­
suppressive therapy with Prednisolone (range 10 - 15 mg daily) 
and Azathioprine (dosage range 50 - 150 mg daily)
In 20 subjects, distributed among the study groups, simultaneous 
serum samples were taken and IgG preparations made (8:3:iv).
Additional IgG preparations used in the experiments described in 
this chapter were those from transfused and untransfused'subjects as 
described in Chapters 7, 9 and 10.
The number of samples analysed varied between assays; the numbers 
of subjects studied are given beside the relevant results.
ii) Methods used
The .percentage of EA rosette-forming cells in peripheral blood 
lymphocyte preparations from study subjects was assessed (8:4:i). 
Concurrent IgG preparations from these subjects were tested for inhibition
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of EA rosette formation by allogeneic peripheral blood lymphocytes.
IgG preparations from normal and transfused subjects were tested 
against cells from normal donors:
a) for inhibition of EA, EAC and.NSE rosette formation simultaneously 
against peripheral blood lymphocytes from the same normal donor. 
(Methods described: 8:4:i; 8:4:ii; 8:4:iii).
b) for inhibition of EA rosette formation (8:4:i) by B and T cell 
enriched lymphocyte preparations (8:l:ii).
c) for inhibition of phytohaemagglutinin (PHA)-induced lymphocyte 
blastogenesis (8:4:iv).
d) for inhibition of antibody-dependent cell-mediated cytotoxicity 
and Natural Killer cell function (8:4:v)
e) for inhibition of polymorph EA rosette formation (8:6:i)
f) for Inhibition of polymorph phagocytosis of IgG-coated latex
beads (8:6:ii)
125g) for inhibition of uptake and ingestion by polymorphs of 1 - 
labelled Staphylococcus aureus (8:6:iii)
h) for inhibition of monocyte EA rosette formation (8:5)
i) for inhibition of collagen-induced platelet aggregation (8:7)
IgG preparations from 3 transfused subjects were tested for 
inhibition of EA rosette formation by peripheral blood lymphocytes 
from 1 normal donor (8:4:i) before and after absorption with the following 
types of cells (8:3:v); erythrocytes (8:l:v); platelets (8:l:vi); 
thymocytes (8:2:ii) and B lymphocytes (8:l:ii) from a patient with 
chronic lymphatic leukaemia. These last were classified as B cells 
according to their reactivity with monoclonal antibodies (OKT 11,.8 and 
4 (Becton Dickinson) and Pan B (DAKO)); they carried surface immuno­
globulin and formed spontaneous rosettes with mouse erythrocytes but
failed to form rosettes with chicken EA.
3. Results
i) Lymphocytes
Figure 14 shows the percentages of EA rosette-forming lymphocytes 
in peripheral blood from groups of transfused and untransfused subjects. 
Statistical analysis, performed by two-tailed Studentfs t test 
assuming normal sample distribution, gave the levels of significance 
in Table 3 for the differences between results for the groups. No 
correlation was found (Figure 15) between the percentage of EA rosette- 
forming peripheral blood lymphocytes and the capacity of the corresponding 
IgG preparations to inhibit rosette formation by allogeneic peripheral 
blood lymphocytes.
Figure 16 shows the results for inhibition at 37°C of EAC and NSE 
rosette formation of normal human peripheral blood lymphocytes by IgG 
preparations from 10 untransfused subjects, 6 of whom were healthy and 4 
of whom were on regular dialysis. These results are provided for 
comparison with those in Figure 17, where IgG preparations from 14 
transfused dialysis patients were tested simultaneously for inhibition 
at 37°C of EA, EAC and NSE rosette formation by peripheral blood 
lymphocytes from the same donor. (Controls >25% EAC, >75% NSE rosettes).
Although some inhibition of EAC rosette formation was noted, this 
occurred to a lesser degree than did inhibition of EA rosette formation.
In no patient was NSE rosette formation inhibited.
Interestingly, when IgG preparations from 3 women in.the second 
trimester of pregnancy were tested specifically against paternal
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lymphocytes, inhibition of both EA and EAC rosette formation was 
noted (Figure 18). Percentages for inhibition of EA rosette formation 
were outwith the range already defined as normal (Chapter 9). Using a 
Mann-Whitney U test IgG preparations from the 3 pregnant women inhibited 
EAC rosette inhibition to a significantly greater extent than did IgG 
preparations from the 6 untransfused normal subjects in Figure 16 
(RIO.05).
Figure 19 shows the results for inhibition of EA rosette formation 
at 37°C by IgG preparations from 10 transfused dialysis patients. The 
Fc'fc-receptor bearing cells used were T and B cell enriched lymphocyte 
preparations from a single normal donor. (Controls >15% T, >35% B).
The upper limit of normal inhibition of EA rosette formation by 
IgG was again taken to be 35%. Although values for T and B cell 
enriched preparations were not established as for peripheral blood 
lymphocytes (Chapter 9), in none of 4 normal IgG preparations tested 
was inhibition greater than 10% (results not illustrated) and the 
limit used, by MacLeod et al (1982 a and b) for B lymphocytes was 40%.
In 7 out of 10 cases illustrated there was concordance between the 
results for the two cell preparations. One IgG preparation had 
Fc^-receptor blocking activity against the T but not the B cell pre­
paration, and 2 inhibited rosette formation of the T but not the B 
cell preparation.
Table 4 shows values for inhibition of K and NK cell cytotoxicity 
by IgG preparations from 5 and 9 transfused dialysis patients 
respectively. In none of 3 normal subjects did inhibition of 
cytotoxicity exceed 15%, but no significant difference between the 
normal and transfused subjects was found (Mann-Whitney U test).
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IgG preparations from 11 normal subjects and 9 transfused dialysis 
patients were tested with peripheral blood lymphocytes from a single 
donor for inhibition of both EA rosette formation (at 37°C) and inhibition 
of PHA-induced biastogenesis. Figure 20 shows the results of inhibition 
of PHA-induced biastogenesis (performed in triplicate with mean 
control value 3967 counts per minute). IgG preparations from the 
transfused patients inhibited biastogenesis to a significantly greater 
degree than did IgG preparations from the normal subjects (B^O.Ol, 
Mann-Whitney U test ). Mean (- standard deviation) percentage inhibition
4- 4-
was 30 (- 4) for the normal, and 46 (- 10) for the transfused group. 
Inhibition of EA rosette formation by each IgG preparation is plotted 
against inhibition of biastogenesis in Figure 21, with a statistically 
significant correlation noted between the two percentages (P40.01).
ii) Polymorphs
Figure 22 shows the results of the EA rosette inhibition assay 
(37°C) using polymorphs from a normal donor. The IgG preparations 
came from'6 normal controls and 27 transfused subjects, all but 2 of 
whom were uraemic subjects on dialysis. None of the 6 normal subjects 
had antibody activity inhibiting polymorph EA rosette formation by more 
than 25%, but samples from 14 of the transfused subjects (including 
both of those without renal disease) gave higher levels of inhibition 
(normal versus transfused groups, P^O.OOl, Mann-Whitney U test).
In Figure 23 the results of EA.rosette inhibition for polymorphs are 
plotted against those for peripheral blood lymphocytes, using the same 
IgG preparations and the same normal cell donor. No significant 
correlation is seen.
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Figure 24 shows the effect of IgG preparations from 6 normal and 
17 transfused uraemic subjects on the percentage of IgG-coated latex 
beads taken up by polymorphs from a normal donor. Control tests
showed that no beads were ingested without prior coating with IgG. No 
significant difference between the normal and transfused subjects was 
detected (Mann-Whitney U test).
The one normal subject whose IgG preparation gave 70% inhibition 
of ingestion of latex beads was a healthy multiparous woman. Three 
women in each of the normal and transfused groups had had previous full- 
term pregnancies; if they are excluded from consideration the 
difference between the normal and transfused groups by the same 
statistical analysis has a p value of 0.05. In the absence of more 
data the association between previous transfusion and IgG inhibition 
of polymorph phagocytosis of IgG-coated latex beads remains not proven.
No correlation was found between percentage inhibition of 
phagocytosis of the beads and percentage inhibition of EA rosette 
formation of polymorphs from the same normal donor (Figure 25).
Uptake of IgG-coated latex beads is mediated through the Fc6- 
receptor; phagocytosis of Staphylococcus aureus is, however, related 
to the C3b receptor (Ross, 1982). The results of experiments to 
assess the effect of IgG preparations on uptake and ingestion by normal 
polymorphs of radiolabelled Staphylococcus aureus are presented in 
Figure 26. IgG preparations from 6 normal and 6 transfused uraemic 
subjects were tested. Both uptake and ingestion were impaired in the 
transfused uraemic, as opposed to. the normal, subjects (Mann-Whitney 
U test, P<0.05 for both parameters). There was a close correlation 
between uptake and ingestion (r •= 0.85, P/L0.001)
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iii) Monocytes
On parallel testing against cells from the same normal donor, none 
of 6 IgG preparations found to inhibit EA rosette formation by peripheral
blood lymphocytes and polymorphs inhibited monocyte EA rosette formation.
o + .
The assay, was performed at 37 C only. Mean - standard deviation
percentage inhibition of EA rosette formation for each of the cell types
tested was as follows:
monocytes 1 + 2  
lymphocytes 6 7 - 7  
polymorphs 5 4 - 1 2
iv) Platelets
IgG preparations from 6 normal and 6 transfused subjects (all but 
one uraemic) were tested for their capacity to inhibit collagen- 
induced aggregation of normal platelets. Figure 28 shows the results, 
with corresponding values for peripheral blood lymphocyte FcJf-receptor 
blocking activity. The difference in degree of inhibition of platelet 
aggregation between IgG preparations from normal and transfused subjects 
was found.to be statistically significant (P<0.05, Mann-Whitney U test).
v) Absorption experiments
IgG preparations from 3 transfused subjects were tested for their 
capacity to inhibit EA rosette formation by peripheral blood lymphocytes 
from a single normal donor before and after absorption with a variety of 
cells. The results (Figure 28) show that Fctf-receptor blocking activity 
was removed by absorption with platelets, which carry the receptor, but 
not by erythrocytes, which do not. Inhibition of EA rosette formation
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was also removed after absorption with thymocytes and B cells from a 
patient with chronic lymphatic leukaemia, neither of which, expressed 
Fc ^ -receptors, as assessed by failure to form EA rosettes.
4. Discussion
The results presented in this chapter show the effects of IgG 
preparations from untransfused and transfused subjects on a variety of 
cell types and functions. Although the intention was to look primarily 
at IgG preparations in relation to their Fcif-receptor blocking activity, 
it seems likely that the range of antigens presented by blood transfusion 
leads to other types of antibodies contributing to the results found 
here.
In some of the experiments, IgG preparations were tested in 
parallel with antiserum to membrane-labile Fc ^ -receptors derived from 
normal peripheral blood lymphocytes. Results for this antiserum have 
been published elsewhere (Sandilands et al, 1985) and provide a standard 
for comparison with the effects of Fc^-receptor blocking IgG preparations.
If Fe^-receptor blocking antibodies suppress the immune response 
to the renal allograft in vivo, they may do so by blocking antigen- 
presenting cells in the graft (Jones, Hans-Hartmut and Feldman, 1972;
Hart and Fabre, 1982), The alternative would be to block the patient’s 
own lymphocytes. MacLeod et al (1985b) suggested that FcJf-receptor 
blocking antibodies are alio- rather than autoantibodies. Reactivity 
of B cell', antibodies with B cells from patients with chronic lymphatic 
leukaemia:has been taken to indicate that they are not autoantibodies 
(Ting and Morris, 1978b). Fc^-receptor blocking activity was removed 
from IgG preparations in this study' by absorption with B cells from a 
leukaemic patient.
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Blood transfusion has been reported as leading to increased 
expression of 0KT8 positive, Xa postive, Fctf-receptor bearing T 
lymphocytes (Mangan et al, 1982; Gascon et al, 1984; Nakao et al,
1984). However, if transfusion were associated with the development 
of antibodies blocking autologous Fctf-receptors, one might expect to 
find in transfused subjects a decrease in the percentage of lymphocytes 
bearing unblocked receptors. Circumstantial evidence for this was 
provided by the reduced percentage of EA rosette-forming lymphocytes 
found in the transfused subjects studied here. No conclusion could 
be drawn without further experiments. It would be interesting to 
test IgG from transfused subjects for inhibition of EA rosette 
formation by autologous lymphocytes obtained and frozen prior to 
transfusion.
IgG preparations from transfused patients blocked EAC and NSE 
less readily than EA rosette formation. This suggests that the antigen(s) 
against which transfusion-associated antibodies are produced are in some 
way linked to the FcX-receptor rather than the other receptors on the 
cell surface. At the same time, removal of Fcft-receptor blocking 
activity by absorption with non-Fc^-receptor bearing thymocytes and 
leukaemic cells underlines the distinction between the receptor and the 
putative antigen(s) (janossy, 1981; Soulillou and Peyrat, 1979).
In contrast, the pregnant women tested had EAC as well as EA rosette 
inhibitory activity against paternal peripheral blood lymphocytes.
If this were confirmed in larger numbers of patients it might indicate 
a difference between Fctf-receptor blocking antibodies associated with 
transfusion and pregnancy.
IgG preparations from transfused subjects had Fc&'-receptor blocking
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activity against both T and B cell enriched lymphocyte populations, 
although not all preparations had activity against both types of cells 
from the same donor. The discrepancy could be explained by the 
suggestion that T and B cell FcY-receptors are antigenically different 
(Cunningham-Rundles et al, 1980) but it is interesting that FCab’)^
fragments from the Fcif-receptor antiserum gave almost identical levels 
of inhibition of EA rosette formation by both cell preparations 
(Sandilands et al, 1985).
No IgG preparations affected the Killer or Natural Killer cell 
functional assays. The assay for Natural Killer cell function is 
independent of the Fctf-receptor but antibody-dependent cell-mediated 
cytotoxicity is mediated through the Fcfc- receptor (Dickler, 19 74;
Kay et al, 19 79).
Like the IgG preparations studied here, the anti-Fc^-receptor 
antiserum preparation did not inhibit antibody-dependent cell-mediated 
cytotoxicity, a finding attributed to the difference between the 
Fc^-re cep tors predominant on Killer cells and the membrane-labile 
receptors against which the antiserum was raised (Sandilands et al, 
1985).
Reduced Natural Killer cell function has been described in 
transfused non-uraemic subjects (Gascon et al, 1984). Bender et al 
(1984) reported that sera from uraemic subjects depressed the function 
of Natural Killer cells from normal subjects, but use of only a handful 
of patients prevented them from drawing conclusions about the role of 
transfusion.
There have been consistent reports of depression of cell-mediated
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immunity with clinical consequences ranging from the prolongation of 
allograft survival, described first for skin grafts in 1957 (Dammin,
Couch and Murray) to the occurrence of tuberculosis in populations with 
renal failure at up to 12 times the rates in control populations 
(Andrews et al, 1980). Although other factors, such as debility and 
poor nutrition, may contribute to these findings, transfusion may also 
be important. The association between transfusion and skin testing 
with Dinitrochlorobenzene has already been discussed (Chapter 5:7).
The T cell mitogen response to phytohaemagglutinin was selected 
as an index of T cell function for the experiments reported here 
(Mills, 1966). This has been widely used in previous studies in 
uraemic patients with emphasis placed on the phytohaemagglutinin 
response of lymphocytes from uraemic patients. Several groups have 
now found this to be normal except in patients who had had around'
20 units of blood. Failure to consider transfusion histories may have 
contributed to previous conflicting reports. (Boulton-Jones et al,
1973; Fehrman and Ringden, 1981; Jeannet et al, 1982; Klatzmann 
et al, 19,83a) .
There have been a number of suggestions that serum from uraemic 
subjects can reduce T lymphocyte responses. Newberry and Sanford 
(19 71) showed that serum from patients with renal failure but not from 
normal subjects was associated with depression of the phytohaemagglutinin 
response. Using a model of adoptive transfer of tuberculin sensitivity 
in acutely uraemic guinea pigs, Johnston and Slavin (1976) suggested 
that lymphocyte unresponsiveness was a consequence of uraemia. Hanicki 
et al (19 76) and Harwick, Kalmanson and Guze ( 19 78) claimed that : 
depression of the mitogen response was a direct chemical effect of renal 
failure. Sengar et al (1975) found in haemodialysis patients that the
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plasma fraction containing IgG could inhibit mixed lymphocyte 
reactivity, but did not associate this finding with transfusion.
Studies of anti-idiotypic antibody production following blood 
transfusion in renal dialysis patients have concentrated on the capacity 
of these antibodies to depress mixed lymphocyte reactivity rather than 
the mitogen, response (for example, Singal et al, 1983; Burlingham et al, 
1985b).
The results reported here show that following transfusion, some 
dialysis patients possess IgG with the capacity to inhibit the mitogen 
response in vitro. This appears to be associated with Fcfc-receptor 
blocking activity but it is possible that both effects are unrelated 
consequences of transfusion. Immune complexes have been implicated 
in the release of soluble suppressor factors by interaction with T cell 
Fcjf-re cep tors (Greene et al, 1981; Moretta et al, 1979); although, not 
described;, it is possible that Fctf-receptor blocking IgG could initiate 
the same process.
Contamination of the IgG preparations with aggregated immunoglobulin 
or immune complexes could have given artefactual inhibition of the mitogen 
response. However, IgG preparations were ultracentrifuged prior to use, 
and there was no evidence of contamination in preparations tested for 
purity with gel electrophoresis.
Untransfused uraemic subjects were not studied in this set of 
experiments so inhibition of the mitogen response due to renal disease 
alone cannot be excluded. However, a direct effect of uraemia is 
unlikely with the extensive dialysis entailed by preparation of IgG 
from serum before testing. The experiments provide the first evidence
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for a possible mechanism of action of IgG preparations with Fc^-receptor 
blocking;activity in the suppression of the immune response.
Because polymorph phagocytosis may be mediated through the Fc'tf- 
receptor, it was decided to assess the effect of Fctf-receptor blocking 
antibody preparations on phagocytosis both dependent on and independent 
of the receptor (Ross, 1982). Polymorph phagocytosis has been 
reported as normal or depressed in renal failure (reviewed by Goldblum 
and Reed, 1980). Not only are the reports contradictory but trans­
fusion history has not generally been considered a possible influence on 
the results.
A recent exception to this was the study by Waterlot et al (1985).
They claimed that raised serum ferritin concentrations consequent on 
transfusion were associated with depressed phagocytosis by.polymorphs 
from dialysis patients. They also linked this finding to the incidence 
of clinical infection.
As Keane and Raij (1983) commented, "while there is a general 
clinical impression that Uraemic patients have an inherent increased 
susceptibility to infection .... this has been difficult to document 
from the literature and in our own experience". Keane and Raij quoted 
a figure of 20% for the proportion of deaths in dialysis patients 
attributed to infection.
No attempt was made in the study reported here to draw an 
association between infective episodes and the effects on normal polymorphs 
of IgG preparations from transfused subjects. Serum ferritin was not 
routinely measured.
Although IgG preparations from some transfused subjects blocked
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polymorph EA rosette formation, no association was found with 
inhibition of rosette formation by peripheral blood lymphocytes from 
the same normal donor. The antiserum raised by Sandilands et al (1985) 
against lymphocyte-derived Fctf’-receptors did not block polymorph 
FcZ-receptors. It may be that FcK-receptors on polymorphs and 
peripheral blood lymphocytes are antigenically distinct. No panel 
experiments were performed using polymorphs.
Although the difference between untransfused and transfused 
subjects did not reach statistical significance for Fc^-receptor 
mediated phagocytosis, (uptake of IgG-coated latex beads) the number of 
untransfused subjects was small. In contrast, with only 12 subjects 
studied there was a striking difference in inhibition by IgG 
preparations from untransfused and transfused subjects of uptake and 
ingestion of Staphylococcus aureus.
The clearance of complement-coated bacteria is mediated not. through 
the Fcft-receptor but through the CR^ receptor (Complement Receptor 
Type I; Ross, 1982). Although IgG preparations from transfused 
subjects failed to show substantial inhibition of EAC rosette formation 
by peripheral blood lymphocytes from a normal donor, they may block 
the CR^ receptor on polymorphs. IgG preparations from untransfused 
subjects with renal disease were not used in this series of experiments 
but the method of preparation of IgG from serum should have eliminated, 
a direct biochemical effect of uraemia in the transfused group.
Staphylococci have been regarded as the major bacterial pathogen in 
dialysis patients (Keane and Raij, 1983). If IgG from transfused 
dialysis patients were shown to inhibit in vitro phagocytosis not only of 
Staphylococcus aureus but also of strains of Staphylococcus epidermidis
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antibody-related depression of phagocytosis could be relevant in vivo 
to infections related to Tenckhoff catheters and vascular access.
In view of the evidence linking Fc^-receptors on antigen presenting . 
cells to augmentation of T cell activation (Chang, 1985), and the central 
role of antigen presenting cells in the initiation of rejection (Austyn 
et al, 1985), it is perhaps a little surprising if antibodies which block 
the Fc^-receptor and are associated with allograft survival have no 
effect on monocyte Fc^-receptors. IgG preparations tested in the
experiments reported here did not inhibit monocyte EA rosette formation 
despite marked inhibition of EA rosette formation by lymphocytes and 
polymorphs from the same normal donor. The antiserum against lymphocyte 
FcY-receptors raised by Sandilands et al (1985) had no effect on 
monocytes either.
Inhibition of platelet aggregation by IgG preparations from transfused 
subjects has not been reported previously, although there has been 
considerable interest in abnormalities of platelet function in uraemia 
(reviewed by Eschbach, 1983). Curry, Messner and Johnson (1984) claimed 
that platelet aggregation was inhibited by a monoclonal antibody 
reactive with the beta-2-microglobulin chain of the HLA complex. Lee
et al (1984) suggested that immune abnormalities in recipients of blood 
products might be related to contamination with HLA-associated 
beta-2-microglobulin.
Contradicting earlier work by Solheim et al( 1976), Morito et al 
(1978) suggested that antibodies against beta-2-microglobulin could inhibit 
EA rosette formation. The IgG preparations tested for inhibition of 
platelet aggregation had no evidence of cytotoxic anti-HLA activity. It 
is possible that the Fcfr-receptor blocking activity in and the inhibition
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of platelet aggregation by IgG preparations from transfused subjects • 
is associated with antibodies against beta~2-microglobulin.
The experiments described in this chapter have demonstrated that 
IgG preparations from transfused subjects can affect a range of cell 
types and functions in vitro. These effects cannot all be attributed 
to Fc -receptor blocking activity, and their relevance to the immune 
response in vivo remains to be established.
5. Conclusions
i) IgG preparations from transfused subjects were shown to block 
Fct -receptors on T and B lymphocytes and polymorphs but not 
on monocytes.
ii) FcVreceptor blocking activity against peripheral blood 
lymphocytes could be removed by absorption of IgG prepatations 
with' a variety of cells, with and without the receptor, 
suggesting that the antibody activity was not directed solely 
against the receptor itself. IgG from transfused subjects 
blocked EAC and NSE less readily than EA rosette formation.
iii) IgG preparations from transfused subjects affected several 
functional assays both related (inhibition of the mitogen 
response and platelet aggregation) and unrelated (inhibition 
of polymorph ingestion of Staphylococcus aureus) to the 
Fc^-receptor. No effect was found on Killer or Natural 
Killer cell function.
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CHAPTER 13
Fc^-RECEPTOR BLOCKING ANTIBODIES IN RECIPIENTS OF CLOTTING
FACTOR CONCENTRATES '
1. Introduction
i) Haemophilia in history
Practical measures to deal with inherited coagulation disorders 
did not wait for understanding of the coagulation process. In the 
Egypt of the Pharaohs a woman was forbidden to bear further children 
if her first son bled to death from a minor wound. The Talmud barred 
circumcision in a family if two successive sons had suffered fatal 
haemorrhages (Rosner, 1969).
Constraints on childbearing did not extend to the family of 
Queen Victoria, through whom haemophilia extended to most of the royal 
houses of, Europe. Lack of appreciation of its hereditary pattern was, 
to the geneticist JBS Haldane, "A symptom of the divorce between royalty 
and reality" (quoted by Massie, 1968). The Spanish royal family put 
its haemophiliac sons in padded suits and padded the trees in the park 
where they played. The last Tsar and Tsarina of Russia turned to 
God and faith healing to protect their son. The undue influence 
bestowed on the faith healer Rasputin has been implicated in the 
failure of the Russian autocracy to retreat into constitutional 
monarchy (Massie, 1968). The high mortality rate in affected 
royalty, not entirely due to haemophilia, precluded reassessment of 
the disorder in the light of understanding of coagulation systems.
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ii) Current management of haemophilia
The concept of "classical” haemophilia antedated unravelling of 
coagulation factors. Although the term is still used to denote 
deficiency of coagulation Factor VIII, also described as "haemophilia 
A", it may in the past have encompassed deficiency of Factor IX, or 
"haemophilia B". The clinical features are indistinguishable 
(Biggs et al, 1952) .
The least uncommon of the inherited disorders of coagulation, 
the incidence of haemophilia A has been estimated at 0.5 per million.
The incidence of haemophilia B is around one-fifth of this. Both 
types of .haemophilia are transmitted as sex-linked recessive gene 
abnormalities, leading to male patient and female carrier populations 
(Bloom, L981). The severity of illness is reflected by the percentage 
of the normal level of clotting factor in the patient’s plasma.
Treatment is by replacement of the deficient factor when bleeding 
episodes occur. This can be achieved using a variety of preparations 
(Rizza, 1981):
a) Plasma - now largely superseded by
b) Cryoprecipitate
By fractionating plasma in the cold, a concentrate is obtained which 
contains approximately 3% of the original plasma protein, 20-85% of the 
original Factor VIII and large amounts of fibrinogen. There is 
insufficient Factor IX to make cryoprecipitate useful for the treatment 
of Factor IX deficiency. The reconstitution before use of
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cryoprecipitate is laborious and it must be stored at -20°C or below. 
These drawbacks make cryoprecipitate less convenient for home use than-
c) Freeze-dried human anti-haemophilic factor concentrate
Several varieties are available commercially (hence lyophilized 
preparations are sometimes described as "commercial Factor VIII").
They may be imported from, for example,the United States. Fractionation 
is achieved by one or more of cryoprecipitation or precipitation with 
ethanol, aminoacid or polyethylene glycol. Most of the materials 
used in the United Kingdom are of intermediate purity, containing up 
to 0.5 iii Factor VUI/mg protein and 40-60% fibrinogen.
d) Concentrates containing Factor IX
Most of the concentrates containing Factor IX are made from the 
supernatant remaining after cryoprecipitation of Factor VIII from plasma. 
Almost all the Factor IX concentrate used in the United Kingdom is 
supplied by National Health Service Laboratories, rather than commercial 
firms (Biggs, 1977).
iii) Immune function in haemophilia
Therapeutic clotting factors are derived from blood donations; 
to achieve a high concentration of the factor multiple donors are 
required. There has been considerable recent interest in the long-term 
immunological consequences of exposure to material from large numbers of 
donors.
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The problem in reviewing recent work on immune function in 
haemophilia is re-interpretation of abnormalities in the light of 
subsequent evidence on the prevalence of retrovirus infection. Doubt 
has been -cast on data derived in the United States since 1980, the 
period during which the prevalence of antibody indicating exposure 
to the apparent causative virus of the Acquired Immunodeficiency 
Syndrome .(AIDS) has escalated to include some two-thirds of the 
haemophiliac population (Lederman et al, 1985).
Before the recognition of AIDS, evidence to link haemophilia to 
susceptibility to infection was slim (Froebel et al, 1983). At an 
anecdotal level, Beddall, Hill and George (1983) reported an out­
break of tuberculosis in a British paediatric ward in 1981. The 
incidence in children with haemophilia was almost as high as in children 
immunosuppressed by neoplasia and chemotherapy, and higher than in 
other children in the ward. Although interesting, this report could 
do no more than hint at some predisposing immune abnormality.
In 1983 came reports of decreased T helper/T suppressor.lymphocyte 
ratios in haemophiliacs, a finding particularly prominent in users of 
commercial lyophilized Factor VIII rather than cryoprecipitate or Factor 
IX (Goldsmith et al, 1983; Kessler et al, 1983; Lederman et al, 1983; 
Menitove et al, 1983). Lymphocytes from these patients also showed 
diminished mitogen responses. Recall antigen testing was particularly . 
poor in patients using commercial concentrates (Tsoukas et al, 1983).
Lee et al (1983) suggested that abnormalities in lymphocyte subsets 
were a consequence of exposure to HLA proteins in plasma products, and 
alluded to the blood transfusion effect on renal allograft survival. 
Measurement of the amount of beta-2-microglobulin in different preparations
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was assumed to provide an estimate of HLA protein contamination. This 
was greatest in commercial Factor VIII and least in National Health 
Service Factor IX preparations.
Froebel et al (1983) showed that both American and Scottish Factor 
VIII preparations inhibited the mitogen response directly if added to 
normal lymphocytes. Lederman et al (1984) confirmed that American 
Factor VIII preparations could inhibit the PHA response and alter 
lymphocyte subsets in culture.
Although a firm association is now apparent between the use of 
American concentrates and seropositivity for human T-cell leukaemia 
virus Typ.e III (HTLV-III) (Melbye et al, 1984), not all immune 
abnormalities in haemophiliacs can be explained by the virus. At the 
time when the experiments described below were performed, the association 
between the virus and AIDS was poorly defined and no antibody screening 
test was available. However, the relative self-sufficiency of the 
Scottish National Blood Transfusion Service supply of clotting factors, 
and consequent relative rarity of use of American products was taken to 
indicate that virus infection was rare (Carr et al, 1984).
This assumption has been borne out by subsequent studies (Melbye 
et al, 1984; Ludlam et al, 1985), underlining the importance of the 
findings of Froebel et al (1983) in Glasgow and Carr et al' (1984) in 
Edinburgh.that T-cell subset abnormalities were present not only in 
patients likely to have been exposed to American pathogens. The 
suggestion from Ludlam et al (1985) that prior depression of the T 
helper subset might predispose to seroconversion to HTLV-III was 
appropriately tentative.
The humoral response to repeated infusion of clotting factor con-
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centrates has been little explored, although increased immunoglobulin 
production has been reported (Menitove et al, 1983; Moffat et al, 1985). 
Proud et al (1979) found that plasma from haemophiliacs who had 
received both whole blood and Factor VIII preparations could inhibit . 
the lymphocyte response to purified protein derivative of 
Mycobacterium tuberculosis. Inhibitory activity was attributed by 
these authors primarily to alpha-2-macroglobulin, but was also present 
in the plasma fraction containing IgG.
iv) Aims of the study
Fcfc -receptor blocking antibodies have not been described in 
recipients of clotting factor concentrates. However, the evidence 
presented in earlier chapters that blood transfusion may be associated 
with the development of such antibodies, and the possibility that the 
antibody production is a histoincompatibility response, lead to con­
sideration of the production of FcX-receptor blocking antibodies in 
response.to alloantigens contaminating clotting factor preparations.
The experiments described below were designed to answer the following 
questions:
a) Are FcX-receptor blocking antibodies present in patients who 
have received Factor VIII and Factor IX?
b) If so, do they exhibit the same properties in vitro.as those 
previously demonstrated in recipients of blood?
c) Do any antibodies found cross-react with antibodies from 
multiply transfused uraemic subjects?
d) If such antibodies are produced, can they be used to remove and 
characterise the inducing antigen(s) from preparations of 
Factor VIII?
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2. Materials and Methods
i) Subjects studied
Serum samples were taken from 39 male patients, 30 with Factor 
VIII and 9 with Factor IX deficiency (full details are given in 
Chapter 7:4). Further serum samples were obtained
from 1 normal and 3 uraemic transfused subjects, all of whom were male.
ii) Methods used
IgG preparations were obtained from the serum samples,• using 
DEAE chromatography as previously described (8:3:iv).
All IgG preparations were tested, using an EA rosette inhibition 
assay at both 4°C and 37°C (8:4:i), for their capacity to block 
Fc'K -receptors on peripheral blood lymphocytes from normal donors. IgG
preparations from 27 subjects were also tested for their capacity to 
inhibit phytohaemagglutinin-induced biastogenesis of normal allogeneic 
lymphocytes (8:4:iv).
Using IgG from patients with strong Fcfl-receptor blocking activity 
attempts were made to extract and characterise the relevant antigen(s) 
from a lyophilized preparation of Factor VIII, by affinity chromatography 
and SDS“PAGE gel electrophoresis. Full details of these methods are 
given in Ctiapter 8:9; 8:10) . The "antigen" fractions obtained by affinity 
chromatography from patients and controls were used for further 
experiments.
Three ,120jul aliquots of each IgG preparation were taken. To the
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first of each trio was added an equal volume of phosphate buffered 
saline. To the second was added "antigen" from the normal subject.
To the third was added "antigen" from one of the haemophiliac subjects. 
IgG preparations from the haemophiliac subjects were also tested using 
autologous "antigen" in a separate experiment using similar controls.
All samples were incubated at 37°C for 1 hour, then tested for EA rosette 
inhibition at 37°C using peripheral blood lymphocytes from an unrelated 
normal subject.
IgG preparations from the 4 haemophiliacs were tested, in parallel 
with autologous "antigen" and the "antigen":IgG combinations, for 
inhibition of phytohaemagglutinin-induced biastogenesis (8:4:iv).
"Antigen" fractions were run over SDS-PAGE gels to try to identify 
the molecular weight of the "antigen(s)".
3. Results
Figure 29 shows the extent to which IgG preparations from the 39 
patients with haemophilia inhibited EA rosette formation by peripheral 
blood lymphocytes from a normal donor. Using the value of 35% as the 
upper limit of inhibition by IgG from normal subjects, as defined in 
Chapter 9, 18 patients had Fc^-receptor blocking activity at 4°C and 
24 at 37°C. As was noted in transfused dialysis patients (Chapter 10) 
no patient had antibody activity at 4°C only.
Figure 30 shows the same results, subdivided by transfusion history. 
Twenty patients had received clotting factor preparations only, and 19 
had had previous blood transfusion. The difference in results between 
these two groups did not reach statistical significance, although when 
the assay was performed at 4°C there did appear to be a trend towards
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higher levels of rosette inhibition in the "transfused" group.
Eleven out of 19 subjects in this group, and only 7 of 20 who had not 
had bloody had results outwith the normal range. (Mean + standard 
deviation percentage inhibition of EA rosette formation: 38 + 28% 
"transfused", 23 + 22% "untransfused").
The main point from the results, however, is that Fctf-receptor 
blocking activity is not dependent on blood transfusion in patients 
already receiving clotting factor preparations. No relation was^ 
found between FcX-receptor blocking activity at either temperature and 
the type of haemophilia (Figure 31), severity of disease (Figure 32), 
or amount- of clotting factor used during the previous year (Figure 34). 
Twenty-four patients with Factor VIII deficiency had used commercial 
concentrates before 1979. Six out of 24 patients tested had antibody 
detected against HTLV-III. IgG FcY-receptor blocking activity was 
not associated with either the use of commercial concentrates (Figure 
35) or HTLV-III antibody (Figure 36). (All results illustrated are 
those for the assay performed at 37°C; nor were any associations 
between Fcft-receptor blocking activity and the factors mentioned noted 
at 4°C).
Figure 37 shows the results for inhibition of phytohaemagglutinin-
induced T- cell activation by IgG preparations from 27 patients with
haemophilia. The results from 11 normal subjects are those already
discussed in Chapter 12. Eighteen out of the 27 IgG preparations from
patients with haemophilia gave levels of inhibition outwith the range
for normal subjects (for the normal group, mean + 2 standard deviations
2= 38% maximum value obtained 39%) (P4.0.001, X test with Yates correction). 
Six patients with haemophilia had levels of inhibition greater than 80%.
The relation between inhibition of the phytohaemagglutinin response and
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use of blood and clotting factors is illustrated in Figures 38 and 39..
The exterit of inhibition appeared independent of FcV-receptor antibody 
or HTLV-III antibody status, previous blood transfusion, type and 
severity of disease, use of commercial concentrates and the amount of 
clotting factor consumed in the previous year.
The demonstration of Fcfc-receptor blocking activity and inhibition 
of the phytohaemagglutinin response by IgG preparations from patients 
who had received only clotting factor preparations rather than blood 
led to attempts to remove the antigen(s) assumed to be inducing these 
antibodies from Hemofil, a Factor VIII preparation. First, Hemofil 
reconstituted in distilled water was ultracentrifuged over a dis-: 
continuous sucrose gradient, using the method described in Chapter 8 
(8:3:iii). Six fractions of graded molecular weight were obtained 
and dialysed into phosphate buffered saline. The protein concentration 
of each fraction was measured by spectrophotometry. From Figure 40 it 
can be seen that the peak protein concentration was found in Hemofil 
fraction ,3. None of the 6 fractions inhibited EA rosette formation by 
peripheral blood lymphocytes from a normal subject.
Affinity chromatography performed using Hemofil and IgG preparations 
from 2 normal male subjects and 4 haemophiliac patients yielded 
preparations empirically described here as "antigen".
Figure 41 shows the protein concentration of substrate eluted from 
Sepharose beads after incubation with Hemofil and with IgG from one 
haemophiliac and one normal subject. A protein peak is seen within the 
first few mis of buffer passed through the chromatography column; this 
was taken to contain the putative "haemophiliac antigen" for the 
purposes of subsequent experiments. "Antigen" preparations from neither
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the normal nor the haemophiliac subjects inhibited EA rosette formation 
by peripheral blood lymphocytes from an unrelated normal subject.
The results of experiments to find the effect of incubation with 
"antigen" on IgG preparations from normal, haemophiliac and transfused 
dialysis patients are shown in Figures 42 to 46.
Figure 42 shows removal of Fc^-receptor blocking activity from 
IgG from a haemophiliac subject by autologous "antigen" but not by 
phosphate buffered saline nor by "antigen" derived using a normal subject. 
The same pattern was found with all 4 haemophiliacs tested (Figure 43). 
Phosphate buffered saline and "normal antigen" had no effect in this or 
subsequent experiments (results not illustrated). When IgG 
preparations from the 4 haemophiliacs were incubated with "antigen" 
derived from one of them, Fc^-receptor blocking activity was removed 
from all 4 (Figure 44). Moreover, Fctf-receptor blocking activity was 
removed by the same "antigen" from IgG from 3 dialysis patients 
(Figure 45) This "antigen" had been derived from Hemofil using IgG 
from a patient with Factor VIII deficiency who had never received blood 
or commercial concentrates. All the dialysis patients had had blood 
but none had had clotting factor preparations. None of the 4 
haemophiliac "antigen" and "antibody" preparations inhibited the 
phytohaemagglutinin response of normal lymphocytes (Figure 46). However, 
when autologous "antigen" and "antibody" were incubated together before­
hand,each combination was inhibitory.
SDS-PAGE gel electrophoresis of "antigen" derived from normal and 
haemophiliac subjects yielded no consistent pattern of protein banding. 
However, several protein bands were identified from "antigen" from 
haemophiliac but not normal subjects. Using dalton markers, these were 
estimated to have molecular weights of 25,000, 66,000 and 74,000.
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4. Discussion
The ! demonstration of Fctf-receptor blocking antibodies in patients 
receiving blood products because of haemophilia is of interest in 
conjunction with the work linking these antibodies with renal allograft 
survival (MacLeod et al, 1982a and b), and with the literature on 
immunosuppression in haemophilia (mentioned in the Introduction above; 
for example, Lederman et al, 1983 and 1984; Froebel et al, 1983;
Ludlam et al, 1985).
IgG preparations from the patients studied here not only had Fc^- 
receptor blocking activity but also were shown to inhibit the mitogen 
response to phytohaemagglutinin in vitro. Patients with haemophilia 
have raised plasma immunoglobulin levels (Menitove et al, 1983; Moffat 
et al, 1985), but IgG preparations used in these experiments were all 
adjusted for use to a concentration of Img/ml in phosphate buffered 
saline.
No similar work has previously been published. The response to 
phytohaemagglutinin of lymphocytes from patients with haemophilia has 
been reported to be normal (Froebel et al, 1983) or reduced (Moffat 
et al, 1985), particularly in those treated with lyophilized Factor 
VIII preparations. (Lederman et al, 1983),
Shenton et al (1979) found that the IgG-containing plasma fraction 
from patients with haemophilia inhibited the response of autologous and 
homologous peripheral blood lymphocytes to purified protein derivative 
of Mycobacterium tuberculosis. All Shenton1s patients had however 
received' at least 10 units of blood in addition to clotting factor 
preparations.
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Like the studies of lymphocyte subpopulations in haemophiliacs 
reported by Froebel et al (1983), Lederman et al (1983) and Moffat 
et al (1985), the results described here show no relationship between 
the amount of clotting factor consumed and the immune abnormalities 
detected. Nor were the effects of the IgG preparations tested associated 
with other clinical parameters such as severity of disease, nature of 
the deficient clotting factor, use of commercial Factor VIII or HTLV-III 
antibody status.
Interestingly, there was no difference in results from IgG pre­
parations between those patients who had received blood as well as blood 
products :and those who had received blood products alone. Blood 
products may be effective in inducing the production of antibodies 
which block Fc^-receptors and inhibit the mitogen response, with the 
relevant antigen(s) being present in preparations of Factor VIII and 
Factor IX.
The hypothesis that the antigen(s) were present in clotting factor 
preparations led to the experiments aimed at extraction and character­
isation. of the antigen(s). Fc^-receptor blocking activity was removed 
by incubation with Hemofil-derived haemophiliac "antigen" from IgG 
preparations not only from the patient with Whose IgG the antigen had 
been prepared, but also from IgG from other patients with haemophilia- 
who had received blood products but never.blood, and from IgG from 
renal patients who had received blood but never blood products. . This 
suggests that FcK-receptor blocking antibodies are produced against 
antigens common to blood and clotting factor concentrates,
HLA products contaminate clotting factor concentrates. Lee et al
(1984) suggested that long-term massive exposure to HLA antigens in
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Factor VIII preparations led to immune abnormalities, and linked the 
low concentration of HLA-associated beta-2-microglobulin in Factor IX 
concentrates to the low incidence of T cell subset abnormalities in 
patients with haemophilia B (Kessler et al, 1983; Moffat et al, 1985). 
The production of antibodies to beta-2-microglobulin from Factor VIII 
preparations could be associated with Fctf-receptor blocking activity 
(Morito et al, 1978) but the presence of Fctf-receptor blocking anti­
bodies in patients with Factor IX deficiency makes less likely this 
explanation for the results presented here.
Lee et al (1984) confirmed, through elution chromatography of 
Factor VIII concentrate, that beta-2-microglobulin was present in 
association with proteins of a mass compatible with that of HLA Class 
I products (55,000. daltons), rather than in free form (mass 
(12,000 daltons). Gel electrophoresis of "antigen" preparations 
showed nd evidence of protein bands corresponding to the molecular 
weights of free or HLA-associated beta-2-microglobulin. The absence
of a consistent banding pattern in the haemophiliac "antigen"
\
preparations may suggest that the method used was not sufficiently 
sensitive to demonstrate the antigen(s) responsible for antibody 
production, particularly as "antigen" preparations removed Fc^-receptor 
blocking .activity from homologous as well as autologous IgG preparations
5. Conclusions
i) IgG preparations from patients with haemophilia were found to 
possess Fc&'-receptor blocking activity and to inhibit the response 
of normal lymphocytes to phytohaemagglutinin.
ii) Theste properties were independent of a history of blood transfusion 
severity and type of disease, amount and type of clotting factor.
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concentrates used, and antibody status against Human T-cell 
Leukaemia Virus Type III.
iii) Fc^-receptor blocking activity in IgG preparations from recipients 
of blood and of blood products appeared to be directed against 
common antigen(s) represented in Factor VIII concentrate.
iv) Although full characterisation of the antigen(s) was not achieved, 
Factor VIII concentrate provides a convenient substrate for 
further attempts to identify the antigen(s) responsible for 
FcV-receptor antibody production in recipients of blood and
of blood products.
CHAPTER 14
Fctf-RECEPTOR BLOCKING ANTIBODIES AND THE ACQUIRED IMMUNODEFICIENCY
SYNDROME (AIDS)
1. Introduction
i) Clinical features of AIDS
In 1981 came the first reports of a fatal acquired immunodeficiency 
syndrome in homosexual American man (Gottlieb et al,1981; Masur et al,
1981). Since then, there has been a vast amount written, in both 
medical and lay press, about this syndrome, empirically defined by the 
American Centres for Disease Control for surveillance purposes as the 
presence of a reliably diagnosed disease at least moderately predictive 
of an underlying cellular immunodeficiency. Such diseases include 
Kaposi’s sarcoma in a patient under 60 years old, Pneumocystis carinii 
pneumonia, or other opportunistic infections. There must be absence of 
any known causes of the underlying immunodeficiency or host defence 
defect such as immunosuppressive therapy or lymphoproliferative 
malignancy (Fauci, 1985). The syndrome has been characterised by 
a number of cellular and humoral immune abnormalities, recently reviewed 
by Lane (1985) and discussed later in this chapter in relation to the 
author’s experimental findings.
'
ii) Evidence for a viral aetiology
In 1983, when the experiments described later in this chapter were 
designed,, there were doubts about the role of virus infection in the 
aetiology of AIDS (Woodruff and van Rood, 1983). These have been 
dispelled by recent research. Early epidemiological evidence showed
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that the syndrome in the United States was concentrated in the homo­
sexual community, but subsequently identified risk groups include 
intravenous drug abusers, immigrants from Haiti, recipients of blood 
or blood products, and heterosexual partners of any of these groups. 
Patterns of spread and case clusters suggest a viral aetiology (Fauci, 
1985).
Identification and characterisation of an AIDS-related virus has 
been rapid. In 1983, Barre-Sinoussi et al in Paris isolated a T- 
lymphotropic retrovirus from a patient at risk of AIDS. The following 
year Gallo et al (1984) in the United States linked AIDS to a retrovirus 
akin to the previously described human T-cell leukaemia virus (Schupbach 
et al, 1984). Although the nomenclature used by the two groups differs, 
with the French describing lymphadenopathy-associated virus (LAV) and 
the Americans human T-cell leukaemia virus Type III (HTLV-III), their 
evidence has tended to converge. Differences beyond nomenclature have 
delayed American acceptance of evidence from Feorino et al (1984) 
equating the viruses.
Seroepidemiological evidence, detecting antibodies to LAV/HTLV-III, 
points strongly to the link with AIDS (Sarngadharan et al, 1984; Fauci,
1985). Moreover, infectious retrovirus has been isolated from Factor 
VIII concentrates (Levy, Mitra and Mozen, 1984), and the transmission of 
the virus in transfused blood has been charted in donor-recipient pairs 
(Feorino et al, 1984; Markham, 1985). The relation between the 
presence of IgG antibody to the virus in a community and the subsequent 
incidence of the clinical syndrome is unknown (Fauci, 1985).
Backing the epidemiological evidence is extensive research in the 
molecular biology of the implicated retrovirus. It appears to attach 
selectively to the T4 antigen (Dalgleish et al, 1984), giving a selective
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deficiency in the ability of the T4 lymphocyte to respond to soluble 
antigen (Lane, 1985) and ultimately causing cell death (Klatzmann et al, 
1984 b). By in vitro passage Montagnier et al (1984) have adapted 
the virus also to infect B cell lines transformed by Eps tein-Barr. virus.
iii) The role of pre-existing immunosuppression
The firm evidence which has accrued to link LAV/HTLV-III with AIDS 
does not preclude a role for pre-existing host immune status in 
determining the clinical outcome of exposure to the virus. On the basis 
that virus infectivity may be enhanced in proliferating T4 cells, Kalish 
and Schlossman (1985) have suggested that synergy with other infective 
agents may explain observations such as the relatively low rate of 
infection among transfusion recipients and health care personnel exposed 
to the virus (Hirsch et al, 1985; Jones et al, 1985).
It has been suggested that chronic immune stimulation by chronic 
infection may interfere with the host’s capacity to eliminate infectious 
agents (Virgin and Unanue, 1985). This has been advanced as an 
explanation for the association between malaria and the development of 
Burkitt’s. lymphoma in response to Epstein-Barr virus infection (Dalldorf,
1982). Malaria has been shown to cause a transient inversion of the 
T helper/suppressor ratio and non-specific B cell proliferation (Whittle 
et al, 1984).
Biggar et al (1985) studied a community in rural Zaire, thought to 
be an endemic focus of the AIDS-related virus (Fauci, 1985). They found 
that the prevalence in healthy subjects of antibody against HTLV-1, -II 
and -III correlated strongly with the level of immune complexes and 
antibodies against Plasmodium falciparum, and considered the possibility
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that malaria could affect the host response to retrovirus'infection.
Levy and Ziegler (1983) proposed that AIDS was an opportunistic 
infection in subjects already immunocompromised by repeated infection. 
Infection with sexually transmitted pathogens such as cytomegalovirus 
and hepatitis B is increasingly prevalent in the semen of homosexual men 
in American cities (Sonnabend, Witkin and Purtilo, 1985).
It is interesting that repeated immune stimulation from viral infection 
has not been widely regarded as an explanation for the transfusion 
affect on renal transplantation (Chapter 5). Similarly, it is interesting 
how little discussion of the immunosuppressive effects of transfusion has 
contributed to the literature on AIDS, even in studies specifically 
focusing on acquired immunodeficiency following transfusion (Curran et al, 
1984).
In response to Curran's 1984 paper, Shearer and Levy (1984) suggested 
that DR-mismatched blood transfusion might be particularly prone to 
dampen the immune response and predispose to infection with the then- 
speculative AIDS agent. Indeed, Shearer has consistently advocated 
exposure to alloantigens of the major histocompatibility complex as a 
cause or contributing factor to the development of AIDS (Shearer, 1983; 
Shearer and Levy, 1985).
Exposure to alloantigens through repeated homosexual contact, has 
been postulated to cause immune suppression and likened to acquired 
immune tolerance of an allogeneic renal allograft (Mavligit et al, 1984). 
Seminal plasma may have immunosuppressive properties (Lord, Sensabaugh 
and Stites, 1977; Marcus et al, 1978; James and Hargreave, 1984).
Murgita et al (1978) suggested that embryonic antigens, as expressed
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on sperm, could suppress T cell proliferation in vitro. Hurtenbach 
and Shearer (1982) showed that germ-cell inoculation in mice led to 
impaired cellular immunity.
Unspecified differences between the mucosal linings of the genital 
and gas tr'o-intes tinal tracts have been cited to try to explain the 
consequences of rectal rather than vaginal insemination. Rectally , 
inseminated rabbits have been shown to develop anti-sperm antibodies, 
immune complexes and serum inhibitors of lymphocyte proliferation. 
(Richards, Bedford and Witkin, 1984; Witkin et al, 1985).
In homosexual men the same workers have demonstrated antibodies
against sperm antigens (Witkin and Sonnabend, 1983; Witkin et al,
1983). Following the demonstration by Mathur et al (1981) of crossr
reactivity between antigens on sperm and T lymphocytes, Sonnabend,
Witkin and Purtilo (1983) proposed that such anti-sperm antibodies 
would cross-react with and inactivate T lymphocytes. This was amplified 
by Hsia et al (1984) who saw virus- and/or sperm-specific anti-idiotypic 
antibodies as a possible cause for AIDS. Rubinstein, Small and Bernstein
(1985) have now demonstrated autoantibodies to T cells in patients with 
AIDS.
iv) Aims of the study
In 1983, at the start of this study, the evidence was thus in favour
of a specific aetiological agent for AIDS, but with no firm indication
as to which. The role of exposure to multiple alloantigens was uncertain. 
However, work on the blood transfusion effect on renal allograft survival
and the studies, mainly in animals, of immune suppression by spermatozoa,
suggested a field for study.
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The presence of Fc'tf-receptors on spermatozoa in both man and 
mice had been shown by Sethi and Brandis (1980). The experiments 
presented below were designed to test the hypothesis that repeated 
exposure to alloantigenic spermatozoa by homosexual contact would 
lead to the production of antibodies which would cross-react with 
Fctf-receptors on spermatozoa and lymphocytes, and that these antibodies 
could be shown in vitro to be potentially immunosuppressive.
2. Materials and Methods
i) Subjects studied
Serum samples were obtained from:
a) 7 patients with AIDS (Chapter 7:6)
b) 33 patients attending a Genitourinary Clinic (Chapter 7:5)
c) 39 patients with haemophilia (Chapter 7:4)
d) 54 renal dialysis patients who had previously received at
least 5 units of blood (Chapter 7:3)
e) 4 patients (2 male) with previous blood transfusion but no
history of renal disease (Chapter 7:2)
f) 17 heterosexual normal subjects (9 male) with no history of 
transfusion or pregnancy (Chapter 7:1)
g) 10 normal multiparous women and 5 normal pregnant women 
(Chapter 7:1)
ii) Methods used
Serum samples from the patients attending the Genitourinary Clinic 
were tested for inhibition of EA rosette formation by peripheral blood 
lymphocytes from a normal subject (Method 8:4:i).
IgG preparations were obtained from serum samples (method 
8:3:iv). Spermatozoa were obtained from anonymous healthy male 
volunteers, and IgG preparations from all study groups were tested 
for anti-sperm antibodies using a tray agglutination test (method 
8: 8) .
IgG preparations from homosexual men with and without clinical 
evidence of AIDS were tested for inhibition of EA rosette formation 
(method 8:4:i) and for inhibition of phytohaemagglutinin-induced 
blastogenesis (method 8:4:iv) using peripheral blood lymphocytes from 
a normal subject.
IgG preparations from 3 subjects with haemophilia were absorbed 
(method 8:3:v) with human thymocytes (method 8 :2:ii), platelets (method 8 : 
l:ivand erythrocytes (method 8 :l:v). Pre- and post-absorption IgG 
preparations were tested for inhibition of EA rosette formation of 
normal peripheral blood lymphocytes (method 8:4:i) and for anti-sperm 
antibodies (method 8 :8 ).
3. Results
Figure 47 shows the results for inhibition of EA rosette formation 
by serum from patients attending the Genitourinary Clinic. No details 
of obstetric history were available for the female patients. The 
difference between values for the male heterosexual and homosexual groups 
was statistically significant (R^O.Ol, Mann-Whitney U test).
On the basis of these preliminary results it was decided to proceed 
to separate IgG from serum from the homosexual group. Two serum samples 
were too small for this, so IgG results for the homosexual group are
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available on only 9 patients instead of the original 11.
Figure 48 shows inhibition of EA rosette formation by IgG 
preparations from 15 male homosexual subjects, 9 of whom had no clinical 
evidence of AIDS and the other 6  with clinically defined AIDS. Four 
out of 9 "asymptomatic" men and all 6  with AIDS had IgG Fc'X-receptor 
blocking activity outwith the normal range (i.e. greater than 35% as 
defined in Chapter 9). IgG from the heterosexual man with AIDS gave 
90% inhibition of EA rosette formation. The difference between results 
for the two groups depicted was significant (P^O.Ol, Mann-Whitney U 
tes t) .
Figure 49 illustrates the titres of anti-sperm antibody activity
found in IgG preparations. Agglutination of normal human spermatozoa
was found with 3 out of 17 of normal IgG preparations (from men or
nulliparous women) compared with 25 out of 54 from multiply transfused
renal patients, 34 out of 39 from haemophiliacs, 5 out of 9 from
asymptomatic homosexuals and by IgG from all of the six homosexual AIDS
patients, as well as from the heterosexual AIDS patient (result not
2
illustrated). (X test: all test groups significantly different from
the normal group). Two multiparous and 1 pregnant normal women also 
had detectable anti-sperm acitivity, but in none of the total of 32 
IgG preparations from normal subjects did agglutination of spermatozoa 
occur beyond a titre of 1 :8 .
In none of 4 subjects transfused for reasons other than renal failure 
was anti-sperm antibody detected.
The results for all subjects tested are considered in Table 5 
in comparison with results previously obtained for FcY -receptor blocking
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activity (Chapters 9, 10 and 13; and Figure 48). The association
between the presence of anti-sperm antibody (detected at any titre) and
Fc#-receptor blocking antibody (greater than 35% EA rosette inhibition
at 37°C on testing with normal peripheral blood lymphocytes) was
. 2
statistically signficant (X test, P<0.01).
Absorption of three IgG preparations with human thymocytes, or ‘ 
platelets was found to remove completely both anti-lymphocyte and anti­
sperm activity (Figure50 ). Absorption with human erythrocytes had no 
effect (Figure 50 ) •
IgG preparations from 6  out of 9 "asymptomatic" homosexual men and 
from all 6  homosexual AIDS patients inhibited the phytohaemagglutinin 
response to an extent greater than seen in normal subjects (Figure 51 
and Chapter 12). IgG from the one heterosexual AIDS patient also 
markedly inhibited the response (result not illustrated).
4. Discussion -
Although a wide range of immune abnormalities has been demonstrated 
in patients with AIDS (reviewed by Lane 1985), the presence of FcS- 
receptor blocking antibodies is a new finding. Raised total IgG 
concentrations (Lane et al, 1983) were unlikely to explain the results 
as all IgG preparations were tested at a standard concentration.
Although the antibodies could be a non-specific consequence of polyclonal 
B cell activation (Lane et al, 1983), there are several points in favour 
of the hypothesis that anti-lymphocyte Fctf-receptor blocking antibodies 
are associated with homosexual contact with allogeneic spermatozoa 
independent of infection with HTLV-III.
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No screening test for HTLV-III antibody was available in 1983 
when samples were collected from the subjects attending a Genitourinary 
Clinic. . One of the homosexual men tested in this study had been 
sexually active in North America but the others had no such history. 
Mortimer et al (1985) assessed the prevalence of HTLV-III antibody in 
homosexual men attending British Genitourinary Clinics in 1984. In 
London 34% of 282 patients were antibody-positive, but the figure for 
5 centres outwith London was only 5%.of 955 patients. It therefore 
seems unlikely that the results here were attributable to HTLV-III 
infection. Use of a control group of heterosexual men with genitourinary 
symptoms reduced the likelihood that other common sexual pathogens were 
responsible for serum Fctf-receptor blocking activity.
The association between anti-sperm antibodies and Fc&-receptor 
blocking antibodies was true not only for homosexual men but also for 
patients transfused with blood or blood products. It would be 
interesting to reassess the strength of the association using sperm and 
lymphocytes from the same donor. No attempts were made to assess 
anti-sperm antibody activity across a donor panel.
Absorption of IgG preparations with thymocytes and platelets, but 
not erythrocytes, removed antibody activity against both peripheral 
blood lymphocytes and spermatozoa. This provides further evidence for 
the association between the antibodies. The absence of FcY-receptors 
on thymocytes (Janossy 1981; confirmed by failure of the thymocytes 
used here to form EA rosettes) suggests that the anti-sperm antibodies 
are, like the anti-lymphocyte antibodies, not directed against the 
Fc^-receptor itself, although Fc^receptors are expressed on spermatozoa 
(Sethi an,d Brandis 1980),
It has been suggested that Fcfr-receptor blocking antibody activity 
against B lymphocytes is directed against an allelic alloantigen 
system other than the defined HLA-A, B and DR systems (MacLeod et al, 
1982b). . Daar et al (1984b) failed to demonstrate Class II antigens
on spermatozoa using a monoclonal antibody which detected a monomorphic 
determinant common to the known Class II antigen groups. Class I 
antigens were detected with a monoclonal antibody against.the heavy 
chain of HLA-A, B and C antigens on sperm in the testis but not in the 
epididymis (Daar et al, 1984a). These monoclonal techniques may have 
failed to detect relevant undefined HLA systems. Alternatively, the 
antibodies described here may be directed against non-HLA determinants 
on spermatozoa.
A connection between AIDS and anti-sperm anti-lymphocyte Fcy- 
receptor blocking antibodies is suggested by the occurrence of these 
antibodies in patients with AIDS, and at risk of AIDS through homosexual 
contact, blood or blood products (Fauci, 1985). The consequences of 
exposure to HTLV-III may be exacerbated by pre-existing immunosuppression 
(Ludlam et al, 1985). There is some theoretical backing for the 
contention that Fctf-receptor blocking antibodies may depress the host 
response to infection or neoplasia.
Organisms expressing FcV-receptor-like structures include bacteria 
(for example, some Staphylococci) and parasites (such as Schistosoma)
(Witz and Ran, 1985). Cells infected with cytomegalovirus may express 
Fctf-receptors (Keller, Peitchel and Goldman, 1976). There is, to the 
author’s knowledge, no published work on Fctt-receptor expression on 
cells infected with HTLV-III. Malignant transformation of tumour cells 
has been linked to increased Fc£-receptor expression (Witz and Ran, 1985).
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The biological advantage of Fchl-receptor expression to infecting 
organisms and neoplastic cells is not known. Sonnabend et al (1985). 
suggested that circulating immune complexes could bind to Fctf-receptors 
on cytomegalovirus-infected cells and prevent virus antigen target 
recognition by cytotoxic lymphocytes. A benefit to malignant cells 
proposed by Witz and Ran (1985) was that Fctf-receptors could bind IgG 
and mask recognition of other surface antigens. Fc$-receptor blocking 
antibodies associated with transfusion or homosexual contact could 
depress the host response by a similar mechanism.
IgG preparations from patients with AIDS, homosexual men and 
transfusion recipients have been shown in this and previous chapters 
to depress the mitogen response of normal lymphocytes in vitro. 
Cunningham-Rundles, Michelis and Masur (1983) documented antibodies to 
T cells and suppression of in vitro lymphocyte activation by serum from 
patients with AIDS.
Witkin et al (1985) claimed that rectal insemination of rabbits 
led to the formation of anti-T cell and anti-sperm antibodies. Serum 
from inseminated rabbits inhibited the phytohaemagglutinin response of 
lymphocytes from normal rabbits. Absorption of serum with protein A 
to remove IgG did not abolish inhibition, suggesting that IgG was not 
responsible. Yet the use of IgG preparations here confirms that IgG
can inhibit the mitogen response in vitro.
Interaction with T lymphocyte FcX-receptors may stimulate suppressor 
function(Moretta et al, 1979) and result in the release of soluble
suppressor factors. So-called "Soluble Immune Suppressor Substance T"
(Greene et al, 19 81) is produced in increased quantities by stimulated 
lymphocytes from patients with AIDS (Laurence, Gottlieb and Kunkel,1983).
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If FcVreceptor blocking antibodies are also associated with
suppression of T cell responses in vivo, they may contribute to the
development of AIDS after exposure to HTLV-III.
5. Conclusions
i) Fc'^-receptor blocking IgG class antibodies were found in patients 
with AIDS and in homosexual men with no clinical evidence of the 
syndrome.
ii) Anti-sperm antibodies were detected in patients with AIDS, 
homosexual men, and patients who had received transfusion of 
blood or blood products.
iii) Evidence for an association between anti-sperm and anti-lymphocyte 
Fc'ij-receptor blocking antibodies was provided by absorption 
experiments.
iv) IgG preparations from patients with AIDS and homosexual men 
inhibited the phytohaemagglutinin response of normal lymphocytes 
in vitro.
v) Experimental results were compatible with the hypothesis that 
homosexual contact may lead to the development of sperm-lymphocyte 
cross-reacting Fc&'-receptor blocking antibodies, which may 
predispose to the development of AIDS.
CHAPTER 15
THE RELATION BETWEEN PRETRANSPLANT Fc^ -RECEPTOR BLOCKING ANTIBODIES
AND RENAL ALLOGRAFT SURVIVAL
1. Introduction
i) Background
The association found in the previous chapters between alloantigen 
exposure and Fctf-receptor blocking IgG class antibodies with possible 
immunosuppressive actions in vitro leads to the consideration of the 
clinical situation of renal transplantation. The original work by- 
MacLeod and her colleagues linking renal allograft survival to 
Fctf-receptor blocking antibodies was published in 1982 (MacLeod et al, 
1982 a and b). No other centre has yet confirmed the findings in this 
retrospective analysis.
ii) Aims of the study
During the period of the other experimental work reported in this 
volume, a prospective study was also in progress to compare renal 
allograft survival with pretransplant FcY-receptor blocking IgG class 
antibody in recipient serum.
2. Materials and Methods
i) Subjects studied
Serum samples were obtained during the day prior to transplantation
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from 63 renal allograft recipients (36 male, mean age 35, range 
16 - 65 years). This group included 7 patients receiving second and 
2 receiving third cadaveric allografts. All patients had received at 
least 5 units of third party whole blood or packed cells.
Tissue match placed the emphasis on DR match,.followed by the B 
and then the A loci. A positive T cell crossmatch on current or 
historical sera precluded transplantation, but a positive B cell 
crossmatch did not.
All'patients were treated peri- and postoperatively with
Prednisolone, initially in a dose of 20 mg daily, tapering to 10 mg
daily at one year. All studies in this chapter were also treated
with Azathioprine, in a starting dose of 3mg/kg/day adjusted to keep
9the white cell count above 4 x 10 /ml. Rejection episodes, diagnosed 
on clinical, biochemical and where possible histological criteria, 
were treated with increased doses of Prednisolone.
For analysis of the results, a patient was classed as a "transplant 
acceptor" if the allograft were functioning one year following 
transplantation. Three kidneys were thought to have infarcted for 
non-immunological reasons; results for these patients were not 
excluded from the analysis.
ii) Methods used
IgG preparations were obtained by DEAE chromatography (method 
8:3:iv) from pretransplant serum samples and used for all experiments 
unless otherwise stated. The EA rosette inhibition assay (method 
8:4:i) was performed using the following Fc)f-receptor bearing cells:
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a) Peripheral blood lymphocytes from normal subjects.
IgG preparations from all 63 transplant recipients were tested 
at both 4°C and 37°C.
b) Peripheral blood lymphocytes from the kidney donor. Blood 
was taken from the cadaveric donor shortly before donor 
nephrectomy.
It was decided to use ultracentrifuged pretransplant serum 
(method 8:3:ii) rather than IgG in these experiments to allow 
the cells to be used within several hours of harvesting.
Serum from 18 transplant recipients was tested at 4°C and 37°C.
c) B lymphocytes from normal subjects.
IgG preparations from 26 transplant recipients were tested 
against B enriched lymphocyte preparations (method 8 :1:ii) . 
Because of the relatively small proportion of B lymphocytes 
available in peripheral blood, the assay was performed at 
only one temperature (4°C).
d) B lymphocytes obtained from the spleen of the cadaveric kidney 
donor and frozen until use (method 8 :1 :ii; 8 :2 :i).
IgG preparations from 31 transplant recipients were tested, 
again at 4°C only.
3. Results
Where IgG preparations were tested with third party rather than 
donor cells, the results are, except where otherwise stated, the mean 
values for inhibition of EA rosette formation of lymphocytes from 3 to 
6  normal subjects. All groups of "acceptors" and "rejectors" studied 
were (fortuitously) comparable in age, sex, primary renal disease and 
duration of dialysis. Any differences in tissue match or transfusion 
history are detailed beside the relevant experimental results.
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Figure 52 shows the results when IgG preparations from all 5 3  
subjects were tested against normal peripheral blood lymphocytes at 
both temperatures. There was no evidence for an advantage to graft 
survival in the presence prior to transplantation of Fc^-receptor 
blocking antibody whether detected at 4°C or 37°C.
Indeed, the converse appeared to be true. Table 6  shows the
same results divided into "antibody-positive" (greater than 35%
inhibition) and "antibody-negative". The presence of Fc'X-receptor
blocking antibody at 4°C was associated with graft failure (P^O.05,
X 2  test). At 37°C a greater proportion of patients had antibody and
the association with graft failure did not reach statistical 
2
significance (X test).
Even in those patients who had functioning transplants after one 
year there was a highly significant correlation between pretransplant 
antibody detected at 4°C and the serum creatinine at one year 
(Figure 53, r = 0.64, P<0.001). '
Another way of looking at the results derived from a panel is not
to take the mean result but to regard any patient with antibody activity
against any one of the panel as positive. When the results are
expressed in this way, 34 patients (26 with a functioning kidney after
one year) were antibody-negative and 29 (14 with a functioning kidney)
were antibody-positive. The association between antibody and graft
2failure remained significant (P^0.05, X test).
This finding could not be explained by difference in the prevalence 
of anti-HLA antibodies in the groups studied. Nor was any difference 
noted in. the number of pretransplant blood transfusions (mean number
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of units: "acceptors" = 9 "rejectors" = 1 1 ) nor in the closeness of 
HLA matching between kidney donor and recipient (Table 7).
Figure 54 shows the relation between one-year renal allograft 
survival and inhibition of EA rosette formation of donor peripheral 
blood lymphocytes by ultracentrifuged pretransplant recipient serum. 
Inclusion in this group necessitated the harvesting of fresh peripheral 
blood lymphocytes from a local cadaveric donor. Even where this was 
practicable, the proportion of EA rosette forming lymphocytes was at 
times as low as 5% and so not acceptable for use in the assay. Only 
18 subjects were studied, and only 4 of these had lost graft function 
within a year. It is, therefore, difficult to draw conclusions from 
the results depicted.
Figure 55 gives the results for Fc^-receptor blocking antibody 
against normal B lymphocytes. No correlation is seen with one-year 
renal allograft survival.
Figure 56 illustrates the relation between one-year renal allograft 
survival and pretransplant IgG antibody activity against B lymphocytes 
derived from the spleen of the cadaveric donor. Only one of the 
patients studied was found on routine crossmatching to have cytotoxic 
antibody against donor B cells; that graft was rejected within a few 
days of transplantation. Six out of 9 "rejectors" had pretransplant 
IgG Fcfc -receptor blocking activity against donor B cells and 15 out of 
22 "acceptors" did not. There was, therefore, no evidence that 
antibody was associated with improved graft survival.
Donor-recipient HLA matching was marginally worse in the "rejector" 
group (Table 8 ) . The "acceptors" had had a significantly greater
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number of units of blood (P^O.05, mann-Whitney U test). The mean 
+ standard deviation units of blood was 13 + 15 for the "acceptors" 
and 6  + 1  for the "rejectors".
4. Discussion
The factors affecting the outcome of renal transplantation are many, 
and even the association with HLA typing may be unclear unless 
thousands of patients are studied (Opelz, 1985b). The failure here' 
to detect an association between pretransplant Fc)5-receptor blocking 
antibody and renal allograft survival could reflect simply the small 
number of patients studied. However, the original work proposing the 
association was based on similar numbers of patients, with correlations 
found between one-year renal allograft survival and pretransplant 
FcK -receptor blocking activity against donor splenic B lymphocytes, 
panels of normal B cells and panels of B cells from patients with 
chronic lymphatic leukaemia (MacLeod et al, 1982 a and b).
The results in this chapter reflect attempts to look in a variety 
of ways at the relation between allograft survival and Fctf-receptor 
blocking IgG class antibody. The experiments in Chapters 10 and 11 
showed an association between blood transfusion and IgG antibodies 
detected by their capacity to block Fc)S-receptors on normal human 
peripheral blood lymphocytes. Although this finding was similar to 
that of MacLeod et al (1982b and 1983) using B lymphocytes, no 
association with allograft survival was found. The converse appeared 
to be true. FcX-receptor blocking activity at 4°C, but not at 37°C, 
was associated with allograft rejection. Also, in patients with 
functioning transplants after one year, serum creatinine correlated 
with pretransplant antibody activity.
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It has been suggested that patients with strong activity widespread 
across, a panel may fall into a different category than those with 
selective activity against lymphocytes from one or two donors (MacLeod 
et al, 1982a). Even patients whose antibody activity was selective 
had poorer transplant survival in.the present study.
IgG preparations were not tested for cytotoxicity against the 
peripheral blood lymphocytes used in the panels. However,, all were 
screened by the routine Tissue Typing service, and only 6  out of 63 had 
antibody activity against more than 30% of the donor panel. It 
seems unlikely that this low prevalence of anti-HLA antibodies could 
explain the failure to confirm the reported association with renal 
allograft survival. Although cytotoxicity against donor cells was 
excluded before transplantation, the experiments using peripheral 
blood lymphocytes from the cadaveric kidney donor contributed little 
further.
The results using third party B lymphocytes failed to sub­
stantiate the possibility that antibody blocking B cell, rather than 
peripheral blood lymphocyte, Fc^-receptors is important to renal 
allograft survival. Using B lymphocytes prepared from donor splenic 
tissue the reported association between transplant function and Fctf- 
receptor blocking activity was not confirmed.
Explanations for the discrepancy between these and previous results 
were sought in experimental techniques. There is no obvious reason 
for the chicken EA technique used here (Sandilands et al, 1980) to give 
different answers than the ox-EA technique used by MacLeod et al 
(1982a and b). Where cells were plentiful, the EA rosette inhibition 
assay was performed at both 4°C and 37°C. Experiments using peripheral
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blood lymphocytes were therefore performed at both temperatures.
4°C was chosen for the B cell experiments to facilitate comparison 
with the Aberdeen assay at that temperature.
MacLeod et al attributed their findings to FcB-receptor blocking 
IgG. The majority of their experiments used recipient serum 
ul.tracentrifuged for 90 minutes at 100,000g to remove immune complexes 
which might also block the receptor. IgG separated from serum by 
DEAE chromatography was used for almost all of the experiments discussed 
here. This process is in standard use and there is no evidence that 
it would remove the relevant IgG antibodies. IgG preparations were 
found to.be pure by radial immunodiffusion and gel electrophoresis, 
and were: ultracentrifuged after thawing prior to use. . It appears 
unlikely that the method of preparation of IgG eliminated an 
association between IgG Fc^-receptor blocking activity and renal allo­
graft survival.
Untracentrifuged serum from 18 patients was tested against peripheral 
blood lymphocytes from the cadaveric kidney donor but the small number 
of patients, particularly in the "rejector" group, hindered inter­
pretation of the results. The question as to whether serum Fctf- 
receptor blocking factors other than IgG might be relevant to renal 
allograft survival is explored further in Chapter 16.
The possibility that the patients studied were in some way 
different from those studied by MacLeod et al (1982a and b) has not 
been excluded. Both studies were however conducted in Scotland. The 
population of the West of Scotland, while larger than that of the 
Grampian, area, is not strikingly cosmopolitan. Most of the patients 
here were born of local parents, lived all their lives locally and
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received blood from local donots. Transfusion policies in the two areas 
were similar. Patients with a spectrum of renal disease were studied 
here, and there was no evidence that primary disease affected antibody 
production or outcome in patients who received transplants. The 
prevalence of HLA-DRw6 , suggested by Hendriks et al.(1983) to indicate 
strong immune responders, was similar in the "acceptor" and "rejector" 
groups.
Few of the patients studied in this chapter had had previous 
transplants or were highly sensitized. Three recipients whose IgG 
preparations were tested against donor splenic B lymphocytes had a 
positive anti-donor B cell crossmatch. These patients were included 
in the analysis; their exclusion did not alter the lack of : 
correlation between Fc^-receptor blocking antibody and transplant 
outcome.
The renal allografts studied by MacLeod et al (1982a and b) did 
not have pretransplant donor-recipient tissue matching for Class II . 
antigens. Those studied here were matched preferentially for DR, then 
the B loci, with relatively little attention to the A loci. This 
policy is reflected in the figures for mismatches depicted in the 
Results section, and may reflect a genuine difference between the 
donor-recipient pairs studied in the two centres.
FcX'-receptor blocking antibody may have more relevance to the 
protection of renal allografts where the match for Class II antigens 
is less favourable. There have been a number of reports of antibodies 
in transplant recipients apparently directed against non-DR Class II 
antigens (for example d'Apice and Tait 1980; Nunez,. McPhaul and 
Stastny, 1983). Evidence linking anti-Class II and FcV-receptor
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blocking antibodies is discussed in Chapter 6 . MacLeod et al 
(1985a) have suggested that Fc Y'-receptor blocking antibodies following 
transfusion may be produced against B lymphocytes from the blood donor 
and his family in a pattern suggesting HLA linkage, but representing 
an as yet undefined antigen system (MacLeod et al, 1982a and b).
Against matching for Class II antigens as an explanation for the 
differing results is the finding in Glasgow that a degree of DR match 
does not appear to make a difference in transplant outcome of 
sufficient magnitude to account for the discrepancy (Watson, personal 
communication).
The failure to confirm the Aberdeen results echoes the findings 
of Suthanthiran et al (1978) and Soulillou et al (1978), discussed in 
more detail in Chapter 6 . If no correlation is seen between renal 
allograft survival and pretransplant FcV-receptor blocking IgG antibody, 
other non-IgG serum factors removed by DEAE chromatography could be 
contributing to previous reports of a correlation. This topic is 
examined further in the next chapter.
5. Conculsions
i) No correlation was found between one-year renal allograft survival 
and the presence in recipient serum before transplantation of ■
IgG class antibody with FcK-'receptor blocking activity against 
normal peripheral blood or B lymphocytes, nor against donor 
peripheral blood or splenic B lymphocytes.
ii) No obvious explanation for the discrepancy between this and 
previous work was found.
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CHAPTER 16
NON-IgG Fcj -RECEPTOR BLOCKING FACTORS AND RENAL ALLOGRAFT SURVIVAL •
1. Introduction
i) Background
The failure reported in Chapter 15 to confirm an association 
between Fcfi -receptor blocking IgG antibody and renal allograft survival 
led to consideration of possible reasons for the discrepancy between 
these results and those of MacLeod et al (1982 a and b). The use in 
the majority of experiments reported here of IgG preparations, rather 
than ultracentrifuged serum as in most of the previous work, represented 
a difference in technique. It was decided to look further not at 
IgG but at other serum Fc^-receptor blocking factors.
ii) Aims of the study
The1 experiments described in this, chapter were designed to answer 
the following questions:
a) Is there a difference in Fc^-receptor blocking activity between 
ultracentrifuged serum and IgG prepared from the same serum 
sample?
b) Is renal allograft survival associated with the presence in 
pretransplant serum of Fctf-receptor blocking factors other than 
IgG?
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2. Materials and Methods
i) Subjects studied
Serum samples were obtained from:
a) 53 (36 male) patients on renal replacement therapy. The mean 
age was 42 (range 19 - 57)years. At the time of sampling 18 
patients had functioning renal transplants, 24 were on haemo- 
dialysis and 1 0  were on continuous ambulatory peritoneal 
dialysis. All had received at least 5 units of blood. Trans­
planted subjects were maintained on Prednisolone and Azathioprine.
b) 78 (48 male) renal allograft recipients during the day before 
transplantation. The mean age was 37 (range 16 - 65) years.
All patients had received at least 5 units of third party whole 
blood or packed cells. Priority was given to donor-recipient 
histocompatibility at the DR, then B then A loci. A positive 
T cell crossmatch on current or historical sera precluded 
transplantation, but a positive B cell crossmatch did not.
All patients were treated peri- and postoperatively with Prednisolone,
initially in a dose of 2 0  mg daily, tapering to 1 0  mg daily at one
year. Fifty-five patients were also given Azathioprine, in a starting
dose of 3 mg/kg/day adjusted to keep the while cell count above 
9
4 x 10 /ml. Because the Renal Unit immunosuppression protocol changed 
during the period of study, the other 23 patients were given 
Cyclosporin in an initial once daily dose of 15mg/kg adjusted to achieve 
optimum serum creatinine. Rejection episodes, diagnosed on clinical, 
biochemical and where possible histological criteria, were treated with 
increased doses of Prednisolone.
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ii) Methods used
Each of the 53 serum samples from patients on renal replacement 
therapy was divided. One aliquot was ultracentrifuged (method 
8:3:ii) .and the other was used to prepare IgG at a concentration of 
Img/ml in phosphate buffered saline (method 8:3:iv). The pre­
parations were then tested in parallel at 4°C for inhibition of EA 
rosette • formation by peripheral blood lymphocytes from the same normal 
donor (method 8:4:i).
Six samples of ultracentrifuged serum which were found to have 
Fc$ -receptor blocking activity at standard concentration (N) were 
retested in doubling dilutions to N/32.
Serum taken shortly before transplantation from 45 subjects was 
ultracehtrifuged (method 8 :3:ii) and tested at 4°C for inhibition of 
EA rosette formation of normal peripheral blood lymphocytes. All 
these subjects were treated with Azathioprine rather than Cyclosporin.
Pretransplant serum from 50 subjects was fractionated over 
discontinuous sucrose gradients (method 8:3:iii). Each serum fraction 
obtained was tested at 37°C for inhibition of EA rosette formation of 
normal peripheral blood lymphocytes (method 8 :4:i)- Twenty-seven of
these subjects were treated with Azathioprine and 23 with Cyclosporin.
3. Results
Figure 5 7 shows the correlation between the Fctf-receptor blocking 
activities of ultracentrifuged serum and IgG, when tested simultaneously 
with the same lymphocytes. There is a highly significant correlation
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between the two values obtained (r = 0.64, P^O.QQl). Where 35% 
inhibition is taken as the upper limit for a "negative" result for 
IgG (Chapter 9) and 30% for serum (Bakkaloglu et al,1980) the paired 
values for 9 out of the 53 samples are not concordant. Eight are 
"positive" with ultracentrifuged serum but "negative" with IgG.
Preparation of IgG as described gives a concentration of IgG lower 
than that in serum (method 8:3:iv). That dilution was unlikely to 
explain loss of FcY-receptor blocking activity following preparation of 
IgG from serum is shown in Figure 58. Six out of the 8  samples of 
ultraceritrifuged serum previously found to be "positive" but with 
"negative"IgG were tested. All maintained FcY-receptor blocking at 
all dilutions to N/32.
Figure 59 shows no association between one year renal allograft 
survival and pretransplant FcK-receptor blocking activity in ultra­
centrifuged serum when normal peripheral blood lymphocytes were used 
as the Fctf-receptor bearing cells. This result was derived using 
lymphocytes from a single normal donor; Figure 54 in Chapter 15 showed 
no association where lymphocytes from the kidney donor were used.
The results for serum fractions collected from discontinuous 
sucrose gradients will be considered separately for the 27 patients 
treated with Azathioprine and the 23 treated with Cyclosporin. The 
reason for this is the influence of Cyclosporin on renal allograft 
survival,, even where relatively small numbers of patients are considered. 
Figure 60 shows the cumulative renal allograft survival for patients 
transplanted in Glasgow in 1983 and 1984, with 71 patients given 
Cyclosporin compared to 71 historical controls given Azathioprine. If 
non-immunological failures were excluded, 85% of kidneys in. the
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Cyclosporin group and 6 6 % in the Azathioprine group were functioning
2
after one year (P<0.05, X test).
Figure 61 shows inhibition by serum fractions from Azathioprine- 
treated patients of EA rosette formation of peripheral blood lymphocytes 
from a normal donor. Within the results for each fraction, values 
are divided into those from the 17 patients with functioning transplants 
after one year ("acceptors") and those from the 1 0  whose transplants 
failed ("rejectors").
If one looks first at the results for fraction 4, which contains
the 7S, or IgG peak, one can see no difference between the values for
the "acceptors" and "rejectors". Moving towards the higher molecular
weight fractions the two groups diverge. In fraction 1, 16 out' of
17 acceptors and none out of 1 0  rejectors had levels of inhibition
greater than the 30% regarded as the upper limit of normal for serum
2
(Bakkaloglu et al, 1980) (P<0.001, X test with Yates correction).
The results for the Cyclosporin-treated group were less clearcut
(Figure 62). There was no significant difference between results for
2
the 14 "acceptors" and 9 "rejectors" in fraction 4 (X test and
Mann-Whitney U test). Fctf-receptor blocking activity in both fraction
3 and fraction 1 was associated with transplant function after one 
2
year (for both, X test with Yates correction, P-C0.01).
The results for all 50 patients from serum fraction 1 are compiled
in Figure 63. The pattern that Fctf^receptor blocking activity was
associated with renal allograft survival was followed in all but 5 cases 
2
(P-40.001, X test with Yates correction).
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Transfusion histories were similar for the different groups of 
patients (Table 9). HLA matching between kidney donors and recipients 
was slightly poorer in the Cyclosporin-treated group but there was no 
apparent association in this small group of patients between 
histocompatibility and graft function.
No association was found in these 50 patients between the presence 
of Fctf-receptor blocking activity in serum fraction 1 and the patient’s 
age, sex, primary renal disease, mode of dialysis, time on dialysis, 
total number of units of blood received, or tissue type. Nor was any 
association noted with serum urea, creatinine or phosphate levels.
The results of skin testing with Dinitrochlorobenzene were 
available for 44 of the patients (Tsakiris, personal communication).
The response to Dinitrochlorobenzene was graded from 0 to 15 with lower 
values indicating depressed cell-mediated immunity (Watson et al,
1979). . There was a significant inverse correlation between the skin
test score and the percentage inhibition of EA rosette formation by 
serum fraction 1 (r = -0.41, P^O.01)(Figure 64).
4. Pis cussion
When IgG and ultracefitrigued serum prepared from the same serum 
sample were tested in parallel against lymphocytes from the same normal 
donor, their capacities to inhibit EA rosette formation were in accord 
in all but 9 out of 53 cases. In 8  of these 9, ultracentrifuged serum 
was inhibitory but IgG was not, suggesting that preparation of IgG had 
removed serum Fc^-receptor blocking factors which were not removed by 
ultracentrifugation. The use by MacLeod et al (1982a and b) of ultra- 
centrifuged serum, instead of IgG as used in the experiments in Chapter
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15, might therefore contribute to the discrepancy between the results 
for the association between Fctf-receptor blocking and renal allograft 
survival.
The decision to fractionate pretransplant serum over discontinuous 
sucrose gradients was taken for several reasons. First, it appeared 
necessary in view of the previous results to look at more than simply 
the IgG FcS'-receptor blocking activity. Secondly, the technique 
was well developed within the laboratory (McLean et al, 1985).
Thirdly, when the technique Was first in use in the laboratory in 
19 77 and 19 78, pretransplant serum from renal patients had been 
fractionated in this way and the fractions tested for their Fci'-receptor 
blocking activity against normal peripheral blood lymphocytes. The 
results are unpublished, but reproduced in Figure 65 (Sandilands and 
Peel, personal communication).
At that time, pretransplant transfusion was not routine. The 14 
patients whose transplants were still functioning at the time of 
writing ( 8  years post-transplant) had received more pretransplarit 
blood (mean 13.1, standard deviation 15.7) than had the 7 who rejected 
their grafts (mean 3.3, standard deviation 5.3). Levels of Fc}(- 
receptor blocking activity in the fraction containing the IgG peak 
(fraction 4) were higher in the group who rejected their transplants. 
Interestingly, those who retained functioning grafts had greater levels 
of inhibition in the higher molecular weight fractions.
This tentative finding was confirmed in the patients studied in 
1983 and 1984. Not only was Fc& -receptor blocking activity in serum 
fraction I (>19S) highly predictive of one-year renal allograft survival,
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but it also correlated with diminished cell-mediated immunity, assessed 
by skin'testing with Dinitrochlorobenzene. It is not possible with
the data shown to exclude a coincidental connection between these two 
factors which may correlate independently with renal allograft survival.
The relation between these results and the findings of MacLeod 
et al (1982a and b) is uncertain. Ultracentrifugation would remove 
serum fraction I, although it is possible that the weaker association 
with transplant survival seen for serum fraction 3 could be explained 
by Fctf-receptor blocking factors left in ultracentrifuged serum.
The Fc&'-receptor blocking factors described by MacLeod et al 
(1982a and b) and the FcK-receptor blocking IgG antibodies described 
in earlier chapters of this volume showed some degree of specificity 
againsh target lymphocytes. The strength of the correlation shown 
between serum fraction I Fctf-receptor blocking factors and renal 
allograft survival suggests that the effect is non-specific, as the 
lymphocytes used were from normal staff members, not the kidney donor. 
The correlation with Dinitrochlorobenzene skin testing, an index of 
non-specific cell-mediated immunity (Watson et al, 1979; Bramwell 
et al, 1985), may also indicate that the effect is non-specific.
Likely candidates for the role of blocking factor(s) are immune 
complexes. Certain types of complexes are known to block the Fc - 
receptor (Sandilands et al, 198Q), Carpentier et al (1982) claimed 
that renal allograft survival was associated with pretransplant 
circulating immune complexes, a finding which Keusch et al (1984) 
failed to reproduce.
Immune complexes have been reported to initiate suppressor T cell
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function by blocking the Fctf-receptor (Moretta et al, 1979), to suppress 
cell-mediated immunity (Virgin and Unanue, 1985), to inhibit macrophage 
tumoricidal activity'(Eparza, Green and Schreiber, 1983) and possibly 
to impair the response to tetanus toxoid after repeated booster 
immunization (Saxon et al, 1981). Caulfield et al (1983) claimed 
that antigen-antibody complexes induced idiotype specific suppressor 
T cells.in mice, while studying the effects of pnemococcal polysaccharide.
Other possibilities for the blocking factor(s) are globulins of 
high molecular weight, such as alpha-2-macroglobulin. Alpha-2- 
macroglobulin is a major serum globulin, whose actions are reviewed 
by James (1980). To date there have been no reports of individuals 
lacking this protein, suggesting that absence of the appropriate genes 
may be a lethal deletion. Alpha-2-macroglobulin has a molecular weight 
of 725,000 daltons and is dissociable into 4 subunits of 185,00 
daltons. It has a variety of potentially immunoregulatory actions, 
including binding to lymphokines and lectins, and inhibition of the mixed 
lymphocyte reaction. There are no reports, to the author's knowledge, 
of its action on FcJf-receptors.
The suggestion that alpha-2-macroglobulin might be relevant to 
transplantation was made by Kamrin (1959), who found that administration 
of alpha-2 -macroglobulin was associated with prolonged skin graft 
survival in mice. This finding was confirmed by Mowbray (1963), but 
not by Davis and Boxer (1965). Ford, Caspary and Shenton (1973) 
suggested that alpha-2 -macroglobulin could block antigen recognition by 
lymphocytes, Davis et al (1978) concurred, and Cooperbrand et al 
(1976) reviewed the evidence for such non-specific immunosuppressive 
substances in a variety of conditions.
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Proud, Shenton and Smith (1979) assessed the capacity of plasma 
from previously transfused uraemic and haemophiliac subjects to inhibit 
the lymphocyte response to purified protein derivative of myco­
bacterium tuberculosis. After the plasma was fractionated according 
to molecular weight, the fraction containing IgG gave some inhibition 
of the lymphocyte response, but considerably more was found in the 
fraction containing macroglobulins.
Proud et al (1979) also claimed an association between the pre­
sence in pretransplant plasma of alpha-2-macroglobiilin and renal 
allograft survival, and demonstrated prolongation of cardiac allograft 
survival in rats given alpha-2-macroglobulin. After a rush of papers 
from the same group (Shenton et al, 1979; Veitch et al, 1980), the 
proposed association between alpha-2-macroglobulin and renal allograft 
survival has lapsed into abeyance.
An immunosuppressive glycoprotein has been described in the serum 
of pregnant women. Suppression of mixed lymphocyte reactivity by 
serum from pregnant women (Bissenden, Ling and Mackintosh, 1980) may 
be related to the IgG antibodies described, for example, by Power et al 
(1983a).; However, Fizet et al (1983) reported that an alpha-globulin:, 
of molecular weight 210,000, reduced maternal lymphocyte responsive­
ness to .paternal antigens and gave non-specific inhibition of the 
mixed lymphocyte reaction between unrelated third party lymphocytes.
Toge et al (1983) claimed that serum from patients with advanced 
gastric carcinoma induced suppressor cell proliferation by normal 
lymphocytes, but did not discuss the nature of the suppressor factor(s). 
There is therefore little evidence associating alpha-2-macroglobulin 
with immunosuppression outwith transplantation.
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It is possible that neither immune complexes nor alpha-2- 
macroglobulin can explain the apparent correlation between high 
molecular weight serum FcV-receptor blocking factors and renal 
allograft survival. Experiments to try to establish the nature of 
the blocking factor(s) are described in the next chapter.
The response to skin testing with Dinitrochlorobenzene has been 
associated with blood transfusion and renal allograft survival 
(Watson et al, 1979 and 1981) and the correlation here with serum 
fraction I Fc^-receptor blocking activity may indicate that blood 
transfusion may be relevant to the production of blocking factor(s). 
The relation between blocking factor(s) and transfusion is discussed 
in the next chapter.
5. Conclusions
i) Preparation of IgG by DEAE chromatography may exclude serum 
Fc^-redeptor blocking factors not removed by ultracentrifugation 
of serum.
ii) High molecular weight Fctf-receptor blocking factors in 
pretransplant serum correlate with renal allograft survival.
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CHAPTER 17
THE NATURE AND RELATION TQ.TRANSFUSION OF HIGH MOLECULAR WEIGHT SERUM
Fey'-RECEPTOR 'BLOCKING FACTORS
1. Introduction
i) Background
The' results presented in the last chapter show a correlation between 
renal allograft survival and the presence in pretransplant serum of, high 
molecular weight (>19S) factor(s) detected by their capacity to block 
peripheral blood lymphocyte Fc^-receptors. The purposes of this chapter 
are to examine the nature and relation to blood transfusion of these 
factor(s).
ii) Aims of the study
The experiments described in this chapter were designed to answer 
the following questions:
a) Is the presence of high molecular weight serum Fc\-receptor 
blocking factor(s) associated with previous transfusion of 
blood or blood products?
b) Can the development of such factors be demonstrated over the 
course of an elective blood transfusion protocol in renal 
dialysis patients?
c) Do high molecular weight serum fractions fr<?m normal and 
transfused subjects inhibit phytohaemagglutinin-induced 
blastogenesis of normal lymphocytes?
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d) What is the nature of the high molecular weight serum FcY-
receptor blocking factors which appear to correlate with renal 
allograft survival?
2. Materials and Methods
i) Subjects studied
Serum samples were taken from the following groups of subjects:
a) 10 healthy laboratory staff. None had received transfusion 
of blood or blood products.
b) 4 (2 male) subjects with serum creatinine greater than 600 
micromols/1, but never transfused. The mean age was 38 
(range 21 - 59) years.
c) 6 (2 male) subjects without known renal disease but previously 
transfused at least 5 units of blood. The mean age was 40 
(range 22 - 5 7) years.
d) 6 patients with haemophilia receiving blood products but not 
blood. All were male, with mean age 26 (range 19 - 38) years.
e) 6 (5 male) renal dialysis patients undergoing elective third 
party blood transfusion prior to entry to the pool awaiting 
cadaveric transplantation. The mean age was 38 (range 20 - 46) 
years. The serum samples used were taken i) before any blood 
was given (no patient had received previous transfusion) and
ii) two weeks after transfusion of the fifth unit of packed cells
f) 34 patients about to undergo renal transplantation. Samples 
were taken as before during the few hours prior to transplantation 
All patients had received at least 5 units of third party blood. 
Tissue typing criteria were as in Chapters 15 and 16.
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ii,) Methods used
All serum samples were fractionated over discontinuous sucrose 
gradients (method 8:4:iii) and the fraction of highest molecular weight,
designated fraction I, was used for subsequent experiments.
Fraction I preparations from serum from the following subjects 
were tested for their capacity to inhibit EA rosette formation at 37°C 
by peripheral blood lymphocytes from a normal subject (method 8:4:i).
a) 6 normal subjects
b) 4 untransfused uraemic subjects
c) 6 non-uraemic transfused subjects
d) 6 haemophiliac subjects
e) 6 uraemic subjects (both pre- and post-transfusion samples)
Fraction I preparations from serum from the following subjects 
were tested for their capacity to inhibit phytohaemagglutinin-induced 
biastogenesis of peripheral blood lymphocytes from a normal subject 
(method 8:4: iv).
a) 6 normal subjects
b) 6 haemophiliac subjects
c) 31 transfused uraemic subjects. . Samples were taken immediately, 
prior to transplantation. All patients were immunosuppressed 
with Prednisolone; in addition 18 received Azathioprine and 13 
Cyclosporin. 16 patients had a functioning transplant one year 
later ('’acceptors”) and 15 had lost the kidney because of 
rejection ("rejectors").
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Fraction I preparations from pretransplant samples from 3 
''acceptors" and 3 "rejectors", and from samples from 3 transfused 
non-uraemic subjects were separated by SDS-PAGE gel electrophoresis 
(method 8: iO).
Pooled serum fraction I preparations were made for transplant, 
"acceptors" (19 subjects), "rejectors" (6 subjects) and normal subjects 
(10 subjects). These pools were tested for inhibition of EA rosette 
formation and phytohaemagglutinin-induced blastogenesis of normal 
peripheral blood lymphocytes, before and after absorption with Sepharose 
beads, both alone and conjugated to Staphylococcal Protein A (methods 
8:4:i; 8:4:iv; 8: 11). SDS-PAGE gel electrophoresis was per­
formed on the absorbed and unabsorbed pools.
Alpha-2-macroglobulin, at a concentration of 250 mg/1 in phosphate 
buffered' saline, was tested for its capacity to inhibit EA rosette 
formation at 37°C by peripheral blood lymphocytes from 3 normal subjects.
3. Results
All the patients in Chapter 16 whose serum contained high molecular 
weight Fc^-receptor blocking factors were renal dialysis patients who had 
received at least 5 units of blood. Figure 66 shows the results of 
experiments performed to see whether the presence of such factors is 
associated with previous transfusion of blood or blood products. No 
difference was found between Fc^-receptor blocking activities of serum 
fraction I from normal and uraemic untransfused subjects. The 
differences between activities of serum fraction I from normal and non- 
uraemic transfused (P40.001) and haemophiliac (P^0.05) subjects reached
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statistical significance (MannnWhitney U Test).
Figure 67 shows the results for inhibition of EA rosette formation
by fraction I before and after transfusion of 6 dialysis patients.
The samples were tested in parallel against peripheral blood lymphocytes 
from the same normal donor. In 3 out of 6 patients there was some 
increase in Fc^-receptor blocking activity after transfusion; in 1 there 
was a marked decrease, and in the other 2 there was no change. The 
difference between the values before and after transfusion did not reach 
statistical significance (Wilcoxon Matched Pairs Signed Rank Test). •
Figure 68 shows the extent to which serum fraction I preparations
inhibited phytohaemagglutinin-induced blastogenesis of normal peripheral 
blood lymphocytes. The difference between the results for normal and 
haemophiliac subjects reached statistical significance at the 5% level 
(Mann-Whitney U Test). The difference between the results for the 
normal and transfused uraemic subjects was much more striking (P^O.OOl, 
Mann-Whitney U Test). There was no significant difference between the 
values obtained for the "acceptor” and "rejector" groups.
Fractions I and 4, alone and in combination, from 3 transfused 
subjects were tested for their capacity to inhibit, the phytohaemagglutinin 
response of the same normal lymphocytes. As Figure 69 shows, the 
inhibitory activities of fractions I and and 4 (containing the IgG 
peak) appeared to be additive.
SDS-PAGE gel electrophoresis of serum fraction I from 3 "acceptors",
3 "rejectors" and 3 non-uraemic transfused subjects showed no obvious
differences among the groups(gel not shown) . Samples from all the non-
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uraemic transfused subjects and from 2 of the "acceptors" were previously 
found to have Fc$-receptor blocking activity.
Nor was any different pattern of protein banding noted on electro­
phoresis, of the pools of normal, "acceptor" and "rejector" fraction I. 
Differing densities of the protein bands from the various pools mirrored 
differing protein concentrations (assessed as before by optical density 
at 280nm): normal 369 mg/1, "acceptor" 222 mg/1, "rejector" 132 mg/1.
The protein band corresponding to molecular weight 150,000 daltons 
(dalton markers not shown) was removed when the fraction I pool was 
absorbed with Sepharose-Protein A, but not with Sepharose alone. When 
the proteins removed by the absorption technique were run over similar 
gels, the protein band obtained was found to correspond to that formed 
by monomeric IgG (gels not shown).
When fraction I pools before and after absorption with Sepharose- 
Protein A were tested for Fc^-receptor blocking activity against peripheral 
blood lymphocytes from 3 normal donors, the results shown in Figure 70 
were obtained. FcX-receptor blocking activity was not fully removed by 
absorption.
Similarly, absorption did not remove the capacity to inhibit the 
phytohaemagglutinin response (Figure 71). On the contrary, the 
inhibitory activity of the "acceptor" pool was increased. This experiment 
was performed with a single normal lymphocyte donor, and requires 
confirmation using other donors.
Alpha-2-macroglobulin, at the concentration used, did not inhibit EA 
rosette formation by peripheral blood lymphocytes from 3 normal donors
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(percentages inhibition 0, 0 and 22%).
4. Discussion
The finding in Chapter 16 that renal allograft survival correlated 
with pretransplant high molecular weight serum Fc&-receptor blocking 
activity led to the experiments described here. Taken in conjunction 
with the results for transfused uraemic subjects in Chapter 16, the 
results here do suggest that the presence of high molecular weight serum 
Fc^-receptor blocking factors may be associated with previous transfusion 
of blood or blood products, although the number of subjects studied here 
was relatively small. In particular, the failure of the pre- and post­
transfusion samples to show a significant increase in Fc)$-receptor 
blocking activity after transfusion may reflect the number of patients 
rather than a lack of association with transfusion. Three of the 6 
subjects did show an increase in fraction I Fc -receptor blocking 
activity after elective transfusion.
Like the pattern when IgG preparations rather than serum fractions 
were tested in earlier experiments, values were outwith the normal 
range for all the non-uraemic patients who had received blood transfusion, 
but for only a proportion of transfused subjects. This discrepancy was
discusse d in Chapter 10, and may reflect depressed responsiveness to
alloantigens in uraemia.
The proportion of haemophiliacs whose serum fraction I had Fcl(- 
receptor blocking activity was not markedly different than the IgG results 
in Chapter 13. This contrasted with the results for inhibition of the 
phytohaemagglutinin response by fraction I, where the modest levels of
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inhibition achieved by samples from haemophiliacs were outstripped by 
those from transfused uraemic subjects (Figure 68). The difference 
between results for recipients of blood and blood products may be 
genuine, but the absence of results for untransfused uraemic or transfused 
non-uraemic subjects makes this difference difficult to interpret.
There was certainly no evidence from the results shown, that renal 
allograft survival was related to pretransplant fraction I inhibition of 
blastogenesis by lymphocytes from random normal donors. No association 
was seen between inhibition of EA rosette formation and the mitogen 
response by fraction 1 (results not illustrated). Inhibition of the 
phytohaemagglutinin response could, therefore, not be regarded as an 
in vitro model of T cell suppression associated with high molecular 
weight serum Fctf-receptor blocking activity.
None of the experiments using gel electrophoresis gave an indication 
as to the nature of the fraction I FcY-receptor blocking factor(s), 
suggesting possibly that the gel method or staining procedures were not 
sufficiently sensitive to detect the relevant factor(s).
As discussed in Chapter 16, major contenders for the factor(s)'...« 
appeared to be immune complexes and alpha-2-macroglobulin. Although 
there is extensive evidence for immunoregulatory roles for alpha-2- 
macroglobulin (reviewed by James 1980), there is no evidence that it can 
inhibit the FcY-receptor. The concentration of alpha-2-macroglobulin 
chosen for the experiments described here was chosen to approximate to 
the protein concentration found in the fraction I pool which had Fctf- 
receptor blocking activity. It is possible that alpha-2-macroglobulin 
might inhibit EA rosette formation if used at a different concentration,
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but it was not found to be inhibitory here*
It would be interesting to absorb the fraction I preparations with 
anti-alpha-2-macroglobulin antibody, and then retest them for Fc#- 
receptor blocking activity. Absorption with antibody against alpha-2- 
macro'globulin of the serum fractions tested by the Newcastle group only 
partially removed their ability to inhibit the response to purified 
protein derivative of Mycobacterium tuberculosis (Proud et al, 1979; . 
Veitch et al, 1980).
Absorption with Staphylococcal Protein A has been regarded as a 
method of removing IgG, in monomeric or complexed form (Burlingham 
et al, 1985b). Gel electrophoresis of serum fraction I showed in all 
groups of subjects a protein band of molecular weight 150,000 daltons. 
This corresponded to IgG, although immunodiffusion techniques gave no 
evidence of monomeric IgG suggesting that IgG was present in serum 
fraction I in the form of immune complexes.
Absorption of fraction I with Protein A appeared to remove these 
presumed complexes, as gel electrophoresis of absorbed fraction I 
preparations showed no corresponding band. Yet the failure to absorb 
out all the FcX-receptor blocking activity suggested the presence of 
Fc^-receptor blocking factor(s) other than IgG-containing complexes.
If the increased inhibition of the phytohaemagglutinin response after 
absorption were confirmed, this might suggest that immune complexes 
mask the inhibitory effect of other unspecified serum factor(s).
IgG preparations from transfused subjects were shown in Chapter 12 
to inhibit the mitogen response, and it was suggested there that the
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mechanism might be by interaction with the Fctf-receptor, as already 
described for immune complexes (Moretta et al, 1979). The additive 
effect oh inhibition of the mitogen response of serum fractions I and 4 
(containing the IgG peak) may indicate that the inhibitory factors of 
differing molecular weights are acting by differing mechanisms.
The experiments described here fail to provide evidence for either 
alpha-2-macroglobulin or IgG immune complexes being responsible for the 
observed', correlation between renal allograft survival and the presence 
in pretransplant serum of high molecular weight Fctf-receptor blocking 
factors.- Nor was any other compound implicated by the gel electro­
phoresis analysis of fraction I from different groups of patientk 
although it is possible that more sensitive electrophoretic techniques 
may be required.
5* Conclusions
i) There appeared to be an association between transfusion of blood 
or blood products and high molecular weight serum FcX-receptor 
blocking activity, although no significant change in activity 
was found when 6 patients were followed over a course of elective 
transfusion.
ii) Inhibition of the phytohaemagglutinin response by pretransplant 
serum fraction I was not association with one-year renal 
allograft survival.
iii) The nature of the high molecular weight serum FcX-receptor blocking 
factors was not established.
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CHAPTER 18
CONCLUSIONS
The' experiments described in the preceding chapters confirmed 
the association between blood transfusion and the production of non- 
cytotoxic IgG class FcX-receptor blocking antibodies (MacLeod et al, 
1982b),Chapters 9 to 11). IgG preparations from transfused patients 
reacted with a range of Fctf-receptor bearing cells in addition to the 
B lymphocytes against which they were initially described. IgG 
Fc'tf-receptor blocking activity was associated with the ability of IgG 
preparations to inhibit the mitogen response in vitro. IgG pre­
parations from transfused subjects also affected polymorph and platelet 
function: in vitro, although clinical correlates in vivo were not 
sought (Chapter 12).
IgG' antibodies with FcK-receptor blocking activity and the ability 
to inhibit the mitogen response were also found in recipients of clotting 
factor concentrates (Chapter 13), in asymptomatic homosexual men and 
and in patients with the Acquired Immunodeficiency Syndrome (Chapter 14). 
The finding of antibodies with potentially immunosuppressive effects 
in vitro in association with Fctf-receptor blocking activity may indicate 
a role for Fc^-receptor blocking antibodies in the transfusion effect 
on renal allograft survival (MacLeod et al, 1982a and b), immune 
abnormalities in haemophilia (Froebel et al, 1983), susceptibility to 
the Acquired Immunodeficiency Syndrome (Fauci, 1985), and the treatment 
of autoimmune disease with pooled immunoglobulin (Templeton et al, 1985), 
all situations with multiple alloantigen exposure (Woodruff and van Rood, 
1983).
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Many factors contribute to renal allograft survival (Opelz, 1985a); 
so the failure in Chapter 15 to confirm the association with Fctf-receptor 
blocking ..antibodies does not wholly exclude their immunosuppressive role. 
The strong association found in Chapter 16 between allograft outcome and 
the presence in pretransplant serum of high molecular weight Fctf-receptor 
blocking factors is not necessarily related to the previous work 
implicating IgG. The correlation between high molecular weight Fc6- 
receptor blocking activity and response in vivo to skin testing with 
Dinitrochlorobenzene suggests that these Fctf-receptor blocking factors 
may be related to the mechanism of depression of cell-mediated immunity 
associated with previous blood transfusion and subsequent renal allograft 
survival (Watson, 1979 and 1981).
Although some evidence was provided in Chapter 17 for an 
association between transfusion of blood or blood products and the 
presence: of high molecular weight serum Fctf-receptor blocking factors, 
preliminary attempts to identify the factor(s) were unsuccessful.
Future work in this area should concentrate, at an experimental level, 
on identification of the factor(s) and confirmation of the association 
with transfusion. At a clinical level, extension of the number of 
patients studied would confirm whether the presence in pretransplant 
serum of high molecular weight FcX-receptor blocking factors may be 
regarded as predictive of renal allograft survival.
The immunosuppressive effect of blood transfusion is of substantial 
benefit in renal transplantation, and the availability of clotting 
factor concentrates has transformed the lives of patients with haemophilia. 
Liberal use of blood or blood products may not only increase the risk 
of transmitted infection, but also lead to immune abnormalities. Where
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transfusion is less crucial, sparing use of blood and blood products 
may minimise the uncertain long-term sequelae of exposure to multiple 
alloantigens.
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SUMMARY
Renal transplantation offers the optimal quality of life for the 
patient requiring renal replacement therapy. The main reason for renal 
allograft failure remains immunological rejection. The discovery that 
pretransplant blood transfusion is associated with decreased graft loss 
through rejection led to the introduction of elective transfusion 
protocols for renal dialysis patients. Despite extensive research, the 
mechanism of the blood transfusion effect on transplant outcome remains 
unclear. Of the many suggested explanations, one proposed by MacLeod 
and her colleagues, claimed that Fctf-receptor blocking, antibodies were 
produced after blood transfusion and correlated with renal allograft 
survival. The initial aims of the work described in this volume were 
to confirm and extend these findings (MacLeod et al, 1982b).
Using IgG prepared from whole serum by standard chromatography, the 
association between Fc)(-receptor blocking activity and blood trans­
fusion was confirmed for both uraemic and non-uraemic subjects. The 
development of Fc^-receptor blocking activity was shown over the course 
of elective transfusion of previously untransfused renal dialysis 
patients.
IgG preparations from transfused subjects were shown to interact 
in vitro not only with B lymphocytes as previously described, but also 
with normal, allogeneic peripheral blood and T lymphocytes, thymocytes? 
polymorphs, platelets and spermatozoa. The pattern of reactivity did 
not correspond to the Fctf-receptor bearing cell populations. The 
significance in vivo of inhibition by IgG preparations from transfused 
subjects of polymorph phagocytosis and platelet aggregation remains
uncertain., Perhaps relevant to attenuation of allograft rejection was 
inhibition of the mitogen response which was associated with IgG 
Fc^-receptor blocking activity.
Confirmation of the presence of FcJ-receptor blocking antibodies 
in patients potentially immunosuppressed by blood transfused was followed 
by similar experiments using IgG preparations from patients exposed to 
a wide range of alloantigens, although not necessarily in blood.
Patients-with haemophilia were chosen, as a group who received clotting 
factor concentrates derived from multiple donors, and in whom there 
were recent reports of impaired indices of immune function. Like the 
recipients of blood transfusion, patients with haemophilia yielded 
IgG which blocked FcV-receptors and inhibited the mitogen response of 
lymphocytes from normal subjects.
Only a small proportion of the haemophiliac subjects were later 
found to have antibody against Human T cell Leukaemia Virus Type III, 
thought now to mark potential development of the Acquired Immunodeficiency 
Syndrome (AIDS). The epidemiology of AIDS, while consistent with 
unifactorial viral aetiology, led to suggestions that pre-existing 
immunosuppression may predispose to the expression of the virus.
Reports of anti-lymphocyte antibodies in the serum of practising
homosexual men, the risk group with the highest incidence of AIDS,
stimulated experiments to assess the prevalence of FcY-receptor blocking
antibodies in AIDS patients and in homosexual men with no evidence of
the syndrome. IgG preparations from both groups blocked FcY-receptors '
and inhibited the mitogen response of normal lymphocytes. Cross­
reactivity with spermatozoa may indicate that anti-lymphocyte antibodies
are induced by rectal insemination, Although, these experiments were 
performed before identification of the virus, and antiviral antibody 
status was not checked, the preyalence of infection in comparable 
populations at the time of testing (1983) has been regarded as too low 
to account for these findings.
Despite the demonstration of.IgG FcY-receptor blocking activity in 
subjects with acquired immune abnormalities, no association was found 
between renal allograft survival and pretransplant IgG receptor blocking 
activity, using a variety of donor and third party FcY-receptor bearing 
cells. No conclusive explanation was found for the discrepancy between
this and previous work (MacLeod et al, 1982a and b).
Lest the method of preparation of IgG eliminate the suggested 
association with transplant outcome, pretransplant sera were instead 
separated into fractions of graded molecular weight. There was :a
highly significant correlation between renal allograft survival and
FcK-receptor blocking activity in the highest molecular weight fraction 
(>19S). Although the serum factor(s) responsible were not identified, 
their presence appeared to be associated with previous transfusion of 
blood or blood products, and with diminished response to skin testing 
with Dinitrochlorobenzene. This may indicate that high molecular 
weight serum Fctf-receptor blocking factors are involved in non-specific 
depression of cell-mediated immunity following blood transfusion, and 
may be regarded as predictive of successful renal transplantation.
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Test
% rosette- 
forming PBL
% inhibition of 
by sample 1
EA rosette formation 
by sample 2
1 19 87 0.
2 21 89 0
3 20 92 7
4 20 73 2
5 20 70 0
6 21 88 12
7 21 94 0
8 21 88 0
9 22 77 9
10 . 20 77 0
Mean + SD 20.5 + 0.8 83.5 + 8.0 3.0 + 4.3
TABLE 1 : Variation in results obtained with the EA rosette
inhibition assay and 10 simultaneous tests:
i) percentage of rosette-forming peripheral 
blood lymphocytes
ii) inhibition of rosette formation by "known 
positive" and "negative" IgG preparations
p
a
t
i
e
n
t
HLA - A, B and DR 
type of patients
Peripheral blood lymphocyte donor
A 1,2 
B 5,8 
DR 3,8
A 2,28 
B 8,14 
DR 3
A 11,24 
B 8,35 
DR 3
A 1,11 
B 5,8 
DR 2
A B DR
1 2,3 35,62 1,4 0 0 27 0
2 1,3 7,16 2,6 21 55 66 31
3 3,11 7,35 2 0 21 17 15
4 1,28 37,40 2,4 0 27 17 0
5 2,29 44,50 2,7 57 75 70 40
6 2,30 13,18 2,7 65 37 76 80
7 2,32 13,27 2,3 50 27 53 65
8 2,28 40,44 4,5 0 9 0 0
9 1,2 14,15 7 56 62 78 93
10 2,11 35,44 2 0 12 7 8
11 1 8 3 20 57 50 34
12 24,11 7,27 4 0 74 68 74
13 3,28 7 2 5 66 67 60
14 2,29 44,50 2,7 55 34 50 59
15 1,2 8 3,4 4 0 0 o
TABLE 2 : Variation with lymphocyte donor of results of the
EA rosette inhibition assay (37°C) for IgG preparations 
from 15 transfused dialysis patients
normal uraemi c 
untransfused
uraemic untransfused P2.0.05 -
uraemic transfused P^O.OOl P<(0.05
transfused transplanted P<0.001 P<0.001
total transfused P<0.001 P<0.001
TABLE .3 : Statistical significance (Student's t test) of
differences between groups of subjects in 
percentages of EA rosette-forming peripheral 
blood lymphocytes
Assay Patient
Number
% Inhibition of
EA-rosette
formation
r........
i| % Inhibition of
; cytotoxicity1
!
1 61
i
tf
! 1|
2 46 j 40/
ADCC 3 44
0
4 34 0}
'
5 27
I
0
1 65 0
2 53 15
3 48 29
NK 4 46 31
1
! 5 14 17
'1t
i 6
i
65 22
j 7 48 0
; 8 44 5
i
....
9 0 0
TABLE 4: Inhibition of killer (K) cell function (ADCC) and
natural killer (NK) cell function by IgG from 
multiply transfused uraemic patients
Fc ^-receptor blocking antibody 
+  -
Anti-sperm
48 20
antibody
+ 31 46
f . ........... , —  ■ ■
TABLE 5 Comparison between Fc#'-receptor blocking and 
anti-sperm antibody activity in 145 subjects
Graft function
Antibody
12 33
11 7
37°C
Graft function
+
Antibody
+
7 22
16 18
TABLE 6 : Association between one-year renal allograft function
and pretransplant IgG antibody blocking FcV -receptors 
on normal peripheral blood lymphocytes
Mean number of HLA mismatches
A B DR
Acceptors (40) 1.1 0.9 0.4
Rejectors (23) 0.9 0.8 0.4
TABLE 7 : Donor-recipient HLA mismatches for 63 renal allografts
Mean number of HLA mismatches
DR
Acceptors (22) 1.0 0.8 0.2
Rejectors (9) 1.2 0.8 0.4
TABLE 8 : Donor-recipient HLA mismatches for 31 renal allografts
Azathioprine
Cyclosporin
acceptors 
rej ectors 
acceptors 
rejectors
Number of 
patients
Mean number 
of units of 
blood
Mean number 
mismatches 
A B
of HLA 
DR
17 9 1.3 1.1 0.3
10 12 0.8 0.7 0.3
14 13 1.5 1.0 0.7
9 10 1.6 0.7 0.9
TABLE 9 Transfusion and tissue matching in 50 renal transplant 
recipients
Cell-mediated Cytotoxicity
A 1 l o g e n e i c  
cel 1
p r e s e n t i n g  
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FIGURE 1: Mechanisms of rejection - cell-mediated cytotoxicity
Delayed - type Hypersensitivity
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FIGURE 2: Mechanisms of rejection - delayed-type hypersensitivity
Antibody-mediated Cytotoxicity
activated
helper
growth factor
B lymphocyte antibody
FIGURE 3: Mechanisms of rejection — antibody-mediated cytotoxicity
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FIGURE 4 : Inhibition of EA rosette formation of peripheral
blood lymphocytes by IgG preparations from 20 
normal subjects
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FIGURE 5 : Inhibition of EA rosette formation of peripheral
blood lymphocytes by IgG preparations from 25 
women
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FIGURE 11: Inhibition of EA rosette formation of normal;
peripheral blood lymphocytes by IgG preparations 
from 10 subjects before and after elective third 
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lymphocytes from 66 untransfused and transfused 
subjects
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lymphocytes and percentage inhibition at 37°C of 
EA rosette formation of allogeneic peripheral blood 
lymphocytes by corresponding IgG preparations 
( n = 20)
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FIGURE 16 : Inhibition of EAC and NSE rosette formation of
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FIGURE 18 : Inhibition of EA, EAC and NSE rosette formation.
of paternal peripheral blood lymphocytes by IgG 
preparations from 3 pregnant women
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FIGURE 21: Relation between inhibitions of EA rosette
formation and. phytohaemagglutinin-induced 
blastogenesis of normal peripheral blood 
lymphocytes by IgG preparations from 20 
subjects
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FIGURE 22: Inhibition of EA rosette formation of normal
polymorphs by IgG preparations from 31 untransfused 
and transfused subjects
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FIGURE 2A: Inhibition by IgG preparations from 23 
untransfused and transfused subjects of 
phagocytosis by normal polymorphs of IgG- 
coated latex beads
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25: Relation between inhibitions of normal polymorph'
EA rosette formation and ingestion of IgG- 
coated latex beads by IgG preparations from 23 
subjects
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FIGURE 26 : Effect of IgG preparations from 12 untransfused
and transfused subjects on uptake and ingestion 
by normal polymorphs of Staphylococcus aureus
Fc X R P-Aggregation
% Inhibition
100-1
80-
60-
oo
20-
oooo-oo—
o normal subjects (6)
transfused subjects (6)
FIGURE 27 : Effect of IgG preparations from normal and transfused
subjects on:
i) EA rosette formation by normal peripheral 
blood lymphocytes (Fc^R)
ii) Collagen-induced aggregation of normal 
platelets (P-aggregation)
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Figure 28 : Removal by absorption of Fc^-receptor blocking
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FIGURE 29: Inhibition of EA rosette formation of normal
peripheral blood lymphocytes by IgG preparations 
from 39 haemophiliacs
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FIGURE 30: Inhibition of EA rosette formation of normal
peripheral blood lymphocytes by IgG from 39 
haemophiliacs according to blood transfusion
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FIGURE' 32 : Comparison between inhibition of EA rosette
formation of normal peripheral blood lymphocytes 
by IgG preparations from 39 haemophiliacs and 
severity of disease (expressed as percentage of 
normal clotting factor activity)
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FIGURE 34: Relation between consumption of clotting factor
concentrates and inhibition of "EA rosette formation 
of normal peripheral blood lymphocytes by IgG 
preparations from 39 haemophiliacs
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FIGURE 35: Relation between use of commercial clotting
factor concentrates and inhibition at 37°C of 
EA rosette formation of normal peripheral blood 
lymphocytes by IgG preparations from 39 
haemophiliacs
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FIGURE 36 : Inhibition of EA rosette formation of normal peripheral
blood lymphocytes by IgG preparations from haemophiliacs ■ : 
with (+). or without (-) antibody to. human T-cell 
leukaemia virus Type III
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FIGURE 37 : Inhibition of phytohaemagglutinin-induced
biastogenesis of normal peripheral blood 
lymphocytes by IgG preparations from normal 
subjects and patients with haemophilia.
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FIGURE 39 : Comparison between use of clotting factor
concentrates and inhibition of the phy tohaemaggliitinin 
response of normal peripheral blood lymphocytes by .
IgG preparations from 27 haemophiliacs
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FIGURE 41 : Elution of Hemofil-derived "antigen" from
Sepharose columns
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FIGURE 42 : Removal of Fc]j-receptor blocking activity from
IgG from a haemophiliac by incubation with 
autologous Hemofil-derived "antigen"
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FIGURE '43 : Removal of Fctf-receptor blocking activity from
IgG from 4 haemophiliacs by incubation with 
autologous Hemofil-derived nantigen,l:
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FIGURE 44: Removal of FcJ-receptor blocking activity from
IgG from 4 haemophiliacs by incubation with 
Hemofil-derived "antigen" from 1 subject
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FIGURE .46: Inhibition of phytohaemagglutinin-induced biastogenesis
of normal peripheral blood lymphocytes by:
i) "antigen" derived from Hemofil (Ag)
ii) IgG preparations from 4 haemophiliacs (Ab)
iii) "antigen" and IgG incubated together (Ag.+ Ab)
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FIGURE 47 : Inhibition of EA rosette formation (37°C) of
peripheral blood lymphocytes from a normal 
subject by serum from patients attending a 
Gerintourinary Clinic
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FIGURE 48: Inhibition of EA rosette formation by IgG
preparations from 15 homosexual subjects, 
6 with clinically defined AIDS
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FIGURE 51; Inhibition of the phytohaemagglutinin response 
of normal peripheral blood lymphocytes by IgG 
preparations from 15 homosexual men, 6 with 
clinically defined AIDS
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FIGURE; 52 : Comparison between one-year renal allograft survival
and pretransplant IgG FcV-receptor blocking activity
against normal peripheral blood lymphocytes
Se
ru
m 
cr
ea
ti
ni
ne
 
in 
ju
mo
l/
1
900 n
800 -
700 -
600 -
500 -
400 -
300 -
200 -
100 -
p<0.001
*
• •
0
!
20
i
40 60
FIGURE 53 :
% inhibition of 6A rosette for m a t i o n  at 4°C
Comparison between serum creatinine one year after 
renal transplantation and pretransplant IgG Fc$-receptor 
blocking activity at 4°C against normal peripheral blood 
lymphocytes
8(
% 
in
hi
bi
ti
on
 
of 
EA 
ro
se
tt
e 
fo
rm
at
io
n
1 0 0 -1
8 0 -
6 0 -
4 0 -
20 —
0
FIGURE 54:
4°C 37°c
A R , A R
—  .....
(14) (4) . (14) (4)
A = "acceptors'1 
R. = "rejectors"
Comparison between one-year renal allograft' 
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56;: Comparison between one-year renal allograft survival and
pretransplant IgG Fctf-receptor blocking activity at 4°C
against donor splenic B lymphocytes
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FIGURE 59: Comparison between one-year renal allograft
survival and inhibition at 4°C of EA rosette 
formation of normal peripheral blood lymphocytes 
by pretransplant ultracentrifuged serum from 45 
patients
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FIGURE 66: Inhibition of EA rosette formation of normal
peripheral blood lymphocytes by serum fraction 
1 from 22 untransfused and transfused subjects
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FIGURE 68: Inhibition of the phytohaemagglutinin response
of normal peripheral blood lymphocytes by serum 
fraction 1 from 43 untransfused and transfused . 
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FIGURE 70: Inhibition of EA rosette formation of normal
peripheral blood lymphocytes by serum fraction 
1 before and after absorption with Protein A
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FIGURE 71: Inhibition of the phytohaemagglutinin response of
normal peripheral blood lymphocytes by serum 
fraction 1 before and after absorption with Protein.A
: T r a n s p l a n t  
a cc e p t o r s
T r a n s p l a n t
rejectors
Normal
subjects
•
